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ABSTRACT 
 
Tumour angiogenesis is a vital process in the pathology of tumour development and 
metastasis. Targeting markers of tumour endothelium provide a means of targeted 
destruction of a tumours oxygen and nutrient supply via destruction of tumour 
vasculature, which in turn ultimately leads to beneficial consequences to patients. 
Although current anti -angiogenic and vascular targeting strategies help patients, more 
potently in combination with chemo therapy, there is still a need for more tumour 
endothelial marker discoveries as current treatments have cardiovascular and other side 
effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is 
performed to obtain putative vascular targets. Also for the first time, deep sequencing is 
applied to freshly isolated tumour and normal endothelial cells from lung, colon and 
bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, 
deep sequencing, public cDNA libraries and microarrays, delivers 5,892  putative 
vascular targets to the science community. These analyses identify Endothelial Specific 
Molecule 1 as a pan vascular target and lysyl oxidase-like 2 as putative novel vascular 
target. It is envisioned vascular targets and angiogenesis genes in this data will destroy or 
inhibit tumour vessel growth without the side effects manifest with current clinical 
regimens.  
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CHAPTER 1; INTRODUCTION 
1.1 Introduction 
The overall theme of this thesis is to provide putative vascular target candidates from new 
data sources combined with public data, so that others can validate interesting candidate 
genes in the laboratory. For the first time, deep sequencing is used to measure mRNA 
contents of freshly isolated tumour endothelial cells and normal endothelial cells from 
multiple organs. Also, embryonic in-vivo biotinylation proteomic data is used to map the 
vascular and extracellular proteome of the chicken to find vascular targets. The 
introduction below gives background to relevant topics related to angiogenesis, vascular 
targeting and RNA-seq gene expression.  
1.2 The endothelial cell and angiogenesis 
Vertebrates have a network of blood and lymphatic vessels to transport gases and 
molecules around the body. Endothelial Cells (ECs) line the inside of the heart and both 
types of vessel throughout the body, forming the interface between blood and vessels. 
Although ECs have traditionally been classed as epithelial cells, they differ as the EC 
cytoskeleton is formed with vimentin filaments whereas epithelial cells have keratin. 
Also, ECs originate from the mesoderm and not the endoderm or ectoderm as epithelial 
cells do. ECs are surrounded by an Extra Cellular Matrix (ECM) and smooth muscle 
cells. Endothelium is not inert, it is a dynamic and specialised tissue involved in many 
important functions including a selective barrier function, inflammation, vascular tone 
(blood pressure regulation) and angiogenesis.  
1.3 Selective barrier and inflammation 
One of the main functions of endothelium is to act as a selectively permeable barrier to 
aid the movement of different molecules between blood and the surrounding tissue. This 
can be done in two ways: 1) paracellular transport by using special junction molecules at 
their cell to cell junctions or 2) transcellular transport by endocytosis through the cell. 
ECs can be specialised depending on the type of tissue or organ they are situated in. For 
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instance, at the blood brain barrier, ECs form tight junctions to only let certain molecules 
and a limited number of amino acids [1] enter the brain. In kidneys, ECs have 300 to 400 
perforations that enable the export of water, urea and other substances out of the body 
[2].  
 
During inflammation, another important EC barrier process is the leucocyte adhesion 
cascade. In response to cytokines, i.e. during inflammation, ECs contact the leucocytes 
via selectins (capture) and enable rolling of leucocytes along the EC surface (rolling and 
slow rolling). Then, cell surface leucocyte genes including integrins, LFA-1 and VLA-4 
strengthen the adhesion bond (firm adhesion) and cause the leucocytes to flatten and 
migrate along the ECs [3]. Finally transmigration takes place as they migrate through the 
endothelium at EC junctions and attach to the extra cellular matrix components at the site 
of inflammation. 
1.4 Blood vessel formation 
Angiogenesis and vasculogenesis are both processes that lead to the generation of new 
blood vessels. Vasculogenesis takes place in the developing embryo and forms the initial 
cardiovascular system whereas angiogenesis is the growth of blood vessels from existing 
blood vessels. Angiogenesis can be a normal physiological process such as tissue growth, 
in exercise, corpus luteum formation, endometrial development in menstrual cycle and 
wound healing but can also arise in pathologies such tumour angiogenesis or age-
dependent macular degeneration [4].  
 
Angiogenesis is firstly initiated by stimulation and activation of endothelial cells that line 
the inside of established blood vessels. This stimulation compels endothelial cells to 
secrete and release proteases (for example matrix metallopeptidases) for the purpose of 
degrading the extracellular matrix to enable endothelial migration escape towards the 
stimulatory signal, most likely VEGF. A second step in angiogenesis is the emergence of 
sprouting and migrating endothelial cells out of established vessels towards the stimulus 
provided by, for example, cancer cell growth factor release. It is the lead tip endothelial 
cells that first enter the basement membrane and migrate towards the VEGF/growth 
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factor stimulus [5], which are closely followed by stalk endothelial cells that 
subsequently orchestrate lumen and extracellular matrix formation [6] and build tight 
cell-to-cell junctions to strengthen the sprout [7]. An overview diagram of the 
angiogenesis process is given in figure 1.4.1 and a representation of the different forms of 
sprouting and intussusceptive vessel formation in figure 1.4.2. 
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  Figure 1.4.1 Overview of tumour angiogenesis process 
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Figure 1.4.1. Angiogenesis is the growth of new blood vessels from existing blood 
vessels and it is portrayed in this figure. Endothelial cells are shown migrating towards a 
gradient of pro-angiogenic growth factors, released by nutrient starved tumour cells, 
whilst they themselves secrete proteolytic enzymes to break down the basement 
membrane. This leads to the formation of tumour blood vessels and leads to tumour 
growth and metastasis. This figure was adapted from [8]. 
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Figure 1.4.2 Sprouting and intussusceptive forms of 
angiogenesis  
 
 
 
Figure 1.4.2. Intussusceptive is a form of angiogenesis where a single blood vessel 
divides into two new blood vessels, which is shown on the top half of the illustration. On 
the bottom panel, the process of sprouting angiogenesis is portrayed where activated 
endothelial cells release proteolytic enzymes to degrade the basement membrane and then 
migrate to form tubes. The leading endothelial cells that lead migration are called Tip 
6 
 
cells. Cells directly behind Tip cells are the Stalk cells and the majority of EC of the 
vessels are termed Phalanx cells [9]. 
1.5 Tumour angiogenesis 
Solid tumours, in their initial growth stage, rely on oxygen and nutrients via diffusion of 
close by blood vessels and tissues. However, for a tumour to grow beyond a certain size, 
estimated to be 2mm
3
, and spread, a tumour must acquire its own blood supply. This was 
proved by an early experiment where they injected the same number of cancer cells onto 
two different areas of an eye: one injection fixed at the anterior chamber (no blood supply 
but nutrients) and the other on the iris where blood vessels were able to grow. They 
showed that tumour cells without a blood supply only grow to 2mm
3
 and tumour growth 
is unlimited with angiogenesis [10]. The process in which a tumour gets a blood supply is 
called tumour angiogenesis. As a result of the environment of tumours, being in 1% 
oxygen (hypoxia) and under oxidative stress, tumour cells release growth factors into the 
surrounding tissue, which can initiate a response from close by vascular endothelial cells. 
The most prolific growth factor responsible is VEGF but it can also include bFGF and 
IL8 growth factors. 
1.6 bFGF and VEGF signalling, the most potent angiogenesis 
initiators and important growth factors for tumour growth   
Although there exist a number of molecules that can stimulate angiogenesis (FGF, PGF, 
TGF, HGF, TNF, angiogenin, IL8 and ANG2) [11], during angiogenesis and 
vasculogenesis the signalling system that is pivotal to EC migration and proliferation 
during vessel formation is Vascular Endothelial Growth Factor (VEGF) and its three 
receptors. VEGFR2 is expressed on the surface of blood vessels and is the main 
perpetrator of the angiogenic effect of VEGFA. Both in-vivo and in-vitro studies using 
VEGFA, which exclusively binds to VEGFR2, showed proliferation, tube formation and 
chemotaxis of ECs [12]. VEGFR3 is expressed on lymphatic endothelial cells and is the 
receptor activated by VEGFC or VEGFD, which stimulates lymphoangiogenesis. 
VEGFR1 is thought to act as a negative regulator of VEGFA, since VEGFA ligand 
binding only causes weak phosphorylation of the receptors intracellular tyrosine residues 
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and does not cause proliferation or migration [13]. Additionally, mice devoid of 
intracellular tyrosine kinase domain of VEGFR1 had no phenotype or any noticeable 
vascular network defects [14]. A soluble, alternative isoform lacking the tyrosine kinase 
domains binds VEGFA and is thought to prevent VEGFR2 activation by VEGFA. Once 
binding of ligands to the VEGF receptors, dimerization of the receptors occurs, which in 
turn leads to auto-phosphorylation of the intracellular tyrosine kinase domains to activate 
intracellular molecules that elicit angiogenesis [15].  
 
Basic Fibroblast Growth Factor (bFGF or FGF2) was one of the first angiogenesis growth 
factors to be discovered and is one of a >20 strong family of growth factors. It is unusual 
in that bFGF does not contain the typical signal sequence that enables proteins to be 
exported from cells [16]. On the surface of cells are heparan sulfate proteoglycans, which 
are proteins that are highly glycosylated, and these bind bFGF and other fibroblast 
growth factor family members, to give reservoirs of growth factors that can be released 
by enzymes (heparanases) or by FGF carrier proteins. It has been shown that Fibroblast 
Growth Factor Binding Protein 1 (FGFBP1) plays a pivotal role in the angiogenic switch 
in colorectal and pancreatic cancers, acting as an extracellular chaperone for FGF [17]. 
There are 4 tyrosine kinases FGF receptors before alternative splicing and this can lead to 
up to 48 different isoforms or paralogs of FGF receptors [18]. It is also known that FGF 
signalling of cell proliferation and/or angiogenesis will not occur without a heparin 
sulphate co-receptor [18]. In fact, Heparan sulfate proteoglycans have a massive impact 
on tumour angiogenesis and this is exemplified if you note that growth, migration, and 
capillary morphogenesis are stimulated in cell cultures of endothelial cells by the addition 
of FGF and heparin [19].   
1.7 Treatment of cancer and anti-angiogenics 
There are several methods of treating solid tumours aside from surgical removal. Two of 
which are chemotherapy and radio therapy that aim to shut down the tumour cells 
themselves by taking advantage of the genetic instability characteristic of tumour cells 
and their hyper-proliferative states. Chemotherapy drugs preferentially target cells that 
are actively dividing, such as tumour cells and attack those in a certain phase of the cell 
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cycle, which leads to apoptosis. However, the drawback is that chemotherapy can also 
damage normal tissues, which is exemplified by the side effects of hair loss and anaemia. 
In a similar manner, radiotherapy treatment involves bombarding tumours with a stream 
of high energy waves that damage fragile DNA and cellular components of cancer cells. 
Whilst it is true that cancer cells are genetically unstable and more susceptible to radio 
therapy, as with chemotherapy, there can be off-target effects on normal tissues.  
 
Anti-angiogenics offer an alternative or complementary treatment as tumours need a 
dynamic and expanding vasculature to assist tumour growth and metastasis [20, 21]. 
Targeting angiogenic pathways is a direct targeted route to treatment with less off-target 
side effects, though there are still some side effects. Since cancer cells have unstable 
genomes they are prone to drug resistance due to high rates of mutations. In contrast, the 
growing endothelial cells of a growing tumour vasculature are essentially normal or un-
mutated, so are less likely to become resistant. This method does not kill tumours outright 
but is rather an approach to containing tumours as even without tumour angiogenesis 
occurring, established close by vessels can supply a tumour with limited oxygen and 
nutrients by diffusion. In homeostasis, there is a fine balance between pro and negative 
angiogenic factors that tightly controls the growth of new blood vessels [22] (corpus 
luteum formation, wound healing and endometrial development in the menstrual cycle 
undergo physiological angiogenesis). In contrast, tumour angiogenesis is an uncontrolled 
excess of pro-angiogenic factors (e.g. hypoxia and chemo-gradient of growth factors) that 
stimulate angiogenesis. A list of the key genes involved in angiogenesis that could be or 
are being targeted with anti-angiogenic therapy are listed in table 1.7.1.  
 
One major method of anti-angiogenic therapy involves blocking the activation of 
endothelial cells by the stimulatory angiogenic factors, released by surrounding stroma 
and tumour cells. The most prominent factor is VEGF that is highly expressed and 
released from cancer cells and from stroma cells in close proximity. Elevated VEGF is a 
critical factor in cancer that has been shown to be a marker of poor outcome in many 
cancers [22]. Endothelial tip cells express the VEGF receptors [5], which attracts the 
endothelial cells towards the gradient of VEGF and other stimulatory factors released by 
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tumours. With VEGF and its receptors being so important in tumour angiogenesis, many 
anti-angiogenic therapeutics have been developed that target this pathway.  
 
An antibody to VEGF that is able to neutralize VEGF in-vivo was approved by the FDA 
in 2004. It is called Bevacizumab (brand name Avastin) and it had been shown, pre-
clinically, to extend the lives of people living with colon cancer, non-small cell lung 
carcinoma, cancer of the breast or brain tumours [23]. However, following FDA approval 
and with the exception of renal cell carcinoma, Avastin has only been effective when 
combined with conventional radiotherapy or chemotherapy. The timing of Avastin 
administration is critical and it has been determined that the Avastin actually normalizes 
blood vessels, possibly enabling better conventional therapy delivery to the tumour [24, 
25].   
 
There are several hundred anti-angiogenic molecules currently under research, with 
apparently only 10 of them having made it into clinical use [23]. Besides anti-VEGF 
pathway inhibitors there are other pathways that can modulate angiogenesis. For 
example, there are immuno-modulating drugs that target tumour necrosis factor, analogs 
of thalidomide, that have been FDA approved for treatment of myeloma [26]. Yet another 
method is to prevent the angiopoietins from binding to the TEK receptor, which has been 
achieved using a Peptidebody that was shown to inhibit angiogenesis. This peptidebody 
(AMG_368) has now gone to clinical trials [27].  
 
One interesting anti-tumour and anti-angiogenic therapy approach in recent research is 
the co-suppression of both Interleukin 6 and VEGF [28]. This abolished glioma U87 
tumour cell growth and invasion in the chicken chorioallantoic membrane (CAM) assay 
and in the brains of xenografted mice [29]. Monoclonal antibodies like Avastin bind to 
VEGFR ligands but Astra Zeneca are investigating an alternative anti-angiogenesis 
molecule that binds to all 3 VEGFRs intracellular tyrosine kinase domains, independent 
of whichever ligands are binding to the receptors. This results in no signal transduction 
and no angiogenesis. This orally administerd therapy is currently in clinical trials for  
non-small cell lung carcinoma, colon cancer and recurrent glioblastoma [15]. There are 
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many other targets and therapeutics under trial, far too many for this introduction, which 
simply provides a glimpse of anti-angiogenic therapies. 
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Table 1.7.1 A list of potential anti-angiogenic therapy targets 
Extracellular matrix genes Gene symbols 
Fibronectin 1 FN1 
Collagens COL4A2, COL4A1, COL1A1, COL3A1, 
COL5A1, COL18A1, COL6A2, COL1A2 etc 
Thrombospondin THBS1 
Fibrin/Fibrinogen FGB, FGA and FGG 
Endostatin COL18A1 
Tumstatin COL4A3 
cysteine-rich, angiogenic inducer, 61 CYR61 
  
Growth vactors Growth factor gene symbols 
vascular endothelial growth factors VEGFA 
fibroblast growth factor 2 FGF2(Bfgf) 
Wnt growth factors WNT2 or WNT9B etc 
placental growth factor PGF (PLGF) 
platelet-derived growth factor beta polypeptide PDGFB (PDGF) 
chemokine (C-X-C motif) ligand 12 CXCL12 (SDF1) 
  
Growth factor receptors Growth factor receptor gene symbols 
vascular endothelial growth factor receptors 1 to 3 FLT1, KDR and FLT4 
fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 and FGFR4 
frizzled family receptors E.g. FZD4, FZD10 
  
Proteinases Proteinase gene symbols 
matrix metallopeptidases MMP1, MMP11, MMP2, MMP9, MMP14 
and MMP3 etc 
plasminogen activator, urokinase PLAU (u-Pa) 
plasminogen activator, tissue PLAT (t-Pa) 
  
Adhesion molecules Adhesion gene symbols 
Integrins ITGA5/ITGB3, ITGA5/ITGB1 
N-cadherin CDH2 
VE-cadherin CDH5 
junctional adhesion molecule 3 JAM3 (JAM-C) 
  
Signalling molecules Signalling gene symbols 
Protein kinase A (PKA) PRKACA 
protein kinase B (PKB) AKT1 
protein kinase C, alpha PRKCA 
mechanistic target of rapamycin (serine/threonine MTOR 
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kinase) 
cytochrome c oxidase subunit II COX2 
ras-related C3 botulinum toxin substrate 1 (rho 
family, small GTP binding protein Rac1) 
RAC1 
Harvey rat sarcoma viral oncogene homolog HRAS (Ras) 
v-raf murine sarcoma viral oncogene homolog B1 BRAF (Raf) 
mitogen-activated protein kinase 1 MAPK1 or MAPK8 
  
Metamorphic or guidance Metamorphic or guidance genes 
angiopoietins/tyrosine kinase with 
immunoglobulin-like and EGF-like domains 1 
ANGPT1,  ANGPT2,  ANGPT4 and TIE1, 
TEK 
Ephrins EPHB4, EPHB3, EPHA2, EPHA7 and EPHB2 
Netrins (deleted in colorectal carcinoma) DCC, UNC5B, UNC5C 
Semaphorins SEMA7A, SEMA4B 
Collapsin response mediator protein family CRMP1, CRMP2, CRMP3, CRMP4 and 
CRMP5 
Roundabout genes ROBO1, ROBO2, ROBO3 and ROBO4 
Slit homolog genes SLIT1, SLIT2 or SRGAP3 
delta-like 4 and notch signalling DLL4 and NOTCH1 
  
Transcription factors Transcription factor gene symbols 
hypoxia inducible factor 1, alpha HIF1A 
 inhibitor of DNA binding 1 and 2 ID1, ID2 
Kruppel-like Factor  KLF2 
forkhead box TFs FOXO1 and FOXO3 
homeobox genes HOXB3 and HOXD3 
NF-kappa B NFKB1 
early growth response 1 EGR1 
SRY (sex determining region Y)-box SOX4, SOX18, SOX7, SOX13 
Table 1.7.1; A list of some of the genes that have been implicated in angiogenesis, which 
could be used as a target in anti-angiogenic therapy. This table is based on previously 
published literature [23].   
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1.8 Tumour micro-environment and endothelial cell gene 
expression repertoires 
Tumour vascular targeting is possible because the tumour micro-environment is vastly 
different to normal conditions, which gives rise to a different gene expression profile and 
cell surface repertoire of proteins. The environment of a tumour and consequently the 
endothelium itself is very different to that in normal tissues. The tumour endothelium and 
adjacent stroma are physiologically and architecturally different to that in corresponding 
normal environments. Tumour vasculature has the characteristics of being tortuous, 
random and with a disorganised vascular architecture [30-32]. The walls of vessels are 
immature and poorly developed with an irregular and discontinuous endothelial cell inner 
lining and with an incomplete covering of smooth muscle cells, coupled with weak 
junctions between endothelial cells and accompanying pericytes [30, 33, 34]. Vessels are 
usually built around a variable and often incomplete basement membrane of aberrant 
anatomy. The randomness, varying vessel diameters and discontinuous vessel network 
leads to a high interstitial pressure. The blood flow around tumour vessels is reduced, 
stopping and starting, which makes tumours susceptible to changes in pressure. In 
tumours, red blood cells and haemoglobin are deficient in oxygen, which can lead to 
variable levels of tissue oxygenation, sometimes as low as 1%. Some regions of a tumour 
are more hypoxic than others [35]. Because of the extensive anaerobic respiration of 
tumour cells, a high level of lactate is present and this produces oxidative stress [36]. The 
tumour environment is also starved of glucose. All these physical forces and attributes of 
the tumour micro-environment lead to endothelial cells being in an active angiogenic 
state, as against a quiescent state found in normal tissues [37]. This ultimately leads to a 
different gene expression profile that is specific to tumour endothelium and this can be 
exploited using vascular disrupting agents (VDA), which specifically target the 
established tumour blood vessels [32]. Most treatments of solid tumours are unspecific 
and since tumour vasculature is irregular and under interstitial pressure, chemotherapy 
agents lack tumour mass penetration, which is not the case for VDAs.  
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1.9 Treatment of cancer and vascular targeting 
As early as 1923, it was proposed by Woglom that damage of tumour capillaries may 
have the highest efficacy in slowing tumour growth [38]. Subsequently, in 1990, 
Denekamp observed that cancer therapeutics were affecting tumour vasculature and it 
should not be ignored [39]. However, even more compelling evidence was demonstrated 
in 1993 when Burrows et al. destroyed a tumour by targeting the ricin poison to a marker 
induced to be expressed on the tumour endothelium [40]. Studies have shown that 
phosphatidylserine becomes exposed on the surfaces of tumour vasculature and can be 
targeted by an antibody Bavituximab, coupled to a radioactive Arsenic analog. This 
approach to targeting tumour vasculature has been used in imaging studies and highlights 
that targeting is possible [41]. It should be noted that there is a differentiation between 
targeting the existing tumour vasculature and targeting angiogenesis molecules expressed 
through active angiogenesis. These are both classed differently: anti-angiogenics, or 
angiogenic inhibitors = AIs and vascular disrupting agents = VDAs. These are different 
approaches and vascular targeting aims to shut down existing tumour vasculature to 
starve a tumour of oxygen and nutrients, plus remove lymphatic vessels that take away 
cellular waste (VDAs). In contrast, anti-angiogenics or angiogenic inhibitors aim to stop 
the active angiogenesis process in tumours (AIs).  
 
In a review by Loi et al. it is stated there are two classes of VDAs, which are 1) small 
molecules and 2) ligand based, which are agents like antibodies that carry a therapeutic 
agent to a specific tumour endothelial target for treatment [32]. The flavone, acetic acid, 
was demonstrated to retard the growth of tumours grown in mice, which was attributed to 
a reduction in vessel perfusion [42]. Other studies of the effects of flavonoids on 
endothelium show that this class of molecules relax vessels, which could be a reason for 
reduced vessel perfusion in the mouse tumour models [43].  
 
An example of the targeted ligand approach, one which is a promising therapy, involves 
coupling an antibody to liposomes that contain the therapeutic agent. This way, a 
characteristic of tumours is exploited, the characteristic that tumours harbour liposomes 
because of vessel architecture. Liposome delivery of therapeutics therefore give a more 
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potent hit because of this unique architecture [44]. One such case, using targeting 
peptides that have an affinity for integrins αvβ3 expressed on tumour vasculature, was to 
deliver liposomes containing the therapeutic agent Combretastatin A4 to tumours [45].   
1.10 Reasons for vascular targeting 
Membrane or secreted vascular targets are an attractive option as they are in contact with 
blood and as such an injected therapeutic can be easily administered to the blood supply. 
Vascular targets also offer an advantage over direct tumour targets as tumour targets can 
sometimes become obsolete due to the genomic instability of cancer cells, whereas 
tumour vasculature is genetically stable. It is also possible that some receptor targets 
could internalise the therapeutic, thus maximising the potential therapeutic hit. An 
example of successful homing of ligands to receptors was performed in a mouse prostate 
disease model, using a peptide found by phage display technology. They coupled a pro-
apoptotic protein to a phage protein which demonstrated a delay in the formation of 
prostate tumours in a genetically engineered mouse, prone to prostate tumours [46]. 
1.11 A recent history of vascular target discovery 
1.12 Silica pellicle 
In early vascular targeting studies, silica pellicle coated endothelium was used to isolate 
membrane proteins [47]. Silica gel was perfused into blood vessels of rat where it formed 
a thin layer onto the surfaces of endothelial cell membranes. Once set, the coated tissues 
were extracted and fragments isolated using gradient centrifugation. The extracted 
regions of coated plaslemma were then processed biochemically and subject to proteomic 
mass spectrophotometer analyses in order to identify plasma associated proteins. A 
similar procedure has been patented [48]. An endothelial caveole protein PV-1 was 
discovered this way in the rat, for which there is the human ortholog, PLVAP [49, 50]. 
An antibody, called Pathologische Anatomie Leiden-endothelium or PALE, has been 
used as a marker for vascular endothelium for greater than 20 years without the 
knowledge of which gene product it was binding to. It has now been discovered that this 
antibody binds to the gene PLVAP [51]. Using a similar approach to the silica method, 
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Oh et al. identified Anexin A1 and aminopeptidase-P as endothelial cell membrane 
markers, using a pipeline of: subcellular fractionation, subtractive mass spectrometry 
proteomics and bioinformatic analyses [52].  
1.13 Chemically coupling membrane and extracellular proteins 
to biotin esters 
In this technique, vascular target genes were identified utilising a chemical reaction that 
occurs between injected biotin and proteins that are in contact with the blood supply 
(extracellular or membrane). The reaction occurs between a functional group of biotin 
and the terminal amine groups of proteins. Following careful homogenization of the 
biotin perfused tissues using a detergent, biotin coupled proteins were isolated using 
streptavidin beads, and subject to trypsin digestion and tandem mass 
spectrometry/chromatography analyses for protein identification. This technique has been 
applied in-vivo to mice with subcutaneous tumours [53-55] and, more recently, to ex-vivo 
human resected organs with tumours [56]. From the mouse experiments, Rybak et al. [53] 
listed 9 proteins that were specific to F9 and/or RENCA tumours. The human orthologs 
of these 9 proteins are: ITGAV, COL4A2, PTK7, ACACA, VTN, TKT, TIAM1, TNNI2 
and GBA. This in-vivo biotinylation method has been customised by removing detergents 
and applying hot water for the recovery process and, for the first time, is applied in the 
chicken embryo, granulation tissue and CAM implanted tumour tissue (see chapter 2).  
1.14 Serial Analyses of Gene Expression (SAGE)  
St. Croix et al. used a comprehensive procedure to isolate endothelial cells from normal 
colon mucosa and tumour colon. For positive antibody selection, they proposed a better 
marker of endothelial cells than had been previously used [57, 58], which was MCAM 
rather than CD31 as this gene is also expressed on macrophages. They included several 
negative selection purification steps to remove non-endothelial cells, using antibodies to 
EPCAM (epithelial cells), CD45 (leukocytes), CD64 (macrophages) and CD14 
(monocyte cells). They validated purity of endothelial cells in two ways: 1) by comparing 
semi-quantitative PCR results of bulk tumour with isolated endothelial cells, using 
markers of endothelium and epithelium, and 2) quantification of SAGE tags for a 
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selection of tissue markers in 4 pools of SAGE libraries (endothelial cell libraries from 
positive bead selection pool, hematopoietic cell pool from the negative selection 
purification procedure, cultured HUVEC pool and the fourth pool, cancer epithelial cell 
lines).   
 
They identified pan endothelial markers (PEMs) by comparing highly expressed genes in 
both tumour and normal colon cells, with 1.8 million SAGE tags derived from cancer cell 
lines. They chose genes as PEMs if their expression was ≥ 20 fold higher in endothelium 
versus cancer cell lines. In-situ hybridization was carried out on frozen human tissue 
sections to validate PEM3 and PEM6, whilst other PEMs were validated based on SAGE 
expression patterns in cultured endothelial cells (HUVEC and human dermal 
microvascular endothelial cells (HMVEC)). They noted that several genes highly 
expressed in-vivo were not expressed in cultured endothelial cells, which was exemplified 
by the Hevin (SPARCL1) gene, where they showed clear in-situ hybridization staining in 
colon tumour endothelium in-vivo but was absent from HUVEC SAGE libraries. Tumour 
Endothelial Markers (TEMs) were also identified; 46 tumour colon endothelial enriched 
SAGE tags were found with ≥ 10 fold enrichment in tumour endothelium versus normal 
endothelium and they focused on the 25 tags most enriched (23 genes), more specifically 
the 9 novel tags for which only EST data was available. Firstly, they showed a positive 
endothelial cell control from normal and tumour derived endothelial cells using semi 
quantitative PCR for both VWF and PEM6 (C-type lectin domain family 14, member A). 
They were highly expressed in endothelial cells of tumour and normal colon but absent 
from an epithelial control. TEM1 (endosialin), TEM7 (plexin domain containing 1) and 
TEM9 (mannose receptor, C type 2) were all absent from the epithelial control and 
normal colon endothelium but strongly expressed in tumour colon endothelium. Both 
TEM7 and TEM1 clearly stained tumour endothelial cells from in-situ analyses. TEM7 
was further shown to stain endothelium on colon metastasis to the liver, and also breast, 
lung, pancreatic, and brain primary tumour endothelium. Corpus luteum vessels also 
showed TEM7 staining, demonstrating overlap between tumour and physiological 
angiogenesis. This article, along with 9 TEM genes, has been cited by many subsequent 
related articles.  
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1.15 cDNA or Expressed Sequence Tag (EST) gene discovery 
cDNA library sequencing is the high throughput and systematic single pass sequencing of 
bacterial clone inserts, picked at random, from a cDNA library representing poly-A 
mRNA from a cell type of interest. It facilitates a snap shot of the gene expression 
signatures of a tissue. Although the transcriptome coverage is low, because of the 
prohibitive cost of sequencing and labour involved, many groups have successfully used 
this method to identify novel genes and genes enriched in target tissues [59-63]. 
Sequences range from 200 to 600bp in length and libraries often contain less than 10,000 
sequences.  
 
Huminiecki and Bicknell [63] explored public expression databases and combined 
differential gene expression analyses of cDNA and SAGE libraries to produce a list of 37 
endothelial markers (4 of them novel). The bioinformatics analyses were done in two 
stages: 1) The first approach used BLAST to search two pools of cDNA libraries, one 
pool endothelial and other pool non-endothelial cell lines, versus Unigene sequences. 2) 
The second approach utilised the xProfiler software [64] where a similar screen was 
performed with public SAGE libraries. The intersection of results were the 37 endothelial 
genes reported. Two of the most promising candidate genes, ROBO4 and TXNDC5 were 
further experimentally validated using in-situ hybridisation and were shown to be tumour 
endothelial enriched [65, 66]. 
 
Herbert et al. performed an extended version of the Huminiecki and Bicknell analyses 
using an EST to gene assignment that negated SAGE library confirmation. In the 8 year 
time lapse since the Huminiecki and Bicknell publication, many new cDNA and SAGE 
libraries had been added to public databases. The latest SAGE and cDNA libraries were 
combined, employing likelihood ratio statistics, to identify 459 endothelial gene 
candidates including CLEC14A, MMP1, ESM1, RHOJ and ECSCR  [62]. RHOJ has 
subsequently been functionally investigated [67].   
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1.16 Differentiating physiological and pathological angiogenesis 
Other researchers aimed to differentiate physiological and pathological forms of 
angiogenesis. Van Beijnum et al. performed an elegant study where suppression 
subtractive hybridization (SSH) experiments were followed by microarray analyses to 
distinguish genes enriched in tumour angiogenesis, in-vivo general angiogenesis and in-
vitro general angiogenesis [68]. They isolated colon tumour endothelial cells (TEC) and 
normal colon endothelial cells (NEC) using a modified version of the method reported by 
St. Croix et al. [69]. This involved combining antibodies for positive selection: the EN4 
antibody (reported to be anti CD31 [70]), another anti-CD31 antibody and an anti-CD34 
antibody. Bead isolated TEC, NEC and placenta endothelial cells (PLEC), plus tumour 
conditioned HUVEC (T.HUVEC) and quiescent HUVEC (Q.HUVEC), were subject to 
suppressive subtractive hybridisation experiments. The resulting 2,746 cDNA clones 
found by SSH were spotted on to microarray filters, where labelled cDNA (
33
P-dCTP) 
from the different endothelial cells types were hybridized to find differentially expressed 
genes. In the results they present 17 tumour angiogenesis genes (TAGs), 46 in-vivo 
general angiogenesis genes (GAG) and 22 in-vitro angiogenesis genes (GAG/B). 15 of 
the TAGs were confirmed by qPCR both in TEC vs. NEC and TEC vs. PLEC contrasts. 
The TAGs CD59, HMGB1, IGFBP7 and VIM were then validated at the protein level; 
Immunohistochemistry results showed that all 4 genes were over-expressed in tumour 
colon endothelium, with CD59 and IGFBP7 producing the most vascular specific staining 
pattern. They then tested if these genes had a role in angiogenesis in-vitro by applying 
antibodies to these genes onto a collagen sprouting angiogenesis assay. Three out of the 
four genes inhibited angiogenesis in this model (HMGB1, IGFBP7 and VIM). The 
chicken chorioallantoic membrane (CAM) was then used in an in-vivo assay to see if the 
same antibodies could inhibit in-vivo angiogenesis. As in the in-vitro collagen sprouting 
assay, the same 3 genes inhibited up to 45% of the angiogenesis in the CAM. This 
suggests that embryonic chicken undergoes similar angiogenesis to tumours. Finally, they 
performed an experiment in Athymic mice with implanted colon tumours, where the gene 
VIM was targeted with an antibody. It was shown that tumour growth was inhibited in a 
dose dependent way and that the microvessel density of the treated mice was reduced 
compared to controls.   
20 
 
Likewise, Seaman et al. endeavoured to dissect pathological and physiological 
angiogenesis using mouse endothelium from a variety of tissues and angiogenic states 
[71]. To achieve this, they used mouse tissues from normal liver, liver tumour and 
regenerating liver (also undergoing angiogenesis). In addition, they too distinguished 
gene signatures of endothelial cells from different organs and identified 15 liver specific 
and 27 brain specific endothelial markers. To do this, endothelial cells were isolated from 
7 normal mouse tissues including: brain, heart, lung, kidney, liver, muscle and spleen. In 
addition, they also extracted endothelial cells from regenerating liver at 3 time points and 
tumour endothelial cells from 5 human/mouse tumour types including liver 
(subcutaneously for all tumour cells implanted into mice, except for the liver metastasis 
which was performed intrasplenically). The implanted tumour cell sources were: 
 
 Mouse colon carcinoma cell line called CT26 [72] 
 Mouse mammary carcinoma cell line called EMT6 
 Human colonic carcinoma cell lines KM12SM 
 Human colonic carcinoma cell lines HCT116 
 Human colonic carcinoma cell lines SW620 
 Mouse Lewis lung carcinoma cell line LLC 
 Human colon adenocarcinoma cell line LS174T 
 
The endothelial cells were isolated using a magnetic antibody coupled beads protocol that 
included 2 negative selection stages: 1) antibodies for the CD19 (B-lymphocyte antigen) 
and 2) CD45 (protein tyrosine phosphatase, receptor type, C or leukocyte common 
antigen). Just prior to positive selection, they were careful to prevent random and non-
specific binding to any FC receptor displaying cells by adding anti CD16/32 antibodies to 
the cell mixtures. Positive selection was carried out by using 3 combinations of 2 
antibodies, depending on tissue source. For heart, liver, kidney, intestine, lung, KM12SM 
and LS174T samples, the positive endothelial cell antibody selection was done with 
Endoglin (CD105). For brain, muscle, SW620 and EMT6 samples the positive selection 
was achieved using a mixture of the antibodies to CDH5 (vascular endothelial cadherin) 
and Endoglin. For the spleen, LLC and CT26 samples, endothelial cells were isolated 
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with antibodies to CDH5 alone. Once the endothelial cells were isolated, they were 
subject to SAGE library sequencing and analyses to find differentially expressed genes 
enriched in tumour, angiogenic and normal endothelium from normal organ tissues. 
Quality control of endothelial isolates was performed using qPCR comparing whole 
tissues with the isolates; they used the endothelial gene ve-cadherin (CDH5) and showed 
≥ 200 fold enrichment of this marker in isolates versus whole tissues. QPCR was also 
used to validate genes that were up-regulated in regenerating liver endothelial cells and/or 
tumour endothelial cells. 25 genes were validated as tumour endothelial enriched, 13 of 
which were not expressed in regenerating liver (physiological angiogenesis). Then 
Seaman et al. also demonstrated 2 brain (Slc2a1 and Slco1a4) and liver (Dnase1l3 and 
Oit3) specific endothelial markers respectively, using in-situ hybridisation. All 4 genes 
clearly stained endothelium in their respective tissues and staining patterns were matched 
using a positive control endothelial staining pattern of the VEGF receptor 2. Several 
tumour endothelial markers were then validated using in-situ hybridisation in a serious of 
different tumours: genes included Apelin, Doppel, Cd109, Cd137, Cd276, Ptprn, Mirp2, 
Ets4 and Vscp that all showed positive vessel staining. A comparison was made of Cd276 
between tumour and normal endothelium. The human ortholog of CD276 was then tested 
with a mono-clonal antibody on a series of paired tumour and normal patient colon 
mucosa samples. A recombinant protein of CD276 was used as a positive control and it 
was evident that CD276 was enriched in the tumour samples from all patients, though it 
was not absent in normal colon mucosa. A range of other tumours: non-small cell lung 
carcinoma, oesophageal cancer, bladder and breast cancers were stained with a poly-
clonal antibody and these all showed positive staining for CD276 on tumour endothelial 
cells. Then more proof was provided by immunohistochemistry to CD276 and VWF, 
which co-localised in the tumour colon endothelium but was absent in normal colon 
endothelium (only VWF was present). Finally, the manuscript lists 27 brain specific 
endothelial markers (25 of which have a human ortholog), 15 liver specific endothelial 
markers (with 13 orthologs in human), 12 angiogenic endothelial markers (12 orthologs 
in human) and lastly, 13 tumour endothelial markers (all with human orthologs).     
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Madden et al. isolated brain endothelial cells from tumour and normal brain samples 
using antibody coupled beads [73]. They removed leukocytes using CD45 antibody 
coupled beads before a positive antibody-bead selection with either anti-MCAM or an 
endothelial-specific plant protein Ulex europaeus agglutinin 1 (UEA-I), which binds to 
alpha-L-fucose on the surface of endothelial cells [74]. This was followed by Serial 
Analyses of Gene Expression (long SAGE [75, 76]) sequencing  to reveal 16 genes that 
were ≥ 4 fold up-regulated in glioma tumour endothelium. They also combined their 
brain SAGE libraries with published colon tumour and normal SAGE libraries from St. 
Croix et al. [69] to identify common tumour induced endothelial genes. Finally, they also 
presented a table of genes that had a tumour endothelial specific expression pattern, with 
little or no expression in normal brain and no counts in other cell types (public SAGE 
libraries). In total, the combined list of tumour endothelial up-regulated and tumour 
endothelial specific genes was 21. They focused on the plasmalemma vesicle associated 
protein (PLVAP) using in-situ hybridisation, custom microarray and PCR. The in-situ 
staining showed PLVAP to be up-regulated in glioma tumour endothelium. 
PCR/microarray results showed that PLVAP was up-regulated in a matrigel medium 
versus endothelial cells grown on plastic plates, thus concluding PLVAP is expressed 
under active angiogenesis. This is a very interesting result since PLVAP has been 
previously shown to be the antigen of the PALE antibody that has been used for several 
years to stain vasculature (see above).  
 
Bhati et al. performed microarray analyses on micro-dissected breast tumour and normal 
endothelial cells to find vascular targets. They reported a list of 48 known genes that were 
greater than four fold up-regulated in tumour endothelial cells versus normal endothelial 
cells. Immunohistochemistry experiments on breast tumours validated several of these 
genes: FAB, SFRP2, JAK3 and SMPD3 [77].  
1.17 Phage display technology and vascular zip codes 
Pasqualini et al. coined the term vascular zip codes (post codes) in a review that 
illuminated research on vascular targeting [78]. Vascular post codes refers to the protein 
heterogeneity between different vascular beds of various tissues and the vascular surface 
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protein differences between normal and pathological states. The post codes enable the 
body to deliver precise and appropriate cells or molecules to specific sites in the body; 
one example is the homing of haematopoietic stem cells (HSCs) to the bone marrow, 
which is mediated by a combination of  α4β1 integrins, vascular cell adhesion molecule 
1, β2-integrins and/or selectin genes [79]. Because of these different vascular post codes, 
depending on tissue type or pathological state, an opportunity exists to target these 
vascular tissue specific post codes for therapeutic or imaging purposes. The key to this is 
to find luminal targets specific to tumour vasculature. Aside from in-vivo biotinylation, 
whole genome arrays and sequencing technologies as discussed previously, there exists a 
combinatorial approach that aims to find both protein receptor post codes and produce 
ligands for these receptors, at the same time. This is called phage display screening [78], 
which is a high-through-put technique to decipher protein-protein interactions (in this 
case, receptor and ligand interactions). This procedure can be performed in-vitro or in-
vivo.  
 
In the phage display system, fragments of DNA coding for 8 or 9 amino acid ligand 
peptides are fused to capsid sequences, which code for phage protein coats, so that 
ligands are present (displayed) on the surface of filamentous phage, hence the phage 
display name [78, 80]. The 8 to 9 amino acid ligands are specifically designed to 
maximise biological effect, usually containing a central tyrosine residue, without 
jeopardising the bacteria phage. Many combinations of ligands can be produced and these 
can be used in panning experiments on a selected surface or microenvironment of 
interest. This has also been achieved in-vivo, where phage display was used to map 
ligands to different vascular beds of different organs and tumours to facilitate therapeutic 
delivery or imaging [81]. One of the peptide ligands was to interleukin 11, which binds to 
both endothelium and prostate epithelium (also seen by others [82, 83]).  They validated 
the peptide mimic of interleukin 11, using a receptor-ligand binding assay where 
immobilised interleukin 11 receptor bound the phage display ligand peptide. This was 
subsequently confirmed with competitive binding with interleukin 11 itself, versus the 
mimic peptide.  
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1.18 DNA and sequencing technologies 
1.19 Sequencing of DNA/RNA 
The polymerase chain reaction and the sequencing of DNA molecules underpins many 
advances in molecular biology. Without being able to determine the sequences of A, G, C 
and T embedded within genomes and transcriptomes, vascular targeting would be limited 
to protein based methods. Although protein methods are good, without the technique of 
PCR to amplify regions of DNA or whole gene sequences, many experiments we take for 
granted would not be possible. The technique of sequencing cloned DNA (cDNA) 
representing poly-A mRNA has facilitated gene discovery and also has indirectly led to 
the production of whole transcriptome gene expression arrays. As this work relies heavily 
on DNA and sequencing, a proportion of this introduction is devoted to illuminating a 
brief history of DNA and sequencing, which goes on to briefly describe the modern 
techniques of 2nd generation sequencing, which have been heavily utilized in this work.  
1.20 Quick history of DNA 
It is apparent that a scientist in 1868, Friedrich Miescher, noticed a substance derived 
from leukocytes that he could not class as protein or fat. Because it originated from the 
centre of the cell, the nuclei, he termed it nuclein. At one stage, he even proposed that 
this new substance could contain the heritable information of cells [83] but later rejected 
it. So it was Friedrich Miescher who first became aware of the existence of DNA. In the 
year 1878, another scientist, Albrecht Kossel, identified the organic chemical bases of 
DNA and RNA (Guanine (G), Cytosine (C), Thymine (T), Adenine (A) and Uracil (U)). 
Later in 1919, an  American-Lithuanian scientist identified the sugar/phosphorus building 
blocks of DNA, which he noted were composed of Deoxyribose, Guanine, Thymine, 
Adenine, Cytosine and Phosphorus [84].   
 
The first system to show and prove that DNA carried heritable information was provided 
by Frederick Griffith. He showed that injection of mice with a mixture of heat killed 
"smooth" bacteria and live harmless "rough" bacteria would result in the transformation 
of the harmless to the virulent ("rough" to "smooth") strain. It was Avery, Macleod and 
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McCartney who later proposed that this transformation was caused by the transfer of 
DNA rather than transfer of proteins between bacterium [85, 86]. Some years later, in 
1937, the first evidence that DNA was a regular structure was provided from the first x-
Ray diffraction pattern of DNA, which was produced by William Astbury [87]. Research 
on DNA structure intensified between 1944 and 1953 that led to the recognised structure 
of DNA.  
 
Between 1949 and 1951, it was Erwin Chargaff who first noticed that the base content or 
genetic composition differed between different species and simultaneously he observed 
that, within the same species, nucleotide bases were evident at fixed ratio levels. These 
findings mean that there were the same number of guanine bases as cytosine bases and 
likewise for the adenine and thymine bases [88, 89]. This was a big step in the right 
direction. It was finally confirmed for sure that DNA was the makeup of heritable genetic 
material. Chase and Hershey showed this by observing the fact that filamentous phage 
inject mostly DNA into cells rather than proteins, when phage infection of bacteria is 
taking place [90]. It was Rosalind Franklin and Maurice Wilkins who decided to produce 
a crystal of DNA to be used in x-Ray crystallography experiments. This extended the 
earlier work by Astbury, which was not successful. Finally, in the end, Rosalind Franklin 
produced two X-ray diffraction pattern photographs of high quality, which were taken by 
Maurice Wilkins and shown to Watson and Crick, who subsequently confirmed the 
double alpha helix model structure of DNA. It is apparent that Wilkins, Franklin, Watson 
and Crick all published data on x-Ray crystallography and the structure of DNA in the 
same Nature journal [91-95]. 
 
The basic structure of DNA is 4 bases in a double alpha-helix structure. The coded 
sequencing DNA or genome is what gives an organism its phenotype, and to better 
understand an organism as well as to find novel and differentially expressed genes, DNA 
sequencing is a pivotal process.  
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1.21 Maxam-Gilbert's early method of sequencing (1st 
generation) 
A first method of DNA sequencing was produced in 1977 by Maxam-Gilbert [96]. They 
developed a method of sequencing using radio isotope labelling, chemical cleavage and 
fragment resolution via gel electrophoresis. First each 5' end of the molecule is labelled 
with a radioactive isotope (usually gamma-
32
P ATP). Then the DNA is broken up by a 
series of 4 chemicals that aim to cleave the DNA strand only once and these can cleave at 
either a specific single base or at two base locations. Guanines are treated with a 
methylating agent (dimethyl sulphate) that aims to methylate a single guanine per 
molecule of DNA. This methylated guanine is then treated with piperdine to remove the 
methylated base and additionally cleave the DNA strand at this position. A second 
reaction is applied to a different aliquot of DNA, which also uses dimethyl sulphate but 
this time in the presence of formic acid. Under these conditions both adenine and guanine 
are both methylated and cleaved following the piperdine treatment. A similar process 
works for cytosine and thymine together using the chemical hydrazine alone, followed by 
piperdine. Or for cleaving Cytosine alone, hydrazine in the presence of NaCl followed by 
piperdine treatment is used. As cleavage occurs at different bases, the DNA fragments are 
all of differing lengths and the 4 separate chemically treated DNA can be resolved on a 
Polyacrylamide gel, where a radio-autograph produces an image of the isotope bands. 
Actual DNA sequences can then be finally deduced. Figure 1.21.1 displays an overview 
of the process.  
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Figure 1.21.1 Overview of Maxam-Gilbert's sequencing process 
 
Figure 1.21.1 Gel electrophoresis separates out fragments of chemically treated DNA that have been cut at specific sites in the 
sequence. Based on fragment lengths and chemical digestions (in different lanes), a sequence can be deduced.  
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1.22 Sanger method of sequencing (1st generation) 
The Sanger method of sequencing was brought about by Frederick Sanger in the year 
1977 [97]. The molecular biology that is pivotal to this technique is the DNA chain 
terminators or ddNTPs (dideoxynucleotide triphosphates) and DNA polymerase that can 
synthesise DNA. ddNTPs terminate the sequence at the point of insertion during the 
polymerase phase of sequencing and these can be labelled with a radioactive isotope or, 
as is more recent, with a fluorescent label. The basic method involves denaturing the 
double stranded template DNA into single strands and then adding a short primer 
sequence that binds to this DNA. A second strand of DNA is then synthesised using the 
DNA polymerase, in the presence of both normal nucleotides and ddNTPs. The growing 
strand is randomly terminated when a ddNTP is incorporated into the synthesised strand. 
This produces many strands of differing lengths that cover the full sequence. Fragments 
are then resolved on a Polyacrylamide gel, initially having the 4 different bases run 
separately in different lanes, with radioactive nucleotide labels. Please see figure 1.22.1 
for clarity. These are read on an autoradiograph. More recently, fluorescent labels 
replaced radio activity and all 4 bases could be combined into a single reaction. The 
human genome project used this method of sequencing, with the majority of machinery 
coming from Applied Biosystems E.g. the ABI 377 slab gel and/or the ABI 3700 
capillary sequencer machines.   
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Figure 1.22.1 Sanger sequencing overview 
 
Figure 1.22.1 Polyacrylamide gel electrophoresis on a slab or capillary gel separates out different lengths of fluorescently labelled 
single stranded DNA. As fragments migrate through gel, they pass through a laser, which excites the attached dyes for base calls.  
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1.23 First generation to second generation 
One problem with 1st generation sequencing, such as the Sanger big dye terminator 
sequencing, is that a lot of space is needed. You have to have a gel that can separate 
fragments of DNA of different lengths, each with a coloured ddNTP on the end. This will 
end up giving you a 500bp sequence but the problem is, you can only run 96 sequences 
per ABI 377 sequencer. Another inconvenience is that you had to pour Polyacrylamide 
slab gels several hours before a sequencing run. Even more fiddly was the loading of 96 
samples onto the gel after carefully removing a comb. A welcome upgrade to the 377 was 
an Applied Biosystems ABI 3700, where you can run up to 96 different sequencing 
reactions using capillary gels instead of slap gels. This saved a lot of preparation time. 
However, even with these improvements, a major problem remained, which was that a 
maximum of 96 samples could be sequenced per run. 
1.24 Illumina (Solexa) 
2nd generation sequencing is completely different. If you consider the Solexa/Illumina 
technology, this immobilises millions of fragments of DNA onto a glass slide or flow 
cell. These separated single stranded DNA molecules are then bridge amplified so that 
you gain clonal clusters that enable enough fluorescent signal strength at each round of 
sequencing (Figure 1.24.1). This is then subject to sequencing by synthesis using a 
polymerase and reversible dye terminators of all 4 bases (dNTPs). The cycle of events in 
the reaction is: 1) A nucleotide is incorporated, 2) fluorescent signal is imaged, 3) the 
blocking chemical group is removed and 4) the next base is incorporated (Figure 1.24.2). 
Solexa was the original name of the technology that was launched in 2006 with the 
Solexa GI analyser that could sequence several million 32bp length sequences per run. In 
2007 Solexa was bought out by another company, Illumina, who replaced the name 
Solexa. The latest machine, an Illumina HiSeq 2500 is able to sequence 600Gb of 
DNA/RNA per 11 day run (approximately equivalent to sequencing 66 human genomes 
to 30 times coverage). This can be paired end or single end sequencing of 100bp length 
reads. The technology that really advanced Illumina was the patent of the reversible dye 
terminator chemistry that was developed by Turcatti et al. [98].  
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Figure 1.24.1 Illumina sequencing, bridge amplification 
 
Figure 1.24.1 Single stranded and size selected cDNA with attached adaptors are washed through a lane of a flow cell. The adaptors 
complement slide bound oligonucleotides. Clonal clusters are amplified through a bridge amplification process to increase  
fluorescence signal.  
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Figure 1.24.2 Illumina, sequencing by synthesis using dye terminators 
 
Figure 1.24.2 Illumina sequencing takes advantage of reversible dye terminators to sequence by synthesis fragments of DNA using a 
polymerase. As of 2012, typical sequencing runs produced ~80 million x 100bp paired end reads per lane of a flow cell. After each 
base incorporation, an image is taken of the flow cell to record base calls.  
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1.25 Roche 454 titanium  
In 2005 Life Sciences launched the first 2nd generation sequencer called a 454. During 
RNA/DNA preparation for this technology, single stranded DNA molecules are bound to 
beads that are subject to clonal amplification using a technique called emulsion PCR. 
Here the reagents of PCR are in aqueous phase droplets within an oil solution. The aim is 
to have a single bead, with a single template of DNA, which is clonally amplified during 
the emulsion PCR process. The method of sequencing used is Pyrosequencing, that is a 
sequencing by synthesis method that adds each base (A, G, C or T) separately and then 
detects the release of pyrophosphate when a nucleotide or nucleotides are incorporated 
[99]. It utilizes a DNA polymerase and 4 different enzymes; the polymerase incorporates 
a base or bases depending on template and this produces a proportional amount of light 
depending on the number of nucleotides incorporated. When pyrophosphate is released, 
an enzyme called ATP sulfurylase converts pyrophosphate to ATP in conjunction with 
Adenosine 5' phosphosulfate (APS). In turn, the produced ATP compels the luciferase 
driven conversion of Luciferin to Oxyluciferin. This generates an amount of light that is 
proportional to the amount of ATP, which is consequentially proportional to the number 
of incorporated bases. The light peaks, after base additions, are analysed to produce a 
sequence, which is prone to poly-A tracts. The main difference if compared to Illumina is 
that the sequence read lengths are variable, from 200 to 500bp in length. However, the 
longer read lengths are offset by the fact that Roche 454 only produces at most 1 million 
sequences per run whereas Illumina can produce 6 billion x 100bp, paired end reads.  
1.26 Applied Biosystems SOLiD sequencing and RNA-seq 
A third 2nd generation sequencing platform is the SOLiD system. The scientific 
principles and methodology behind this technology were first reported by Shendure et al. 
[100] in 2005. This technology also uses the emulsion PCR to clonally amplify beads 
containing templates of DNA. This is followed by an enrichment of clonal beads that are 
then covalently immobilised onto a glass slide. The sequencing chemistry used with the 
SOLiD system is different to both Roche 454 and Illumina. Using a preparation method 
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of RNA-seq as an example, the SOLID system of sequencing will be described (Figures 
1.26.1 to 1.26.5).  
 
Poly-A mRNA is selected from total RNA using a poly-T cellulose medium, from a 
tissue of interest (e.g. tumour endothelial cells). This is then fragmented using an RNAse 
III enzyme digest and the resulting fragmented RNA is hybridised/ligated to adaptors. 
cDNA generation is achieved by reverse transcription and second strand synthesis. The 
purified cDNA is then size selected, amplified and finally subject to bead template 
preparation and emulsion PCR [101]. On the glass slide, the covalently bound beads are 
combined with a mixture of ligase, a universal sequencing primer and a large pool of di-
base probes. These di base probes are labelled with four fluorescent dyes. Each coloured 
dye represents 4 out of the 16 possible di-nucleotide combinations. The complementary 
probe hybridises to the template DNA strand using the di-nucleotide sequence to 
interrogate the template. This probe is then ligated with the ligase enzyme and the 
fluorescent dye imaged. Following this, the dye is cleaved off, and 7 more cycles of 
ligation, imaging and cleaving occurs. The sequencing is performed in colour-space and 
each base in the template sequence is interrogated twice. The colour space sequences are 
finally converted to nucleotide sequences by using knowledge of the first base in the 
universal sequencing primer. A cartoon of the process is displayed in figure 1.26.4. A 
guide for the different di-nucleotide codes/colours and how a colour space sequence is 
decoded to base-space, is in figure 1.26.5. 
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Figure 1.26.1 Overview of RNAseq protocol (A); poly-A mRNA isolation 
 
Figure 1.26.1 Basic overview of the experimental process of RNAseq (part A). Total RNA is isolated from endothelial cells (~5uG). 
This is incubated with cellulose containing poly-T sequences to bind poly-A tails of mRNA. Bound mRNA is washed and incubated 
before a final elusion to produce an enriched population of poly-A mRNA.   
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Figure 1.26.2 Overview of RNAseq protocol (B); fragmentation, cDNA synthesis 
 
Figure 1.26.2; Basic overview of the experimental process of RNAseq (part B). RNA is hybridised/ligated to adaptors, followed by 
cDNA generation achieved by reverse transcription and second strand synthesis. The purified cDNA is then size selected, amplified 
and finally subject to bead template preparation and emulsion PCR (for Roche or SOLiD technologies).  
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Figure 1.26.3 Overview of RNAseq protocol (C); emulsion PCR and sequencing 
 
Figure 1.26.3 Basic overview of the experimental process of RNAseq (part C). Sequencing reagents (P1 adaptor beads, P2 adaptors 
and PCR reagents) are suspended in an oil/aqueous liquid. Single stranded cDNA molecules are mixed so that a single cDNA 
molecule in each bead droplet of the mixture is attained. Emulsion PCR takes place to amplify a clonal fragment, prior to sequencing.   
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Figure 1.26.4 Overview of SOLiD colour-space sequencing 
process 
 
Figure 1.26.4 SOLiD sequencing; First the universal primer 1 is hybridised to the clonal 
bead template (top). Then one of the 16 di-nucleotide dye-labelled probes hybridises to 
the template, ligation occurs and an image is taken. This is followed by cleavage of the 
dye and another round of hybridization, ligation, imaging and cleavage. There are gaps in 
the sequencing, so all probes are removed and a second universal primer is applied which 
is offset by one base (bottom). Again the ligation, image, cleave sequencing procedure is 
repeated and eventually there are 26 consecutive colours representing a 50bp sequence.   
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Figure 1.26.5 SOLiD colour space decoding 
 
Figure 1.26.5; The image defines the 16 possible di-nucleotide codes. You start to 
decode the colour space sequence by using the last T base from the universal primer as 
the first di-nucleotide base. A T base followed by a red colour is an A base. Then an A 
base followed by a green colour is a C base and so on. A sequence is built up and this is 
all done with bioinformatics, with a read aligner of choice (possibly bowtie [102]).  
1.27 Transcriptome RNA-seq or deep sequencing  
Gene expression, although it is not always the case, measures the mRNA level that is 
loosely proportional to protein level. Therefore certain technologies have been developed 
that aim to measure gene expression at the mRNA level on a genome scale. These 
techniques are: cDNA libraries (low coverage), SAGE libraries, microarrays and more 
recently, 2nd generation RNA-seq sequencing. In addition, there are also shotgun 
proteomic approaches that can reveal differentially expressed genes in tissues.  
 
RNA-seq is the whole transcriptome sequencing, performed by 2nd generation 
sequencers (also known as deep sequencing). mRNA is fragmented into 250bp fragments 
and is subject to amplification and massive parallel sequencing using Illumina or SOLiD 
sequencers. RNA-seq enables researchers to attain a gene expression snapshot and the 
transcripts present within in a tissue or disease state of interest. One advantage that RNA-
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seq has over microarrays is that it does not need any previous knowledge of sequences 
and as such it can provide researchers with novel transcripts and new isoforms of known 
genes. In addition, the dynamic range of gene expression surpasses that of microarray and 
there are no possible cross-hybridising probes. This technique enables you to measure 
gene expression, find new transcripts, discover non-coding RNAs, unearth micro-RNAs 
and find pseudo genes. As an illustration, a recent Illumina RNA-seq data set contained 
80 million x 100bp paired end reads (~500x transcriptome coverage). Paired end means 
100bp of each end of a 250bp fragment is sequenced. Read alignments and paired end 
read information can aid transcript assembly programs like Cufflinks to assemble 
transcripts isoforms, by understanding the distance between paired ends and using intron 
spanning reads. This information is applied in statistical models to calculate the most 
likely isoforms and transcript assemblies (see Tophat and Cufflinks [103, 104]).  
 
In this work, Illumina, SOLiD and Roche 454 were all used for different samples of 
endothelial cells, isolated from different environments. The only 2nd generation 
sequencing method used was RNA-seq, which is a method for finding differentially 
expressed genes, isoforms and identifying the presence of novel sequences.  
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1.28 Need for new targets is the driving force behind work 
Figure 1.28.1 displays a Metro newspaper article published December 2010, which gives 
one good example of the need and motivation to find new vascular targets. To provide 
possibly cheaper, alternative strategies by using one or more of the new targets found in 
this work. It is the aim of the author to supply the scientific community with as many 
potential markers of established tumour vasculature and/or angiogenic targets as possible, 
which could, in the long run, end up with patient benefit and treatment of solid tumour 
cancers. 
Figure 1.28.1 Newspaper article relating to the expense of some 
current treatments 
 
Figure 1.28.1; There is an apparent need for new and cheaper vascular targets and/or 
angiogenic disrupting agents.  
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1.29 Chapter 2, Overview; characterisation and identification of 
vascular targets in an embryonic system.  
For the first time, in-vivo biotinylation of a chicken embryo is combined with both high-
resolution proteomics and bioinformatics to characterise an embryonic organism and to 
find potential vascular targets. This additionally looks at differences between tumour and 
wound models, also used in the chicken embryonic system.   
1.30 Chapter 3 combining 1st and 2nd generation sequenced 
cDNA libraries to identify vascular targets 
For the first time, public cDNA libraries are combined with long read 2nd generation 
sequencing of Roche 454 Titanium. The long read lengths of 454 provide some similarity 
to cDNA libraries but with a vast superior transcriptome coverage. Public and in-house 
data are combined to provide a list of putative vascular targets.  
1.31 Chapter 4; using RNA-seq deep sequencing to find putative 
pan-vascular targets 
In this chapter, the latest 2nd generation sequencing technologies are utilised to 
illuminate the tumour endothelial transcriptome of freshly isolated tumour endothelial 
and normal endothelial cells from multiple organs. One overriding aim is to find vascular 
targets that are present in multiple organ types. A second analyses using tumour 
conditioned HUVEC and liver endothelial cells, cultured for 24 hours in 1% oxygen, are 
combined and compared against multiple normal adult human RNA-seq libraries from 
the public domain (RPKM analyses).  
1.32 Chapter 5; identifying vascular targets in lung cancer using 
microarray data from multiple patient tumour endothelium 
Here, 4 biological replicate tumour and normal fresh isolated endothelium were subject to 
microarray analyses. This was to take into account biological variation and to see if there 
were perpetual vascular targets in lung tumours.  
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CHAPTER 2; CHARACTERISATION AND 
IDENTIFICATION OF VASCULAR TARGETS IN AN 
EMBRYONIC SYSTEM 
2.1 Introduction 
A novel in-vivo biotinylation procedure has been developed by the Bikfalvi group to 
facilitate the elucidation of vascular extracellular and membrane proteins of the chicken 
embryo. This is the first time in-vivo biotinylation has been performed in an embryo. It 
also extends and improves on a previous method presented by Rybak et al. 2005 [53] to 
capture a more complete proteome. In-vivo biotinylation involves a functionally reactive 
analog of biotin, which is injected into the blood stream of the chicken chorioallantoic 
membrane (CAM), where it perfuses blood vessels and surrounding tissues. Here the 
biotin chemical reacts and covalently bonds to the N-terminal amine groups of vessel and 
stroma genes that are in contact with blood and the vasculature. These are then recovered 
by homogenisation and elution with hot water but not detergent. To make the technique 
more sensitive than in previous work, which involved digesting streptavidin bound 
biotin-coupled-proteins with trypsin (Rybak et al. [53]), this work removed proteins with 
hot water prior to trypsin digestion to produce a more complete proteome. This procedure 
was applied to chicken embryonic liver, kidney, intestine, CAM and granulation (wound 
incision on the CAM) tissues as well as glioma cells implanted onto a CAM. Mass 
spectrometry proteomic data from each condition was combined with bioinformatic 
analyses to characterise the data and to identify likely vascular and matrix associated 
genes that could be used as vascular targets. The high resolution proteomics also enabled 
differential expression between the different tissues. Two pools of proteomic data were 
generated: 1) CIKL, which stands for CAM, Intestine, Kidney and Liver pool and 2) 
CTW that represents the CAM, Tumour and Wound pool. To characterize matrix and 
vascular proteins of the chicken embryo within these samples, some of which potentially 
could be suitable vascular targets, the following bioinformatics analyses were carried out:  
 biological replicate reproducibility and principle component analyses  
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 human orthologs identification of chicken proteins 
 distribution and differential expression between the different tissues 
 identification of gene ontology and molecular pathways  
 peptide matching to identify glioma specific genes  
 the generation of an "Angioscore", derived from literature keyword scanning 
 endothelial cell expression signatures of orthologs  
 potential vascular targets 
 
Please note, appendix tables are given in a separate volume, also downloadable from 
http://sara.molbiol.ox.ac.uk/userweb/jherbert/tissue_diffex/appendix_files.html. 
2.2 Principle component analyses 
Three biological replicates were generated for all conditions and chicken proteins were 
identified from mass-spectrums using the Mascot proprietary software [105, 106]. 
Briefly, the Mascot mass spectrometry analyses were performed using label free 
quantification to produce Protein Abundance Index (PAI) values, which were computed 
using mass-spectrum peaks from the 3 most abundant peptides, from the same Uniprot 
protein.  
 
Principle component analyses were then performed on the PAI data to see if biological 
replicates of like samples clustered. Prior data transformations were carried out as 
follows: any missing PAI values were imputed, replicate protein PAI values were 
averaged and all data was quantile normalized (see methods). The results of the principle 
component analyses of the normalized data can be seen in figures 2.2.1 to 2.2.3. The 
results show that, with the possible exception of one kidney replicate, alike samples 
cluster close together and organ specific samples show more variation along the first 
principle component than the CAM, tumour and wound samples (Fig. 2.2.1). To attain 
higher resolution of each individual pool, principle component analyses were carried out 
independently (CIKL and CTW). As can be seen in figures. 2.2.2 and 2.2.3 there is 
greater variation between sample groups of both pools. Pearson correlation coefficient 
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(PCC) values were generated to assess the reproducibility of biological replicates and 
figure 2.2.4 shows the full list of values, which were all greater than 0.83. 
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Figure 2.2.1 Principle Component Analyses of normalized protein counts for CIKL and CTW 
 
Figure 2.2.1 shows the plot of a principle component analyses of both protein pools combined. This plot shows the two directions of 
most variance in the data and it can be seen that the same tissue replicates cluster together. The liver, kidney and intestine samples 
show more variation along the first principle component than the CAM, tumour and wound samples. 
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Figure 2.2.2 Principle Component Analyses of the CIKL pool 
 
 
Figure 2.2.2; this figure portrays an independent principle component plot of CIKL pool. The higher resolution reveals a kidney 
replicate as being different to the other kidney samples.  
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Figure 2.2.3 Principle Component Analyses of the CTW pool 
 
 
Figure 2.2.3; shows an independent principle component analyses of the CAM, wound and tumour samples. The largest variation in 
the first principle component shows that the wound and CAM samples show less global gene expression difference than the tumour 
sample. 
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Figure 2.2.4 Pearson Correlation Coefficient values of biological replicates 
 
 
Figure 2.2.4; this figure shows a heat-map of the Pearson Correlation Coefficient results of all biological replicates from both pools. 
For replicates from the same tissue type, a minimum correlation of 0.84 was seen.  
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2.3 Human ortholog identification 
Although chicken is a model organism and there exists a draft genome, the transcriptome 
of the chicken, unlike human, is not comprehensively annotated. To facilitate literature 
keyword, gene ontology and endothelial expression analyses, the human ortholog of each 
chicken protein was sought. The entire set of proteins from both pools totalled 1370 (non-
redundant) from the Uniprot database. The orthologs of each protein was found 
employing a BLAST sequence analyses pipeline similar to Herbert et al. [107]. Appendix 
table A.2.3.1 shows the full protein and ortholog results for both CIKL and CTW pools. 
Table 2.3.1 displays the counts for proteins and orthologs; of the total proteins found, 18 
proteins were not assigned an ortholog since: 1) 11 proteins were chicken specific (no 
human orthologs) and 2) 7 proteins did not hit a human gene with a significant enough 
BLAST hit (1e-9). 1352 proteins were assigned an ortholog and the non-redundant set of 
human orthologs was 1157.   
Table 2.3.1 lists the number of proteins assigned an ortholog 
 Number of Chicken proteins Number of orthologs found 
PAI quantification data  1370 1157 
Table 2.3.1; This table depicts the number of non-redundant proteins and orthologs 
found in the PAI data for both the CTW and the CIKL pools combined.  
2.4 Differential expression of proteins 
Normal distribution; the linear model moderated T-test assumes a normal distribution of 
data. To test the proteomic PAI data for Gaussian/normal distribution, a histogram for 
each pool was produced (Fig. 2.4.1). The results show a bell like shape for both pools, 
characteristic of a normal distribution, which enables valid parametric test statistics to be 
used on this data. 
51 
 
Figure 2.4.1 PAI value distribution histograms of both proteome pools (CIKL and CTW) 
 
 
Figure 2.4.1. The histogram plots show that both proteomic PAI pool values show an approximate normal distribution, enabling 
statistically valid differential gene expression with a parametric moderated T-test statistic. 
CIKL plot CTW plot 
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2.5 Differentially expressed genes and tissue enriched genes 
This approach used the PAI data in a moderated T-test differential gene expression 
analyses, called "decide tests" from the Bioconductor Limma package [108]. This tests 
for differential expression between multiple tissues and the results of the most specific 
genes for each tissue from the CIKL pool are listed in table 2.5.1. The column of this 
table labelled "Significant enrichment" details a tissue for which a gene was enriched. 
There are three numerical codes for the decide tests; 1 stands for significantly up-
regulated, -1 for significantly down regulated and 0 for no differential expression. 
Statistical significance was reached for a contrast with the following conditions met; a 
logarithmic to base 2 fold change of ≥1 and an adjusted p-value ≤ 0.01. The number of 
tissue enriched genes for CIKL: liver = 16, kidney = 10, intestine 20 and CAM = 33. 
Table 2.5.2 lists the genes enriched in the CTW pool and the number of enriched genes 
were for the CAM = 3, the tumour = 6 and the wound = 10. To confirm tissue specific 
expression, 2-dimensional clustering was performed using normalized expression PAI 
values of these genes. Biological replicate samples clustered together as well as 
differentially expressed genes as can be seen in the cluster heatmaps presented in figures 
2.5.1 and 2.5.2. This provides confirmation of the tissue enriched expression.  
 
A download file of tissue clustered genes with AngioScore and cDNA library endothelial 
enrichment can be downloaded from; 
http://sara.molbiol.ox.ac.uk/userweb/jherbert/tissue_diffex/appendix_files.html (file 
called "Tissue enriched protein clusters with AngioScore and Endothelial cDNA 
enrichment").   
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Table 2.5.1 Linear Model decide tests applied to the CIKL pool 
PAI data set  
 
Gene intestine 
- kidney 
intestine 
- liver 
Liver - 
kidney 
intestine 
- cam 
kidney - 
cam 
liver - 
cam 
Significant 
enrichment 
SEPT2 -1 0 -1 0 1 0 Kidney 
ANO4 -1 0 -1 0 1 0 Kidney 
CNNM2 -1 0 -1 0 1 0 Kidney 
CRB2 -1 0 -1 0 1 0 Kidney 
DBH -1 0 -1 0 1 0 Kidney 
FAAH -1 0 -1 0 1 0 Kidney 
FLT4 -1 0 -1 0 1 0 Kidney 
MGST3 -1 0 -1 0 1 0 Kidney 
RIMS2 -1 0 -1 0 1 0 Kidney 
SLC16A7 -1 0 -1 0 1 0 Kidney 
BRP44L 0 -1 1 0 0 1 Liver 
CPZ 0 -1 1 0 0 1 Liver 
DYNLL1 0 -1 1 0 0 1 Liver 
FABP2 0 -1 1 0 0 1 Liver 
GOT1 0 -1 1 0 0 1 Liver 
GRHPR 0 -1 1 0 0 1 Liver 
GSTA1 0 -1 1 0 0 1 Liver 
GSTZ1 0 -1 1 0 0 1 Liver 
HAPLN1 0 -1 1 0 0 1 Liver 
HPD 0 -1 1 0 0 1 Liver 
HPGDS 0 -1 1 0 0 1 Liver 
LAMC3 0 -1 1 0 0 1 Liver 
LDHB 0 -1 1 0 0 1 Liver 
NQO1 0 -1 1 0 0 1 Liver 
PYGL 0 -1 1 0 0 1 Liver 
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SEC23A 0 -1 1 0 0 1 Liver 
ADAMTSL1 1 1 0 1 0 0 Intestine 
C9orf30-
TMEFF1 
1 1 0 1 0 0 Intestine 
CAV1 1 1 0 1 0 0 Intestine 
CNTNAP2 1 1 0 1 0 0 Intestine 
EML4 1 1 0 1 0 0 Intestine 
EPHA1 1 1 0 1 0 0 Intestine 
FNDC1 1 1 0 1 0 0 Intestine 
GPA33 1 1 0 1 0 0 Intestine 
GPLD1 1 1 0 1 0 0 Intestine 
GRM7 1 1 0 1 0 0 Intestine 
KDELR2 1 1 0 1 0 0 Intestine 
KIAA1731 1 1 0 1 0 0 Intestine 
LIPH 1 1 0 1 0 0 Intestine 
LRIG1 1 1 0 1 0 0 Intestine 
MDGA1 1 1 0 1 0 0 Intestine 
MEGF6 1 1 0 1 0 0 Intestine 
MYLK 1 1 0 1 0 0 Intestine 
NTNG1 1 1 0 1 0 0 Intestine 
TNR 1 1 0 1 0 0 Intestine 
SYK 1 1 0 1 0 0 Intestine 
ACAT2 0 0 0 -1 -1 -1 Cam 
ACTA1 0 0 0 -1 -1 -1 Cam 
ACTA2 0 0 0 -1 -1 -1 Cam 
ACTB 0 0 0 -1 -1 -1 Cam 
ALDOC 0 0 0 -1 -1 -1 Cam 
ANXA1 0 0 0 -1 -1 -1 Cam 
BPNT1 0 0 0 -1 -1 -1 Cam 
CNN2 0 0 0 -1 -1 -1 Cam 
DSTN 0 0 0 -1 -1 -1 Cam 
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E1BYN5 0 0 0 -1 -1 -1 Cam 
E1BYN6 0 0 0 -1 -1 -1 Cam 
EPCAM 0 0 0 -1 -1 -1 Cam 
FAT2 0 0 0 -1 -1 -1 Cam 
GSTT1 0 0 0 -1 -1 -1 Cam 
JUP 0 0 0 -1 -1 -1 Cam 
KRT17 0 0 0 -1 -1 -1 Cam 
LCP1 0 0 0 -1 -1 -1 Cam 
LYG2 0 0 0 -1 -1 -1 Cam 
MYL6 0 0 0 -1 -1 -1 Cam 
NEU2 0 0 0 -1 -1 -1 Cam 
NUCB2 0 0 0 -1 -1 -1 Cam 
P02659 0 0 0 -1 -1 -1 Cam 
P02845 0 0 0 -1 -1 -1 Cam 
PAFAH1B2 0 0 0 -1 -1 -1 Cam 
PLS3 0 0 0 -1 -1 -1 Cam 
PPIC 0 0 0 -1 -1 -1 Cam 
PSCA 0 0 0 -1 -1 -1 Cam 
S100A11 0 0 0 -1 -1 -1 Cam 
SERPINB3 0 0 0 -1 -1 -1 Cam 
TMPRSS6 0 0 0 -1 -1 -1 Cam 
TNFRSF6B 0 0 0 -1 -1 -1 Cam 
VWA2 0 0 0 -1 -1 -1 Cam 
ZP3 0 0 0 -1 -1 -1 Cam 
 
Table 2.5.1. This tables shows the Linear Model decide tests differential gene expression 
contrasts between the liver, kidney, intestine and CAM tissues. The following number of 
genes were significantly enriched in each tissue with a logarithmic to base 2 fold change 
of ≥1 and an adjusted p-value ≤ 0.01. Tissue enriched genes: kidney = 10, liver = 16, 
intestine 20 and CAM = 33. A value of 1 is up-regulated, -1 down regulated and 0 is no 
change.   
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Table 2.5.2 Linear Model decide tests applied to the CTW pool 
PAI data set  
Gene tumour - cam tumour - wound wound - cam Significant 
enrichment 
CNTFR -1 0 -1 Cam 
F13A1 -1 0 -1 Cam 
SGCD -1 0 -1 Cam 
C1R 1 1 0 Tumour 
C1S 1 1 0 Tumour 
CTHRC1 1 1 0 Tumour 
GFPT1 1 1 0 Tumour 
OAS3 1 1 0 Tumour 
VIM 1 1 0 Tumour 
ANK1 0 -1 1 Wound 
BPGM 0 -1 1 Wound 
CD276 0 -1 1 Wound 
EPB41 0 -1 1 Wound 
EPB42 0 -1 1 Wound 
FECH 0 -1 1 Wound 
PON2 0 -1 1 Wound 
PTPRB 0 -1 1 Wound 
SLC4A1 0 -1 1 Wound 
TSPO 0 -1 1 Wound 
 
Table 2.5.2. This tables shows the Linear Models differential gene expression contrasts 
between tumour, wound and CAM samples. The following number of genes were 
significantly enriched in each tissue with a logarithmic to base 2 fold change of ≥1 and an 
adjusted p-value ≤ 0.01. Tissue enriched genes were the CAM = 3, tumour = 6 and 
wound = 10. A value of 1 is up-regulated, -1 down-regulated and 0 is no change. 
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Figure 2.5.1 Two-dimensional clustering of differentially expressed genes of CIKL samples 
 
Figure 2.5.1. Hierarchical 2-dimensional clustering of differentially expressed genes found in the CIKL pool by Limma decide tests. 
Cluster distance calculated by 1-correlation. There is clear separation of replicate tissues by the differentially expressed genes. 
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Figure 2.5.2 Two-dimensional clustering of differentially expressed genes of CTW samples 
 
Figure 2.5.2. Hierarchical 2-dimensional clustering of differentially expressed genes from the CTW pool found by Limma decide 
tests. Cluster distance calculated by 1-correlation. 
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2.6 Tumour versus wound differential expression 
Wounds and tumours both undergo angiogenesis but one is a homeostatic process and the 
other pathological. To determine the molecular differences between the wound and 
tumour implanted samples, an additional moderated T-test was performed between 
tumour and wound samples alone. A list of the most significant differentially expressed 
genes, with positive B-value > 0 and adjusted p-value ≤ 0.02, are listed in table 2.6.1. A 
volcano plot displaying the most significant differentially expressed genes can be seen in 
figure 2.6.1, which are those genes highlighted in blue. 
Table 2.6.1 Tumour vs. wound differentially expressed genes 
ID Product logFC AveExpr adj.P.Val B 
NAMPT nicotinamide phosphoribosyltransferase 6.13 19.08 0.00 6.52 
C1R complement component 1, r 
subcomponent 
5.71 18.76 0.00 4.86 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 5.68 18.91 0.00 2.13 
RAC2 ras-related C3 botulinum toxin substrate 
2 (rho family, small GTP binding protein 
Rac2) 
5.37 18.12 0.00 3.56 
POMGNT1 protein O-linked mannose beta1,2-N-
acetylglucosaminyltransferase 
5.24 18.71 0.00 6.28 
P27177  5.15 18.70 0.00 5.93 
PSMA7 proteasome (prosome, macropain) 
subunit, alpha type, 7 
4.98 18.65 0.00 4.46 
PDIA3 protein disulfide isomerase family A, 
member 3 
4.60 25.53 0.00 6.19 
TAGLN Transgelin 3.78 18.60 0.00 2.89 
SPTB spectrin, beta, erythrocytic 3.64 25.02 0.00 2.94 
GFPT1 glutamine--fructose-6-phosphate 
transaminase 1 
3.43 18.36 0.00 3.18 
TNFAIP6 tumor necrosis factor, alpha-induced 2.61 21.31 0.00 1.68 
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protein 6 
RAB27A RAB27A, member RAS oncogene family 2.52 18.22 0.01 0.42 
SERPINA10 serpin peptidase inhibitor, clade A (alpha-
1 antiproteinase, antitrypsin), member 10 
2.30 18.22 0.01 0.51 
S100P S100 calcium binding protein P 2.06 26.50 0.01 0.00 
ITGB5 integrin, beta 5 1.90 23.93 0.01 0.24 
CALCRL calcitonin receptor-like -6.37 18.91 0.00 3.26 
H1F0 H1 histone family, member 0 -5.77 19.51 0.00 2.83 
FECH Ferrochelatase -5.49 19.30 0.00 3.74 
EPB42 erythrocyte membrane protein band 4.2 -5.33 20.18 0.00 6.58 
AHNAK2 AHNAK nucleoprotein 2 -4.84 18.43 0.00 1.77 
EPB41 erythrocyte membrane protein band 4.1 
(elliptocytosis 1, RH-linked) 
-4.81 19.85 0.00 4.63 
ANK1 ankyrin 1, erythrocytic -4.69 21.16 0.00 5.65 
BPGM 2,3-bisphosphoglycerate mutase -4.57 19.16 0.00 4.17 
CD276 CD276 molecule -4.51 18.51 0.00 3.97 
SLC4A1 solute carrier family 4, anion exchanger, 
member 1 (erythrocyte membrane 
protein band 3, Diego blood group) 
-4.22 23.95 0.00 1.72 
PTPRB protein tyrosine phosphatase, receptor 
type, B 
-4.03 19.40 0.00 1.77 
TSPO translocator protein (18kDa) -3.91 18.78 0.00 1.92 
ABCE1 ATP-binding cassette, sub-family E 
(OABP), member 1 
-3.78 19.34 0.00 2.40 
BLVRB biliverdin reductase B (flavin reductase 
(NADPH)) 
-3.77 22.88 0.01 0.86 
PON2 paraoxonase 2 -3.46 18.59 0.01 0.36 
PABPC4 poly(A) binding protein, cytoplasmic 4 
(inducible form) 
-3.43 18.70 0.01 0.27 
CPT1A carnitine palmitoyltransferase 1A (liver) -3.16 18.32 0.01 0.24 
FZD2 frizzled family receptor 2 -2.78 19.21 0.01 1.03 
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MRC1 macrophage mannose receptor 1-like -2.61 19.33 0.00 1.51 
NMT1 N-myristoyltransferase 1 -2.12 19.75 0.01 0.31 
 
Table 2.6.1. Differential protein expression analyses were performed on normalized 
tumour versus wound sample data and the results are presented in this table. 16 human 
ortholog genes were found to be significantly up-regulated in tumour samples (portrayed 
in red as tumour up-regulated) and 20 ortholog genes significantly up in the wound 
samples (displayed in blue as tumour down-regulated).   
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Figure 2.6.1 Volcano plot of tumour versus wound differential 
gene expression 
 
 
 
Figure 2.6.1. Differentially expressed genes in the tumour vs. wound samples were 
sought using Linear Models. 20 genes and 16 genes were found to be up-regulated with a  
statistical significant positive B-value > 0 (adjusted p-value ≤ 0.02) in the wound and 
tumour samples respectively (those genes are highlighted in blue on the volcano plot).  
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2.7 Tumour versus wound keyword searches 
To find if genes have been reported in the literature as being involved in wound healing 
and or glioma tumours, an abstract keyword search was performed using "glioma", 
"glioblastoma", "wound", "healing" and "granulation" as keyword baits. The results of 
this can be seen in table 2.7.1. Four genes enriched in tumours (ITGB5, RAC2, C1R and 
NAMPT) have abstracts containing glioma related keywords and two other tumour 
enriched genes (RAB27A and S100P), contain wound related keywords. For wound 
enriched genes, the results were that CALCRL, FECH, EPB41 and PABPC4 had wound 
related keywords, with PTPRB and TSPO having glioma related keywords.  
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Table 2.7.1 Tumour and wound enriched genes, abstract keyword search results 
Gene Total abstracts Matching 
keywords 
glioma glioblastoma wound healing granulation 
NAMPT 213 1  18728403    
C1R 42 1 8227070     
RAC2 78 3 18217210 
19423540 
 10758162   
RAB27A 81 4     18571497 21693760 
15548590 19704116 
S100P 56 1   18575778   
ITGB5 79 4 11934885 
21978494 
 20404485 
11287419 
  
CALCRL 69 1   12538603 
FECH 82 1   19703464   
EPB41 96 1   21750196   
PTPRB 36 2  11313993 
12615970 
   
TSPO 64 2 15769477 18791274    
PABPC4 37 1   9030741   
 
Table 2.7.1. Genes found to be differentially expressed between tumour and wound were subject to keyword searches for words 
relevant to glioma and wound healing. 12 out of the 36 genes had articles related to the biology being investigated, which are listed in 
this table (those not matching a keyword were omitted). Some genes enriched in tumours had articles relating to both glioma and/or 
wound healing and the vice versa was seen with wound enriched genes. Pubmed identification numbers are reported for an abstract 
matching a keyword in this table. Tumour enriched genes are in red text and wound enriched are in blue. 
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2.8 Gene ontology and pathways  
Gene ontology and molecular pathways give an insight to the biology and processes 
occurring in given lists of genes. Gene ontology (GO) biological process for the entire set 
of orthologs from all tissues was carried out using the online DAVID software. Figure 
2.8.1 shows the percent proteins and the most enriched GO biological process categories. 
To class each ortholog gene as either intracellular, extracellular or membrane, textual 
gene cellular component for each gene was studied by eye and classified. Figure 2.8.2 
shows the results of cellular component analyses where 51% of orthologs are either 
extracellular or plasma membrane genes. This agrees with the Rybak study who 
performed a similar approach [53].  
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Figure 2.8.1 Gene ontology biological process, all orthologs 
 
Figure 2.8.1. Global overview of Gene Ontology biological process for all proteins from 
all tissues. All tissues have evidence of embryonic development and matrix development 
as shown by the presence of response to wounding, extracellular-matrix organization and 
cell/biological adhesion ontology categories. 
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Figure 2.8.2 Gene ontology cellular component 
 
Figure 2.8.2. Global overview of Gene Ontology cellular component for orthologs 
proteins classed as either intracellular, extracellular or membrane proteins. It is evident 
that 51% of all proteins are either extracellular or plasma membrane proteins. This agrees 
with the Rybak study, who performed a similar approach [53].  
 
2.9 Molecular pathways;  
Figures 2.9.1 and 2.9.2 shows the pathways enriched in all of the genes present for 
KEGG and Panther as found by a DAVID enrichment analyses.  
 
Gene count 
Extracellular 
Membrane 
Intracellular 
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Figure 2.9.1 KEGG pathway enrichment from DAVID 
 
Figure 2.9.1. Global overview of KEGG pathways for all genes found by DAVID.  
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Figure 2.9.2 Panther pathway enrichment from DAVID 
 
Figure 2.9.2. Global overview of Panther pathways for all genes found by DAVID.  
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2.10 Identifying human glioma genes from the tumour sample 
To find human glioma expressed genes from the tumour sample, the peptides specific to 
the U87 glioma implanted tumour cells were identified using a program. 2,470 unique 
peptides from the total tumour sample were matched exactly to the Swissport/Trembl 
chicken and human database of proteins, which contained 118,018 and 27,333 human and 
chicken proteins respectively.  
 
The number of peptides matching either or both species was as follows;  
 Peptides matching only human = 176 (7.1%) 
 Peptides matching only chicken = 1942 (78.6%) 
 Peptides that matched both species = 352 (14.3%) 
 
86% of tumour sample peptides were classified specific to either human or chicken 
genes. 48 genes had peptides specific to human (glioma cells) with 8 genes matching ≥ 7 
different human specific peptides. These are listed in table 2.10.1 and 10 genes had 
promiscuous but human specific peptides (data not shown). 
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Table 2.10.1 Human specific peptides identify glioma expressed genes 
Gene Number of different peptides matched  Product 
KRT1 24 keratin 1 
KRT10 18 keratin 10 
KRT9 16 keratin 9 
KRT2 12 keratin 2 
PCCA 9 propionyl CoA carboxylase, alpha polypeptide 
GAPDH 7 glyceraldehyde-3-phosphate dehydrogenase 
PKM2 7 pyruvate kinase, muscle 
VIM 7 Vimentin 
ALB 6 Albumin 
PC 5 pyruvate carboxylase 
ENO1 4 enolase 1, (alpha) 
ALDOA 3 aldolase A, fructose-bisphosphate 
ANXA5 3 annexin A5 
FN1 3 fibronectin 1 
KRT14 3 keratin 14 
KRT5 3 keratin 5 
LDHA 3 lactate dehydrogenase A 
MCCC1 3 methylcrotonoyl-CoA carboxylase 1 (alpha) 
TGFBI 3 transforming growth factor, beta-induced, 68kDa 
TNC 3 tenascin C 
AKR1B1 2 aldo-keto reductase family 1, member B1 (aldose reductase) 
ANXA1 2 annexin A1 
ANXA2 2 annexin A2 
COL1A1 2 collagen, type I, alpha 1 
HRNR 2 hornerin 
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HSPD1 2 heat shock 60kDa protein 1 (chaperonin) 
ITGA5 2 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
TPI1 2 triosephosphate isomerase 1 
AEBP1 1 AE binding protein 1 
ALDOC 1 aldolase C, fructose-bisphosphate 
COL4A1 1 collagen, type IV, alpha 1 
EEF2 1 eukaryotic translation elongation factor 2 
ENO2 1 enolase 2 (gamma, neuronal) 
GPI 1 glucose-6-phosphate isomerase 
HSP90AB1 1 heat shock protein 90kDa alpha (cytosolic), class B member 1 
HSPA5 1 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 
LDHAL6B 1 lactate dehydrogenase A-like 6B 
LMNA 1 lamin A/C 
LOXL1 1 lysyl oxidase-like 1 
MYH14 1 myosin, heavy chain 14, non-muscle 
MYH9 1 myosin, heavy chain 9, non-muscle 
PDIA4 1 protein disulfide isomerase family A, member 4 
PDIA6 1 protein disulfide isomerase family A, member 6 
PGK1 1 phosphoglycerate kinase 1 
PHEX 1 phosphate regulating endopeptidase homolog, X-linked 
PRDX4 1 peroxiredoxin 4 
SBSN 1 suprabasin 
TUBB8 1 tubulin, beta 8 
 
Table 2.10.1. This lists glioma genes identified by peptide matching. 48 genes had peptides specific to human (glioma cells) with 8 
genes matching ≥ 7 different human specific peptides. 10 genes had promiscuous but human specific peptides (data not shown). 
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2.11 Literature searches of glioma involvement of human 
specific peptide genes 
Keyword searches using "glioma" and "glioblastoma" revealed 17 of the 48 genes had 
published evidence of glioma involvement and these are listed with Pubmed id numbers, 
in table 2.11.1.  
Table 2.11.1 17 genes with glioma published evidence 
Gene Total 
abstracts 
Abstracts matching  
keywords 
Pubmed id of glioma or glioblastoma matching 
publications 
TNC 149 11 18794852 20622113 7694284 11920587 18757408 
16292494 11313993 16388320 8548761 19459858 
19147558 
VIM 238 9 3027087 8381971 12169273 16944923 11082283 
18046501 21317457 12084347 18947333 
FN1 407 5 20819642 10783396 21980357 10470109 1409674 
ANXA2 221 5 20018898 21033036 21976520 10777578 7518469 
HSPA5 285 4 10085239 21112319 18708359 18403493 
ITGA5 227 4 16569642 20514406 18992284 18464290 
COL4A1 122 2 10382266 9506531 
COL1A1 459 1 1409674 
HSPD1 230 1 20978188 
GAPDH 188 1 17597534 
TGFBI 159 1 20419098 
ANXA1 146 1 19767728 
ENO1 108 1 19795461 
KRT1 72 1 16944923 
KRT10 63 1 16944923 
ALDOC 24 1 2209624 
Table 2.11.2. This table lists the 17 glioma related genes with publication evidence.   
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2.12 List of candidate vascular targets from proteomic data 
With the novel proteomic approach of targeting membrane and extracellular matrix 
proteins in an embryo, there is an opportunity to identify potentially novel vascular 
targets. An AngioScore was first generated that gives a rough estimate on whether known 
angiogenic related genes were in fact being selected with the proteomic technique. Here, 
angiogenesis and tumour angiogenesis keywords were searched against total publications 
for a gene to derive an "AngioScore" (the percentage of publications matching a word to 
the total number of publications). Table 2.12.1 shows the 43 genes that have an 
AngioScore ≥ 50 and appendix table A.2.12.1 lists all AngioScores for all orthologs.  
Table 2.12.1 Genes with the highest AngioScores 
Human 
Gene 
Human Protein Human Product GO CC 
class 
Angio
Score 
KDR NP_002244 kinase insert domain receptor (a type III 
receptor tyrosine kinase) 
M 94 
CDH5 NP_001786 cadherin 5, type 2 (vascular endothelium) M 90 
FLT4 NP_891555 fms-related tyrosine kinase 4 M 86 
EDNRA NP_001948 endothelin receptor type A M 81 
PROCR NP_006395 protein C receptor, endothelial M 80 
TEK NP_000450 TEK tyrosine kinase, endothelial M 77 
ECE1 NP_001106819 endothelin converting enzyme 1 M 74 
CA9 NP_001207 carbonic anhydrase IX I 74 
wAOC3 NP_003725 amine oxidase, copper containing 3 (vascular 
adhesion protein 1) 
M 70 
COL18A1 NP_569712 collagen, type XVIII, alpha 1 E 70 
VCAM1 NP_001186763 vascular cell adhesion molecule 1 M 70 
PECAM1 NP_000433 platelet/endothelial cell adhesion molecule M 70 
NRP2 NP_003863 neuropilin 2 M 69 
SERPINB5 NP_002630 serpin peptidase inhibitor, clade B 
(ovalbumin), member 5 
E 68 
TUSC5 NP_758955 tumor suppressor candidate 5 M 67 
NRP1 NP_001231902 neuropilin 1 M 66 
ANGPT2 NP_001138 angiopoietin 2 E 66 
MCAM NP_006491 melanoma cell adhesion molecule M 65 
CADM1 NP_055148 cell adhesion molecule 1 M 65 
IGFBP7 NP_001544 insulin-like growth factor binding protein 7 E 63 
ADAM17 NP_003174 ADAM metallopeptidase domain 17 M 63 
ANG NP_001091046 angiogenin, ribonuclease, RNase A family, 5 E 62 
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TIE1 NP_005415 tyrosine kinase with immunoglobulin-like and 
EGF-like domains 1 
M 62 
CDCP1 NP_073753 CUB domain containing protein 1 M 59 
ENG NP_000109 endoglin M 59 
MFI2 NP_005920 antigen p97 (melanoma associated) 
identified by monoclonal antibodies 133.2 
and 96.5 
E 58 
PLXND1 NP_055918 plexin D1 M 58 
LRIG1 NP_056356 leucine-rich repeats and immunoglobulin-like 
domains 1 
M 57 
JAM3 NP_116190 junctional adhesion molecule 3 M 57 
RECK NP_066934 reversion-inducing-cysteine-rich protein with 
kazal motifs 
M 56 
ANGPTL1 NP_004664 angiopoietin-like 1 E 55 
DMBT1 NP_060049 deleted in malignant brain tumors 1 E 55 
FGFBP1 NP_005121 fibroblast growth factor binding protein 1 E 55 
THBS1 NP_003237 thrombospondin 1 E 55 
NME1-
NME2 
NP_001018146 NME1-NME2 readthrough I 54 
STAB1 NP_055951 stabilin 1 M 53 
LYVE1 NP_006682 lymphatic vessel endothelial hyaluronan 
receptor 1 
M 53 
SERPINF1 NP_002606 serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived 
factor), member 1 
E 52 
PROM1 NP_006008 prominin 1 M 51 
ENPP2 NP_001035181 ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
M 51 
COLEC12 NP_569057 collectin sub-family member 12 M 50 
EDIL3 NP_005702 EGF-like repeats and discoidin I-like domains 
3 
E 50 
KLF2 NP_057354 Kruppel-like factor 2 (lung) I 50 
Table 2.12.1. This table shows the 43 genes that have an AngioScore ≥ 50 and appendix 
table A.2.12.1 lists all AngioScores for all orthologs. 
 
2.13 cDNA library endothelial enrichment  
cDNA libraries have been used in a differential gene expression experiment to identify 
endothelial and tumour endothelial enriched genes [62]. In this work, we combined the 
earlier endothelial screen with a Roche 454 RNA-seq hypoxia liver endothelium library 
to increase the potential of identifying new vascular targets within the proteomic data. 
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For the full set of orthologs, analyses were performed that matched gene symbols 
between orthologs and endothelial enriched genes; those that matched were reported. 
Genes that were membrane or secreted proteins were given preference as these are 
directly targetable via the blood stream. The criterion used to rank the genes was 1) a 
gene was log2(FC) ≥ 1 (2 fold) up-regulated in endothelial cells or 2) genes showed an 
endothelial specific profile by having zero counts in the non-endothelial pool. 81 
membrane and 43 extracellular genes were found to have an endothelial enriched cDNA 
library profile, as well as 81 intracellular genes. Table 2.13.1 contains the full list of 
endothelial enriched genes.  
Table 2.13.1 Putative vascular targets, 205 genes with an 
endothelial enriched expression profile 
Human 
Gene 
Product GO CC 
class 
Angio 
Score 
log2 
(FC) 
Endo 
Specific 
CDH5 cadherin 5, type 2 (vascular endothelium) M 90 8.45 specific 
HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 M 18 8.2 specific 
CALCRL calcitonin receptor-like M 25 8 specific 
ELTD1 EGF, latrophilin and seven transmembrane 
domain containing 1 
M 10 7.99 specific 
CD93 CD93 molecule M 23 7.87 specific 
LOC1006
52938 
macrophage mannose receptor 1-like M 0 7.72 specific 
TEK TEK tyrosine kinase, endothelial M 77 7.3 specific 
SLC12A2 solute carrier family 12 
(sodium/potassium/chloride transporters), 
member 2 
M 8 7.04  
PVRL3 poliovirus receptor-related 3 M 23 5.73 specific 
NRCAM neuronal cell adhesion molecule M 13 5.73 specific 
PECAM1 platelet/endothelial cell adhesion molecule M 70 5.56  
CUBN cubilin (intrinsic factor-cobalamin receptor) M 6 5.44 specific 
FAT4 FAT tumor suppressor homolog 4 (Drosophila) M 20 5.08 specific 
LYVE1 lymphatic vessel endothelial hyaluronan 
receptor 1 
M 53 4.94 specific 
THBD thrombomodulin M 43 4.78 specific 
PODXL podocalyxin-like M 37 4.69  
PTPRB protein tyrosine phosphatase, receptor type, B M 25 4.62  
CDH13 cadherin 13, H-cadherin (heart) M 42 4.35  
INSR insulin receptor M 5 4.3  
CD109 CD109 molecule M 24 4.16  
77 
 
PLXND1 plexin D1 M 58 4.15 specific 
PLXNA4 plexin A4 M 17 4.15 specific 
EPHB1 EPH receptor B1 M 35 4.02 specific 
KDR kinase insert domain receptor (a type III 
receptor tyrosine kinase) 
M 94 4  
PTPRG protein tyrosine phosphatase, receptor type, G M 31 3.87 specific 
ACP2 acid phosphatase 2, lysosomal M 4 3.7 specific 
ENG endoglin M 59 3.63  
CD47 CD47 molecule M 22 3.52  
TMEM11
9 
transmembrane protein 119 M 0 3.51 specific 
STT3A STT3, subunit of the oligosaccharyltransferase 
complex, homolog A (S. cerevisiae) 
M 0 3.5  
PLXNA2 plexin A2 M 10 3.25  
CXADR coxsackie virus and adenovirus receptor M 24 3.08  
FABP2 fatty acid binding protein 2, intestinal M 13 3.03 specific 
CNTNAP1 contactin associated protein 1 M 6 3.03 specific 
ADAM17 ADAM metallopeptidase domain 17 M 63 2.95  
ADAM10 ADAM metallopeptidase domain 10 M 30 2.93  
IL31RA interleukin 31 receptor A M 11 2.72 specific 
IL1RAP interleukin 1 receptor accessory protein M 10 2.72 specific 
FREM2 FRAS1 related extracellular matrix protein 2 M 14 2.72 specific 
NRP1 neuropilin 1 M 66 2.68  
ITGA6 integrin, alpha 6 M 27 2.67  
ENPP2 ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
M 51 2.65  
CD9 CD9 molecule M 28 2.56  
LRRN4 leucine rich repeat neuronal 4 M 13 2.55  
TMEM33 transmembrane protein 33 M 0 2.49  
FLRT2 fibronectin leucine rich transmembrane protein 
2 
M 0 2.47  
TIE1 tyrosine kinase with immunoglobulin-like and 
EGF-like domains 1 
M 62 2.4  
PTPRS protein tyrosine phosphatase, receptor type, S M 9 2.31 specific 
MGST3 microsomal glutathione S-transferase 3 M 5 2.15  
MCAM melanoma cell adhesion molecule M 65 1.95  
LPHN2 latrophilin 2 M 14 1.93  
IL6ST interleukin 6 signal transducer (gp130, 
oncostatin M receptor) 
M 14 1.9  
CD36 CD36 molecule (thrombospondin receptor) M 23 1.88  
LIFR leukemia inhibitory factor receptor alpha M 15 1.87  
SDK1 sidekick homolog 1, cell adhesion molecule 
(chicken) 
M 0 1.75 specific 
PLA2R1 phospholipase A2 receptor 1, 180kDa M 18 1.75 specific 
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NEGR1 neuronal growth regulator 1 M 6 1.75 specific 
NAALAD
2 
N-acetylated alpha-linked acidic dipeptidase 2 M 11 1.75 specific 
LCAT lecithin-cholesterol acyltransferase M 10 1.75 specific 
FAM171
A1 
family with sequence similarity 171, member A1 M 0 1.75  
COLEC12 collectin sub-family member 12 M 50 1.75 specific 
STOM stomatin M 0 1.66  
IGF1R insulin-like growth factor 1 receptor M 30 1.63  
PTGFRN prostaglandin F2 receptor negative regulator M 11 1.62  
UPK1B uroplakin 1B M 28 1.55  
ITGAV integrin, alpha V (vitronectin receptor, alpha 
polypeptide, antigen CD51) 
M 45 1.5  
ESAM endothelial cell adhesion molecule M 29 1.5  
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 
M 34 1.4  
MAGT1 magnesium transporter 1 M 4 1.38  
ATP1B3 ATPase, Na+/K+ transporting, beta 3 
polypeptide 
M 5 1.26  
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 
M 33 1.24  
PTPRM protein tyrosine phosphatase, receptor type, M M 23 1.15  
PCDH1 protocadherin 1 M 7 1.04  
SLC26A1 solute carrier family 26 (sulfate transporter), 
member 1 
M 25 0.82 specific 
SDK2 sidekick homolog 2 (chicken) M 0 0.82 specific 
ODZ3 odz, odd Oz/ten-m homolog 3 (Drosophila) M 10 0.82 specific 
MMP15 matrix metallopeptidase 15 (membrane-
inserted) 
M 19 0.82 specific 
ITGA9 integrin, alpha 9 M 35 0.82 specific 
FGFR3 fibroblast growth factor receptor 3 M 24 0.82 specific 
DCHS1 dachsous 1 (Drosophila) M 17 0.82 specific 
BOC Boc homolog (mouse) M 7 0.82 specific 
ANGPT2 angiopoietin 2 E 66 10.68 specific 
MMRN1 multimerin 1 E 42 9.54 specific 
VWF von Willebrand factor E 30 8.81 specific 
SRPX sushi-repeat containing protein, X-linked E 44 6.79 specific 
MMRN2 multimerin 2 E 13 6.71 specific 
PROS1 protein S (alpha) E 7 5.21 specific 
ENPP6 ectonucleotide 
pyrophosphatase/phosphodiesterase 6 
E 0 4.69 specific 
EFEMP1 EGF containing fibulin-like extracellular matrix 
protein 1 
E 17 4.46  
CAPZA1 capping protein (actin filament) muscle Z-line, 
alpha 1 
E 6 4.27  
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COL15A1 collagen, type XV, alpha 1 E 30 4.15 specific 
A2M alpha-2-macroglobulin E 9 3.8  
C8orf84 chromosome 8 open reading frame 84 E 0 3.7 specific 
C7 complement component 7 E 15 3.7 specific 
GPC5 glypican 5 E 6 3.29 specific 
THBS1 thrombospondin 1 E 55 3.24  
GPI glucose-6-phosphate isomerase E 28 3.24  
TXN thioredoxin E 24 3.2  
SPINK5 serine peptidase inhibitor, Kazal type 5 E 4 3.03 specific 
MAMDC2 MAM domain containing 2 E 0 3.03 specific 
ASPN asporin E 3 3.03 specific 
SERPINB
5 
serpin peptidase inhibitor, clade B (ovalbumin), 
member 5 
E 68 2.72 specific 
PON2 paraoxonase 2 E 17 2.68  
CTNNB1 catenin (cadherin-associated protein), beta 1, 
88kDa 
E 41 2.63  
SERPINB
9 
serpin peptidase inhibitor, clade B (ovalbumin), 
member 9 
E 34 2.56  
EMILIN3 elastin microfibril interfacer 3 E 14 2.31 specific 
SRPX2 sushi-repeat containing protein, X-linked 2 E 29 2.1  
COL4A1 collagen, type IV, alpha 1 E 28 2.09  
LAMA4 laminin, alpha 4 E 36 2.04  
NUCB2 nucleobindin 2 E 12 2.01  
PTX3 pentraxin 3, long E 36 1.98  
LAMB1 laminin, beta 1 E 20 1.98  
NID1 nidogen 1 E 10 1.96  
ADAMTS
L5 
ADAMTS-like 5 E 0 1.75 specific 
ACE angiotensin I converting enzyme (peptidyl-
dipeptidase A) 1 
E 21 1.75 specific 
TINAGL1 tubulointerstitial nephritis antigen-like 1 E 7 1.71  
CTSZ cathepsin Z E 12 1.26  
ALCAM activated leukocyte cell adhesion molecule E 46 1.2  
MR1 major histocompatibility complex, class I-
related 
E 6 1.19  
CFH complement factor H E 13 1  
ZP3 zona pellucida glycoprotein 3 (sperm receptor) E 0 0.82 specific 
VWA2 von Willebrand factor A domain containing 2 E 0 0.82 specific 
LYG2 lysozyme G-like 2 E 0 0.82 specific 
CPXM2 carboxypeptidase X (M14 family), member 2 E 0 0.82 specific 
ATP5H ATP synthase, H+ transporting, mitochondrial 
Fo complex, subunit d 
I 0 8.31 specific 
SGCE sarcoglycan, epsilon I 3 6.04 specific 
DPYSL2 dihydropyrimidinase-like 2 I 3 5.42  
80 
 
TLK1 tousled-like kinase 1 I 0 5.11  
ABCA1 ATP-binding cassette, sub-family A (ABC1), 
member 1 
I 12 5.05  
EIF2S3 eukaryotic translation initiation factor 2, 
subunit 3 gamma, 52kDa 
I 6 5.01  
PAFAH1B
2 
platelet-activating factor acetylhydrolase 1b, 
catalytic subunit 2 (30kDa) 
I 14 4.96  
SLC25A4
3 
solute carrier family 25, member 43 I 0 4.94 specific 
CAV1 caveolin 1, caveolae protein, 22kDa I 39 4.78  
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 I 31 4.21  
HSPE1 heat shock 10kDa protein 1 (chaperonin 10) I 18 4.18  
BPHL biphenyl hydrolase-like (serine hydrolase) I 13 4.15 specific 
PTBP2 polypyrimidine tract binding protein 2 I 8 3.7  
ANXA1 annexin A1 I 25 3.64  
DHTKD1 dehydrogenase E1 and transketolase domain 
containing 1 
I 14 3.53  
NAT1 N-acetyltransferase 1 (arylamine N-
acetyltransferase) 
I 8 3.51 specific 
MYH11 myosin, heavy chain 11, smooth muscle I 9 3.51 specific 
TACC1 transforming, acidic coiled-coil containing 
protein 1 
I 33 3.3  
POFUT2 protein O-fucosyltransferase 2 I 18 3.29 specific 
ACTA1 actin, alpha 1, skeletal muscle I 7 3.29 specific 
SULT1C4 sulfotransferase family, cytosolic, 1C, member 4 I 0 3.03 specific 
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
I 14 2.82  
CA13 carbonic anhydrase XIII I 0 2.72 specific 
HNRNPH
1 
heterogeneous nuclear ribonucleoprotein H1 
(H) 
I 11 2.66  
SLC44A1 solute carrier family 44, member 1 I 10 2.65  
DAD1 defender against cell death 1 I 8 2.64  
CPT1A carnitine palmitoyltransferase 1A (liver) I 10 2.55  
ADK adenosine kinase I 18 2.47  
PSMA2 proteasome (prosome, macropain) subunit, 
alpha type, 2 
I 1 2.46  
CYP2W1 cytochrome P450, family 2, subfamily W, 
polypeptide 1 
I 44 2.31 specific 
CEP128 centrosomal protein 128kDa I 0 2.31 specific 
PRPS2 phosphoribosyl pyrophosphate synthetase 2 I 6 2.27  
DECR1 2,4-dienoyl CoA reductase 1, mitochondrial I 3 2.22  
ATP5J2 ATP synthase, H+ transporting, mitochondrial 
Fo complex, subunit F2 
I 7 2.14  
SSR3 signal sequence receptor, gamma (translocon- I 0 2.12  
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associated protein gamma) 
ATP5I ATP synthase, H+ transporting, mitochondrial 
Fo complex, subunit E 
I 5 2.11  
ANXA5 annexin A5 I 18 2.08  
KPNA4 karyopherin alpha 4 (importin alpha 3) I 1 2.07  
PTGR1 prostaglandin reductase 1 I 23 2.05  
LAP3 leucine aminopeptidase 3 I 0 1.92  
VCL vinculin I 15 1.91  
HNRNPK heterogeneous nuclear ribonucleoprotein K I 12 1.91  
ACP1 acid phosphatase 1, soluble I 10 1.88  
MYL6 myosin, light chain 6, alkali, smooth muscle and 
non-muscle 
I 5 1.85  
BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 I 0 1.84  
MDH1 malate dehydrogenase 1, NAD (soluble) I 3 1.82  
VIM vimentin I 21 1.8  
ACLY ATP citrate lyase I 9 1.79  
NIPSNAP
3A 
nipsnap homolog 3A (C. elegans) I 0 1.77  
CORO1C coronin, actin binding protein, 1C I 4 1.77  
VSX1 visual system homeobox 1 I 6 1.75 specific 
SULT1E1 sulfotransferase family 1E, estrogen-preferring, 
member 1 
I 7 1.75 specific 
SLC25A2
2 
solute carrier family 25 (mitochondrial carrier: 
glutamate), member 22 
I 0 1.75 specific 
S100P S100 calcium binding protein P I 38 1.75 specific 
PLS3 plastin 3 I 24 1.74  
DLD dihydrolipoamide dehydrogenase I 2 1.73  
MYH10 myosin, heavy chain 10, non-muscle I 7 1.63  
CPM carboxypeptidase M I 23 1.61  
TOMM70
A 
translocase of outer mitochondrial membrane 
70 homolog A (S. cerevisiae) 
I 4 1.54  
RPL7 ribosomal protein L7 I 0 1.52  
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 
1, 75kDa (NADH-coenzyme Q reductase) 
I 0 1.48  
S100A11 S100 calcium binding protein A11 I 17 1.47  
HADHB hydroxyacyl-CoA dehydrogenase/3-ketoacyl-
CoA thiolase/enoyl-CoA hydratase (trifunctional 
protein), beta subunit 
I 5 1.44  
NPEPPS aminopeptidase puromycin sensitive I 8 1.4  
NQO1 NAD(P)H dehydrogenase, quinone 1 I 15 1.38  
FANCI Fanconi anemia, complementation group I I 5 1.29  
RAB8B RAB8B, member RAS oncogene family I 0 1.26  
HIBCH 3-hydroxyisobutyryl-CoA hydrolase I 8 1.25  
PPP2R2A protein phosphatase 2, regulatory subunit B, I 19 1.24  
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alpha 
IFT81 intraflagellar transport 81 homolog 
(Chlamydomonas) 
I 0 1.23  
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(soluble) 
I 0 1.23  
PRPF4B PRP4 pre-mRNA processing factor 4 homolog B 
(yeast) 
I 3 1.2  
DBT dihydrolipoamide branched chain transacylase 
E2 
I 3 1.19  
SFXN1 sideroflexin 1 I 0 1.18  
NADKD1 NAD kinase domain containing 1 I 0 1.15  
ST13 suppression of tumorigenicity 13 (colon 
carcinoma) (Hsp70 interacting protein) 
I 16 1.14  
RPN2 ribophorin II I 8 1.14  
NUDT5 nudix (nucleoside diphosphate linked moiety X)-
type motif 5 
I 0 1.14  
CPPED1 calcineurin-like phosphoesterase domain 
containing 1 
I 0 1.08  
HSDL2 hydroxysteroid dehydrogenase like 2 I 0 1.05  
LTA4H leukotriene A4 hydrolase I 8 1.01  
Table 2.13.1. 205 putative vascular targets found in the chicken proteomic data. 81 
membrane (M) and 43 extracellular genes (E) were found to have an endothelial enriched 
cDNA library profile, as well as 81 intracellular genes (I).  
2.14 summary 
In this chapter we utilized proteomic data that aimed to extract proteins in contact with 
the blood supply in a developing chicken embryo. The majority of this chapter was 
surveying the proteomic data for validation and identifying tissue specific genes. In 
respect to vascular targeting, many endothelial and tumour endothelial genes were found, 
confirmed by endothelial cell cDNA expression and AngioScore analyses. The results 
will be discussed in chapter 6, focusing on the vascular target/endothelial results.  
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CHAPTER 3; COMBINING 1ST AND 2ND 
GENERATION SEQUENCED CDNA LIBRARIES TO 
IDENTIFY VASCULAR TARGETS 
3.1 Introduction 
Differential gene expression analyses in previous work and work contributing to this 
thesis ([62]) identified endothelial and tumour endothelial enriched genes using public 
cDNA and SAGE libraries. In this chapter, to increase vascular target (VT) gene 
discovery, four enhancements were made. The first was the production of an RNA-seq 
library of liver Sinusoidal Endothelial Cells (hHSEC) cultured for 24 hours at 1% oxygen 
that generated an additional 823,750 sequences to add into the endothelial cDNA library 
pool (using long-read, Roche 454 Titanium 2nd generation sequencing). The second was 
the addition of liver tumour and normal bulk cDNA libraries. A third improvement was 
to pool organs, plus foetal and tumour tissues as a single foetal/tumour versus normal 
angiogenic screen. The final improvement was the introduction of an up to date 
Reference Sequence project transcriptome (Refseq [109], June 2012), containing 44,203 
sequences that includes 6,525 recently annotated non-coding RNAs (4 years have passed 
since the previous differential gene expression screens). Please note, appendix tables 
are given in a separate volume, also downloadable from 
http://sara.molbiol.ox.ac.uk/userweb/jherbert/tissue_diffex/appendix_files.html. 
3.2 Using two differential gene expression contrasts to identify 
Vascular Targets 
A two-step analysis was performed to predict vascular targets (VTs). The first stage 
identified endothelial genes by comparing the expression patterns of genes between 
endothelial and non-endothelial cells. The second stage involved a comparison of bulk 
tumour/foetal versus bulk normal cDNA libraries to identify genes up-regulated in foetal 
tissues (undergoing angiogenesis, thus called the angiogenic screen) and tumours. 
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Putative VTs were genes both endothelial enriched and preferentially expressed in 
foetal/tumour tissues.  
3.3 data collection and differential gene expression 
Sanger 1st generation sequenced cDNA libraries are restricted by costs and labour, and so 
the number of sequences they contain ranges from a single sequence to approximately 
one hundred thousand Expressed Sequence Tags (ESTs). To add more sequences to the 
endothelial cell pool, antibody coupled magnetic beads (anti-CDH5) were used to select 
for sinusoidal liver endothelial cells. These cells were cultured in normal conditions until 
80% confluent and then transferred to a 1% hypoxia chamber for 24 hours. Total RNA 
was sent for Roche 454 Titanium sequencing at Genepool (Edinburgh) and that produced 
823,750 sequences (ranging from 200 to 500bp in length). Public endothelial, non-
endothelial, bulk normal and bulk foetal/tumour tissues libraries were collected using the 
Cancer Genome Anatomy Project (CGAP) tissue library browser [110]. The bulk tissues 
collected were from brain, skin, colon, kidney, lung, liver and prostate. Table 3.3.1 lists 
the cDNA EST/454 counts for the different tissues and a full list of cDNA library names 
can be found in Herbert et al. additional files [62] (open access), with the exception of the 
liver libraries which are listed in table 3.3.2. The methodology employed for the analyses 
in this work is similar to that described in Herbert et al. [62], except for the EST to gene 
assignments, which were made with megablast [111] database searching instead of 
BLAST [112] (more details in methods and Herbert et al. [62]). 
 
The statistics in these analyses were designed by Dov Stekel [62], which combined a 
generalised likelihood ratio test with a False Discovery Rate (FDR). Briefly, two 
hypotheses were compared; the null hypothesis, inferring there is no difference in gene 
expression between the two cDNA library pools and any differences are due to sampling, 
and an alternative hypothesis stating a genuine difference in gene expression was due to 
biological effects. The likelihood ratio statistic (R-statistic) was derived by dividing the 
likelihood of seeing the data under the null hypothesis by the likelihood of seeing the data 
under the alternative hypothesis. A log2 fold change was also employed, adding a 
constant (0.1) value to both pool counts and pool sizes to derive a log2 fold change 
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(preventing any errors of dividing by zero). Putative VT genes were chosen that had a 
positive (up-regulation) in both the endothelial and angiogenic screens.  
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Table 3.3.1 Lists of cDNA/454 mRNA transcript libraries 
RNA sequence library Library information Number of sequences 
Endothelial cells Endothelial cells from CGAP 
and dbEST databases 
31,114 
Liver Hypoxia ECs  Roche 454 Titanium RNA-seq 
library (generated in this work) 
823,750 
Non-endothelial cells Non-endothelial cells from 
CGAP and dbEST databases 
136,622 
Brain tumour, normal and 
foetal libraries 
Bulk cDNA libraries taken from 
CGAP and dbEST databases 
140,621 100,554 
69,862 
Liver tumour and normal 
libraries 
Bulk cDNA libraries taken from 
CGAP and dbEST databases 
27,568 31,023 
Prostate tumour and 
normal libraries 
Bulk cDNA libraries taken from 
CGAP and dbEST databases 
19,125 68,480  
Colon tumour and normal 
libraries 
Bulk cDNA libraries taken from 
CGAP and dbEST databases 
143,025 37269 
Skin tumour and normal 
libraries 
Bulk cDNA libraries taken from 
CGAP and dbEST databases 
12,484 33,218 
Lung tumour, normal and 
foetal libraries 
Bulk cDNA libraries taken from 
CGAP and dbEST databases 
108,107 82,757 
112,690 
Kidney tumour, normal 
and foetal libraries 
Bulk cDNA libraries taken from 
CGAP and dbEST databases 
38,519 72,476 2,605 
Table 3.3.1. This table lists the endothelial, tumour, foetal and normal tissue mRNA 
cDNA and Roche 454 expression libraries used to predict the identity of tumour vascular 
targets. The raw sequence counts of each mRNA library are included. 
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Table 3.3.2 Additional liver tumour and normal cDNA libraries 
Liver bulk cDNA library Histology EST 
count 
subtractive library of hepatocellular carcinoma hepatocellular 
carcinoma 
7 
human hepatoblastoma cDNA hepatoblastoma 7,898 
GKA hepatocellular 
carcinoma 
84 
GKB hepatocellular 
carcinoma 
1547 
GKC hepatocellular 
carcinoma 
17736 
GKD hepatocellular 
carcinoma 
180 
GK hepatocellular 
carcinoma 
80 
Human hepatocellular carcinoma subtracted cDNA 
library 
liver tumour 36 
L7N800102 normal liver 1,350 
L7N800102s1 normal liver 1,702 
Stratagene liver (#937224) normal liver 8,417 
GLA normal liver 93 
GLC normal liver 19,285 
GLD normal liver 176 
Table 3.3.2. All bulk tumour, foetal and normal cDNA libraries were divided into 2 
pools; tumour/foetal and normal. All bulk cDNA libraries are listed in the additional files 
of Herbert et al. [62] (open access) except for the liver tumour and normal libraries that 
are listed in this table.   
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3.4 Putative Vascular target results 
From the differential gene expression contrasts (endothelial cells versus non-endothelial 
cells and bulk foetal/tumour versus bulk normal tissues) 3,069 genes were found as up-
regulated in both contrasts and are listed in appendix table A.3.4.1. To focus on which 
genes are more likely to be accessible targets via the blood stream, bioinformatics 
sequence analyses tools were then used through the online website, Center for Biological 
Sequence Analysis [113], to predict which of these genes contained transmembrane or 
signal peptide domain sequences. 698 genes were found to have either one or both of 
these domains and are listed in appendix table A.3.4.2 as vascular targets. 
3.4 Vascular targets and possible functional trends 
To be able to gain an understanding of any functional trends present in the vascular target 
list, the complete set of differentially expressed genes and the transmembrane/signal 
peptide containing VT proteins was analysed independently using the online DAVID 
resource [114]. This clusters genes with similar functions (selected as Gene ontology 
biological process) were placed into annotation clusters. The most abundant categories 
for the whole set of differentially expressed genes (Fig. 3.4.1) were "transcription", "cell 
cycle", "regulation of transcription" and "metabolic processes", which appear consistent 
with a developing tumour mass. "Angiogenesis" and "vascular development" categories 
were also present but at a lower False Discovery Rate (FDR) significance level.  
 
The 698 transmembrane and/or secreted VT genes were separately used as input to 
DAVID to find enrichment of functional Gene Ontology Biological Process terms (≤ 1e-2 
FDR, Fig. 3.4.2). Biological process functions involved in "vascular development" and 
"cell adhesion" were present, consistent with the predicted angiogenesis and extra-
cellular matrix remodelling processes usually occurring in solid tumour growth.  
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Figure 3.4.1 All differentially expressed genes, Gene ontology 
Biological Process 
 
Figure 3.4.1. The 3,069 differentially expressed genes were analysed using the online 
DAVID resource. The significant terms found enriched (≤ 1e-4 FDR) were 
"transcription", "cell cycle", "regulation of transcription" and "metabolic processes". 
"Angiogenesis" and "vasculature development" were also found at a lower significance 
level (< 1e-1 FDR). 
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Figure 3.4.2 Gene ontology Biological Process of transmembrane/signal-peptide protein genes 
 
Figure 3.4.2. 698 vascular targets were used as input to DAVID to find enrichment of Gene Ontology Biological Process terms (≤ 1e-
2 FDR). Biological processes involved in "vascular development" and "cell adhesion" were present, consistent with predicted 
angiogenesis and extra-cellular matrix remodelling usually associated with tumour growth. 
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3.5 VT potential involvement in angiogenesis, tumours and 
endothelium 
Abstract keyword searches were used to generate an "AngioScore" for all differentially 
expressed genes. An "AngioScore" is calculated as the percentage of abstracts containing 
a given keyword divided by the total number of abstracts for that gene (only from 
publications that Entrez Gene at Genbank assign to a gene). A list of the keywords used 
is as follows (more details in methods): "vascular", "tumour", "tumor", "angiogenic", 
"angiogenesis", "neovascularization", "neovascularisation", "vasculogenesis", "hypoxia", 
"endoth" and "VEGF". The notion was to rank genes that had been previously reported to 
be involved in angiogenesis, tumours and endothelial cell expression. This serves to give 
confidence in the list of genes found and enable further experiments on other genes that 
have not been previously researched. A full list of the "AngioScore" keyword results are 
listed in appendix table A.3.5.1 and the top 24 "AngioScore" genes are listed in table 
3.5.1, where there are characterised endothelial genes such as cadherin 5, type 2 (vascular 
endothelium) and endothelial cell-specific chemotaxis regulator (ECSCR or Endothelial 
Cell Specific Molecule 2); and also known tumour endothelial (VT) genes: ANGPT2, 
ESM1 and IGFBP7.  
 
Table 3.5.2 lists a selection 33 VT candidates with the least number of publications to the 
present date (June 2012). Experimental proof of VT expression profiles would have to be 
performed to confirm the novel VT candidates.  
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Table 3.5.1 VT genes with highest scoring "AngioScore" 
Gene Product Total abstracts AngioScore 
CDH5 cadherin 5, type 2 (vascular endothelium) 115 90 
ECSCR endothelial cell-specific chemotaxis regulator 6 83 
HIF3A hypoxia inducible factor 3, alpha subunit 21 71 
ANGPT4 angiopoietin 4 25 68 
ESM1 endothelial cell-specific molecule 1 25 68 
ANGPT2 angiopoietin 2 225 66 
PDPN podoplanin 96 66 
IGFBP7 insulin-like growth factor binding protein 7 63 63 
ADAM17 ADAM metallopeptidase domain 17 194 63 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 409 62 
LECT1 leukocyte cell derived chemotaxin 1 15 60 
PEAR1 platelet endothelial aggregation receptor 1 5 60 
DLL4 delta-like 4 (Drosophila) 52 60 
ENG endoglin 242 59 
HPSE heparanase 193 58 
PLXND1 plexin D1 19 58 
JAM3 junctional adhesion molecule 3 46 57 
RECK reversion-inducing-cysteine-rich protein with kazal motifs 55 56 
STAB1 stabilin 1 30 53 
SELE selectin E 321 53 
TNFRSF25 tumor necrosis factor receptor superfamily, member 25 39 51 
S1PR2 sphingosine-1-phosphate receptor 2 32 50 
IGFLR1 IGF-like family receptor 1 2 50 
VSIG1 V-set and immunoglobulin domain containing 1 2 50 
Table 3.5.1. This table shows 24 genes with the highest "AngioScore" from the 698 VTs. 
Known endothelial and tumour endothelial genes are found in this list; e.g. CDH5 and 
ECSR are published as being highly endothelial specific and ANGPT2, ESM1 and 
IGFBP7 are published tumour endothelial markers.  
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Table 3.5.2 Potential novel VT genes with fewest publications 
Gene Product Total 
abstracts 
Angio 
Score 
LOC100506250 NPIP-like protein 1-like 0 0 
C15orf24 chromosome 15 open reading frame 24 0 0 
TMPRSS11BNL TMPRSS11B N terminal-like 0 0 
LOC100509247 hypothetical protein LOC100509247 0 0 
LOC100506504 hypothetical protein LOC100506504 0 0 
LOC100652934 hypothetical protein LOC100652934 0 0 
XKR5 XK, Kell blood group complex subunit-related family, 
member 5 
1 0 
LOC100507050 hypothetical LOC100507050 1 0 
LOC147670 hypothetical protein LOC147670 1 0 
LRRC38 leucine rich repeat containing 38 1 0 
RPRML reprimo-like 1 0 
UPK3BL uroplakin 3B-like 1 0 
NANOGNB NANOG neighbor homeobox 1 0 
PRR23A proline rich 23A 1 0 
IGFLR1 IGF-like family receptor 1 2 50 
VSIG1 V-set and immunoglobulin domain containing 1 2 50 
SVOP SV2 related protein homolog (rat) 2 0 
MFSD11 major facilitator superfamily domain containing 11 2 0 
TMEM80 transmembrane protein 80 2 0 
FAM18A family with sequence similarity 18, member A 2 0 
STEAP1B STEAP family member 1B 2 0 
C19orf18 chromosome 19 open reading frame 18 2 0 
C18orf26 chromosome 18 open reading frame 26 2 0 
MILR1 mast cell immunoglobulin-like receptor 1 2 0 
TMEM183B transmembrane protein 183B 2 0 
NTN5 netrin 5 2 0 
TTC9B tetratricopeptide repeat domain 9B 2 0 
FAM69B family with sequence similarity 69, member B 3 33 
C14orf101 chromosome 14 open reading frame 101 3 0 
TLCD1 TLC domain containing 1 3 0 
TMEM194B transmembrane protein 194B 3 0 
GJD4 gap junction protein, delta 4, 40.1kDa 3 0 
TMEM179B transmembrane protein 179B 3 0 
Table 3.5.2. This table shows the 33 putative VT genes with the fewest publications. The 
full set of 3,069 genes with publications and "AngioScore" are in appendix table A.3.5.1.  
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3.6 Summary of VT discovery using combined 1st and 2nd 
generation sequencing 
In summary, 698 putative vascular targets were predicted combining the old Sanger 
sequencing technologies (cDNA libraries) with the newer 2nd generation sequencing 
technology of Roche 454 Titanium. Functional enrichment showed tumour growth, whilst 
angiogenesis related functions and searches of published literature suggested that the 
gene list could include previously unreported novel vascular targets. During the time of 
this PhD work, the basis of the cDNA library analyses presented in this chapter was 
published in BMC Genomics, entitled "A novel method of differential gene expression 
analysis using multiple cDNA libraries applied to the identification of tumour endothelial 
genes" [62].  
 
3.7 Serving the scientific community 
1) Also, during the work of this thesis, a simple guide to analysing cDNA libraries to 
identify genes of interest was produced and published in a book called "cDNA 
libraries: Methods and Applications, Methods in Molecular Biology 729. 
Springer" [115].  
2) An accompanying website was also created where researches can run their own 
analyses, either through an interactive web page or with provided command line 
tools [116]. The book chapter website and tool downloads are available at; 
http://sara.molbiol.ox.ac.uk/userweb/jherbert/ 
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CHAPTER 4; USING RNA-SEQ DEEP 
SEQUENCING TO FIND PUTATIVE PAN-
VASCULAR TARGETS 
4.1 Introduction 
In the previous 2 chapters, VTs were sought using proteomic, cDNA and 2nd generation 
sequencing (Roche 454 long read data). In this chapter, pan-VT markers were identified 
combining RNA-seq data (2nd generation, Illumina and SOLiD short read technologies) 
from tumour endothelial cells freshly isolated from lung, colon and bladder organs, 
together with an in-vitro, tumour conditioned HUVEC library (tumour Huvec) and the 
hypoxic Sinusoidal endothelial library (hHsec). Also from this data, a novel endothelial 
transcriptome was assembled by merging the assemblies of each RNA-seq library. This 
was subsequently followed by a screen to identify differentially expressed novel 
intergenic transcripts and an analyses to test for evidence of isoform switching. This was 
to see if there exist coding isoforms for larger proteins in tumours and, at the same time, 
to see if shorter proteins are enriched in normal tissues, based on Cufflinks results. If 
proven, these are potentially similar to those previously reported (TNC [117] and FN1 
[118]). The ultimate objective was to identify vascular targets from deep sequencing data 
of tumour endothelium.  
4.2 Sequencing an in-vitro tumour conditioned endothelial 
transcriptome(Tumour Huvec) 
The term hypoxia means a reduced level of oxygen tension within tissues and this can 
happen in cancer, leading to therapy resistance and a poor prognosis. Hypoxia is a key 
regulator of tumour growth [119] because the protein level of Hypoxia-inducible factor-
1alpha (HIF-1alpha) is induced by hypoxia and this increases VEGF production, which is 
the most pivotal and potent growth factor in angiogenesis activation. The tumour 
environment is also acidic and it has been shown in-vitro that a low pH does not affect 
endothelial cell activation in the presence of angiogenic factors such as bFGF or VEGF 
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[120]. The aim of this experiment was to sequence a tumour endothelial transcriptome 
from an in-vitro source of RNA. If the environment is truly that of a tumour, using 
HUVECs in a culture dish negates any chance of contaminating tissues such as 
perivascular or smooth muscle cells in the resulting transcriptome. A good example of 
this, is the tumour endothelial marker 1, endosialin (TEM1/CD248) [69] which was first 
thought to be expressed on tumour endothelium but is in fact expressed on surrounding 
perivascular cells [121, 122]. 
 
To simulate the environment of a tumour, passage 0 HUVECs were grown from fresh 
cords at a Ph of 6.8, 1% oxygen (hypoxia), without glucose and in the presence of the 
potent angiogenic factor, VEGF. To minimise the effects of individual HUVEC gene 
expression, 4 cord HUVEC cell isolates were mixed to give a heterogeneous population. 
The cells were grown in a hypoxic incubator (1% O2) for 24 hours at pH 6.8, in glucose 
free media and with VEGF. The RNA was extracted using a Qiagen RNeasy kit and the 
18 and 28s rRNA integrity tested on a 1% gel, which were intact (see Fig. 4.2.1). 
4.3 Up-regulation of the hypoxia related gene, DLL4 
As a control, a gene known to be up-regulated by VEGF and hypoxia [123, 124] is delta-
like 4 (Drosophila), (DLL4). Therefore, to give evidence of a tumour environment 
transcriptome, DLL4 was tested versus a Normoxia control (4% oxygen, Ph 7.4, glucose 
and restricted growth factors 10% FCS). This was done using Quantitative PCR (qPCR), 
using flotillin 2 as a house-keeping gene. The relative expression of DLL4 to the control 
gene FLOT2 in triplicate was quantified and the results are shown in figure 4.3.1. DLL4 
showed up-regulation in tumour conditioned HUVEC (tumour Huvec) versus the normal 
conditioned counterpart and the sample was sent to the University of Edinburgh 
(Genepool) for 3 lanes of Illumina GII, 50bp paired-end RNA-seq transcriptome 
sequencing.  
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Figure 4.2.1 RNA Agarose gel test for mRNA integrity  
 
Figure 4.2.1. This figure shows the results of loading total RNA isolated from Human 
Umbilical Cord samples onto a 1% Agarose gel. High quality and intact mRNA was 
inferred from the clearly visible 18s and 28s rRNA bands.  
Figure 4.3.1 Testing for induction of the hypoxia gene DLL4  
 
Figure 4.3.1. DLL4 was validated as being up-regulated in the tumour conditioned 
HUVEC versus HUVEC cultured under normal conditions (in the presence of glucose, 
reduced growth factors, 4% oxygen and a pH of 7.4).  
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4.4 Collection of normal healthy adult transcriptome libraries 
To contrast the tumour Huvec and hHsec transcriptomes, samples representing normal 
adult healthy tissues were taken from a publication where human splice variants had been 
surveyed [125]. The corresponding author was contacted to ascertain whether the tissues 
originated from normal and healthy adults. This was confirmed and the tissues used here 
were from the brain, cortex, lung, liver, heart and muscle (Sequence Read Archive (SRA) 
accession numbers: Lung = SRR014265, heart = SRR014263, liver = SRR014264, brain 
= SRR036966, cerebral cortex = SRR014262 and muscle = SRR014266).  
4.5 Vascular targets from a Tumour Huvec and hHsec versus 
normal human tissue screen 
An early measure of RNA expression for short read next generation sequencing was 
devised by Mortazavi et al. [126], who invented the term Reads Per Kilobase of exon 
model, per Million reads mapped (RPKM). This measure of gene expression took into 
account differing gene transcript lengths and performed a rough normalizing step as 
RNA-seq libraries were sequenced to different depths (total numbers of reads sequenced). 
Using the Refseq transcriptome as a measure of gene length (the average was taken when 
multiple isoforms were present), RPKM values were calculated for the tumour Huvec, 
hHsec and normal adult tissue libraries to be used in an initial 2nd generation sequencing 
differential gene expression experiment. Fold change to the logarithm base 2 (log2(FC)) 
was used to rank the genes, using the average RPKM of tumour Huvec + hHsec 
compared to the average RPKM of all normal tissues. A log2(FC) ≥ 3 was used as a cut-
off for selecting differentially expressed VT genes versus normal tissues and 753 genes 
were found using this criterion (appendix table A.4.5.1). Please note, 4 of these genes 
have now been removed from the NCBI (LOC100127894, LOC100130764, MIR1274B, 
and MTND4P). The top 252 genes in this list are classed as membrane or extracellular by 
either signal peptide, membrane domain or cellular component from Gene Ontology 
(Entrez Gene). Table 4.5.1 lists the top 33 genes with the highest endothelium enrichment 
versus normal bulk tissues. Several known vascular related targets are listed; MMP1, 
ESM1, ANGPT2 and ANXA1. 
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Table 4.5.1 Potential VT found from the RPKM analyses 
Log2(FC) tumour 
huvec and hHsec 
combined 
 Product Best 
TM 
Signal 
peptide 
13.37 TMSB4X thymosin beta 4, X-linked 0 extracellular 
9.38 ESM1 endothelial cell-specific molecule 1 0 signal 
9.07 MMP1 matrix metallopeptidase 1 (interstitial 
collagenase) 
0 signal 
8.00 SERPINE1 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), 
member 1 
0 signal 
7.62 RELL1 RELT-like 1 2 signal 
7.50 CAPZA1 capping protein (actin filament) muscle Z-
line, alpha 1 
0 extracellular 
7.29 CLIC1 chloride intracellular channel 1 0 membrane 
7.07 THBS1 thrombospondin 1 0 extracellular 
6.98 CLDN11 claudin 11 4 signal 
6.96 AXL AXL receptor tyrosine kinase 1 signal 
6.89 EFEMP1 EGF containing fibulin-like extracellular 
matrix protein 1 
0 signal 
6.83 NUDT19 nudix (nucleoside diphosphate linked 
moiety X)-type motif 19 
0 signal 
6.78 SLC35F2 solute carrier family 35, member F2 9  
6.54 ANGPT2 angiopoietin 2 0 signal 
6.38 PTX3 pentraxin 3, long 0 signal 
6.32 ANXA1 annexin A1 0 extracellular 
6.30 LOXL2 lysyl oxidase-like 2 0 signal 
6.23 SEP15 15 kDa selenoprotein 0 signal 
6.21 MARCKS myristoylated alanine-rich protein kinase C 
substrate 
0 membrane 
6.20 TFPI2 tissue factor pathway inhibitor 2 0 signal 
6.19 CRIM1 cysteine rich transmembrane BMP 
regulator 1 (chordin-like) 
1 signal 
6.12 GDF6 growth differentiation factor 6 0 signal 
6.10 ECSCR endothelial cell-specific chemotaxis 
regulator 
1 signal 
6.09 CTGF connective tissue growth factor 0 signal 
6.07 SULF1 sulfatase 1 0 extracellular 
6.04 HHIP hedgehog interacting protein 0 signal 
6.04 TM4SF18 transmembrane 4 L six family member 18 4 signal 
6.01 MMRN1 multimerin 1 0 membrane 
6.01 EDN1 endothelin 1 0 signal 
5.97 SLC12A2 solute carrier family 12 12 membrane 
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(sodium/potassium/chloride transporters), 
member 2 
5.95 HSPG2 heparan sulfate proteoglycan 2 0 extracellular 
5.89 MGP matrix Gla protein 1 signal 
5.77 MMP10 matrix metallopeptidase 10 (stromelysin 2) 0 Signal 
 
Figure 4.5.1. On this table are the 33 VT's with the highest log2(FC) of endothelium 
versus normal bulk tissues from the RPKM analyses. Several known vascular related 
targets are listed; MMP1, ESM1, ANGPT2 and ANXA1.  
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4.6 Using short read 2nd generation sequencing data to find pan 
Vascular Targets 
Depending on the endothelial environment, different repertoires of genes are being 
expressed. Within different organ tumours, it is hypothesized that both organ specific and 
general vascular genes are being expressed due to the tumour environment of the organ. 
In this study, we sought to find those specifically expressed in a tumour environment of 
multiple tumours. Given general markers of tumour endothelium and the fact that 
endothelium is in contact with blood, gives the opportunity to deliver a multiple tissue 
vascular target drug directly into the blood stream as a general cancer therapeutic. Next 
generation sequencing facilitates snapshots of mRNA repositories in cells types of 
interest. Here we use the in-vitro tumour environment Huvec RNA-seq library combined 
with RNA-seq libraries from tumour endothelial cells freshly isolated from lung, colon 
and bladder tumours using Ulex europaeus agglutinin 1 coupled magnetic beads, to 
identify pan-TEM or pan-VTs.  
 
The RNA-seq paired-end libraries were sequenced on either a SOLiD4 or an Illumina 
sequencing machine. The different samples are listed in the bullet point list below: 
  
 in-vitro; Tumour conditioned Human Umbilical Vein Endothelial Cells (Tumour 
Huvec), Illumina GII sequencing 
 Bead isolated lung tumour endothelium x2 (one SOLiD4 sequenced and the other 
Illumina Hiseq sequenced) 
 Bead isolated lung normal endothelium (SOLiD4) 
 Bead isolated tumour bladder endothelium (SOLiD4) 
 Bead isolated tumour colon endothelium (SOLiD4) 
 Bead isolated normal colon endothelium (SOLiD4) 
 Public domain, bulk lung normal Illumina GI library from an adult human [125] 
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4.7 High quality and intact RNA attained before sequencing 
High quality and intact RNA from endothelial cells was isolated from the fresh tumour 
and normal lung, bladder and colon tissues using Ulex europaeus agglutinin 1 (UEA-1) 
coated magnetic beads.  A schematic diagram of the approach is displayed in figure 4.7.1. 
The high quality of RNA can be seen in figure 4.7.2. The top panel of this figure shows 
the results of an Agilent Bioanalyser, which generates an RNA integrity number (RIN), 
dependent on the quality of RNA, and RIN values ≥ 7 were attained for all samples 
sequenced. To ascertain that successful endothelial cell isolation was occurring during 
extraction, a QPCR test was performed comparing the expression levels of an endothelial 
cell marker in both EC isolates and bulk tissue controls. Significant up-regulation of the 
endothelial marker CD31 (PECAM1) was seen in isolated endothelium versus bulk tissue 
(bottom panel of figure 4.7.2), suggesting high endothelial cell enrichment.  
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Figure 4.7.1 Tumour endothelial cell isolation from lung, bladder and colon 
 
Figure 4.7.1; This figure portrays the procedure used to isolate enriched populations of endothelial cells from bulk tumour tissues 
(same as applied to normal tissues). Fresh tumours were immediately stored on ice and transported to the laboratory for endothelial 
cell isolation using Ulex Europaeus protein coated beads that bind to sugar molecules on the surface of endothelium. 
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Figure 4.7.2 Validation of endothelial cell enrichment and RNA 
integrity 
 
 
Figure 4.7.2. The top panel of this figure portrays the RNA integrity assessed using an 
Agilent Bioanalyser. 18s/28s RNA remained intact following the isolation procedure and 
RIN values ≥ 7 were attained for all samples sequenced. The bar chart shows QPCR 
validation of the enrichment of CD31 expression in bead isolated endothelial cells from 
normal and tumour tissues versus that of bulk tissue. FLOT2 was used as a housekeeping 
control. 
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4.8 Bioinformatics pipeline to analyse RNA-seq data 
Figure 4.8.1 gives a diagrammatical overview of the bioinformatic differential gene 
expression experiments carried out to find putative VT's using short read SOLID4 and 
Illumina Hiseq sequencers. A more detailed protocol is listed in the next bullet list, which 
is based on a Nature Protocol [127].  
 
 First a Gene Transfer Format (GTF) reference file (Refseq GTF) was chosen as a 
reference genome annotation file to guide transcript assemblies [128].   
 To determine fragment sizes of sequenced fragments, bowtie 0.12.7 [102] was run 
in paired end mode and parsed with a Perl program to establish fragment lengths 
and length standard deviations of the different samples.  
 The Tophat algorithm [103], which is able to map reads spanning an intron, was 
run to map all reads from each sample separately onto the human genome, version 
hg19.  
 Each set of mapped reads for all samples were separately assembled into a 
transcriptome using the Cufflinks program (using the Refseq GTF file as a guide) 
from the Cufflinks suite of programs [104].  
 A tumour and normal endothelial transcriptome was then assembled using the 
Cuffmerge program (from Cufflinks) to merge all the different transcript 
assemblies.  
 Differential gene expression was then performed using the Cuffdiff program (also 
from Cufflinks) and output files parsed to find differentially expressed genes, 
novel genes and those with a potential inserted coding exon.  
 
The success statistics of Tophat read mapping are given in table 4.8.1. All libraries were 
paired end reads except for the public SRA data, accession SRR014265. At best, a total 
of 82% of fragments from the Illumina Hiseq library were mapped to the genome, which 
was the RNA-seq library with the longest read length of 101bp. The normal lung 
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endothelium library was the library with the highest percentage (56%) of reads mapped 
using the SOLiD technology (paired end, 50bp and 35bp).  
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Figure 4.8.1 Overview of 2nd generation sequence experiments 
performed 
 
Figure 4.8.1. This figure overviews the experimental design for 7 samples of endothelial 
cells isolated from various organs and sequenced on a mix of 2nd generation sequencing 
technologies. Red and blue ovals depict bead isolated endothelium subject to SOLiD4 
sequencing, orange squares to Illumina Hiseq/GII sequencing and an Illumina GI library 
taken from the Gene Expression Omnibus database (GEO). Note; Tumour HUVEC is 
HUVEC cultured under tumour conditions for 24 hours before library preparation and 
sequencing. 
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Table 4.8.1 Tophat fragment mapping statistics for all RNAseq sample libraries 
Technology Tissue Total fragments Number of 
mapped 
fragments 
% fragments 
mapped 
Read 
length 
Paired or single 
end 
Source 
Illumina GAI Normal bulk 
lung 
25862057 18204695 70 32 single Publication 
SRR014265 
Illumina GAII Tumour 
conditioned 
HUVEC 
24469421 16508654 67 50 - 50 paired Genepool 
Illumina Hiseq Tumour 
Endo Lung 
84197750 69247065 82 101 - 101 paired Genepool 
SOLiD4 Tumour 
Endo colon 
86542525 42402875 49 50 - 35 paired Birmingham 
SOLiD4 Tumour 
Endo lung 
79086167 34649254 44 50 - 35 paired Birmingham 
SOLiD4 Tumour 
Endo 
bladder 
76774924 31875963 42 50 - 35 paired Birmingham 
SOLiD4 Normal Endo 
lung 
84430299 47478222 56 50 - 35 paired Birmingham 
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SOLiD4 Normal Endo 
colon 
79929637 21564021 27 50 - 35 paired Birmingham 
Table 4.8.1. Each RNAseq library was mapped to the human genome (hg19) using Tophat and the number of fragments that mapped 
is given. All libraries were paired end reads except for the public data from the Sequence Read Archive accession number  
SRR014265. At best, a total of 82% of fragments from the Illumina Hiseq library were mapped to the genome, which were the longest 
read length of 101bp. The normal endothelium library from SOLID4 was the library with the highest percentage of reads mapped 
using SOLiD (paired end, 50bp and 35bp). Source = where the sequencing was performed. Publication = Pan et al. [125], Genepool = 
sequencing service at Edinburgh University and Birmingham = Technology hub sequencing and bioinformatics, University of 
Birmingham.
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4.9 Endothelial enrichment in the RNA-seq libraries 
In previous studies that used magnetic coupled antibodies to isolate endothelium, a 
measure of enrichment or endothelial cell purity was made by measuring gene expression 
levels of certain cell type specific genes. For instance, St. Croix et al. divided 8 genes into 
4 groups of two (Selection, Epithelial, Hematopoietic and Endothelial groups) and 
measured the Serial Analysis of Gene Expression (SAGE) library tag abundances for 
each of those genes, verifying their endothelial cell enrichment [69]. As Cuffdiff 
produces a measure of gene expression (FPKM, which is the same as RPKM, except for 
the word fragment is used instead of read; as you get 2 reads per paired end sequenced 
fragment), a similar analyses was carried out; for this a log2 fold change of endothelial 
markers versus markers of other cells was used. The 7 endothelial specific/enriched genes 
were PECAM1, CDH5, MCAM, TIE1, ANPEP, ECSCR and ROBO4 and the markers of 
other cell types: EPCAM, KRT8 and CDH1 as markers of epithelium, CD14, CD68 and 
ITGAM for Hematopoietic markers, and PDGFRA as a marker of pericytes. As can be 
clearly seen in figure 4.9.1, there is significant endothelial enrichment, particularly in the 
tumour Huvec in-vitro model system. Positive log2(fold changes) were also seen for the 
Lung tumour (SOLiD4), Lung Tumour (Illumina), Bladder tumour (SOLiD4) and Lung 
normal (SOLiD4) bead isolated endothelium.  
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Figure 4.9.1 Endothelial cell markers contrasted with markers of other cells 
 
Figure 4.9.1. This figure shows the log2(FPKM fold change ratio) of seven markers of endothelial cells versus seven markers of other 
cell types. The seven endothelial markers were: PECAM1, CDH5, MCAM, TIE1, ANPEP, ECSCR and ROBO4, and the markers 
from other cell types were: EPCAM, KRT8 and CDH1 as markers of epithelium: CD14, CD68 and ITGAM as Hematopoietic 
Markers, and PDGFRA as a marker of pericytes. The in-vitro tumour environment Huvec was found the purest source of endothelial 
cells. The purest bead isolated endothelium were those from the normal lung and bladder tumour tissues. 
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4.10 Differentially expressed, enriched genes in tumour EC  
Differentially expressed genes were sought employing the Cuffdiff algorithm version 
1.3.0, performing five different contrasts as follows; 
 Tumour lung EC (SOLiD4) versus normal lung EC (SOLiD4) 
 Tumour lung EC (Illumina) versus bulk normal lung (Illumina, public) 
 Tumour bladder EC (SOLiD4) versus normal colon EC (SOLiD4) 
 Tumour colon EC (SOLiD4) versus normal colon EC (SOLiD4) 
 Tumour conditioned HUVEC versus bulk normal lung (Illumina, public) 
 
The output of Cuffdiff is a series of files, one of which portrays the differentially 
expressed genes. A criterion was chosen that defined whether a gene was significantly 
differentially expressed; a gene was enriched in tumour endothelial cells if the log2(fold 
change) was ≥ 2 in tumour endothelium versus normal endothelium. For the five 
individual contrasts, the number of differentially expressed genes was as follows:  
 
 Lung tumour EC = 2,477 differentially enriched genes (SOLiD4) 
 Lung tumour EC = 409 differentially enriched genes (Illumina) 
 Bladder tumour EC = 768 differentially enriched genes (SOLiD4) 
 Colon tumour EC = 570 differentially enriched genes (SOLiD4) 
 Tumour Huvec = 215 differentially enriched genes (Illumina) 
 
The full list of genes symbols for the above contrasts can be seen in appendix table 
A.4.10.1, where a total of 3,922 non-redundant genes were enriched in tumour 
endothelium using the log2(FC) ≥ 2 for all 5 contrasts combined.  
4.11 pan-Vascular Target genes; genes enriched in multiple 
contrasts 
Instead of finding tissue specific enriched vascular targets, pan-vascular-targets (pan-VT) 
were identified using a Venn diagram approach. Appendix table A 4.10.1 has a column 
stating the number of contrasts a gene was differentially expressed in, and a Venn 
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diagram in figure 4.11.1 displays the count overlaps. Zero genes were found to be 
enriched in all five contrasts, 3 genes were found in four contrasts, 61 genes in three 
contrasts, 386 genes in two contrasts and the remaining 3,472 in a single contrast. Since, 
from the five contrasts, two were lung endothelial contrasts using different sequencer 
technologies, these were combined to make a four contrast Venn diagram. This approach 
identified a pan-VT for all tissues types contrasted and this gene was Endothelial Specific 
Molecule 1 (ESM1); the Venn results can be seen in figure 4.11.2 where ESM1 was in all 
four contrasts, 23 genes were up-regulated in three contrasts, 358 in two contrasts and 
3,540 genes in a single contrast. ESM1 was the most prominent pan VT found in these 
analyses, which is exemplified when looking at the histogram of reads mapped to the 
ESM1 exons from the RNA-seq data. There is a striking difference between the results of 
tumour (Figure 4.11.3) and normal (Figure 4.11.4) endothelium.  
 
As it is preferable for VT genes to be easily accessible via the blood stream, two tables of 
genes listing VT of multiple contrasts can be viewed in tables 4.11.1 and 4.11.2, which 
list membrane and extracellular putative VT genes respectively.  
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Figure 4.11.1 Venn diagram showing overlaps between all five 
differential gene expression contrasts 
 
 
Figure 4.11.1. Pan-Tumour endothelial enriched or pan-VT genes were sought that had 
log2 fold change of two or more up-regulation in tumour versus normal in multiple 
contrasts. Each coloured circle represents one differential gene expression contrast. A 
total of 3,922 genes were found from all contrasts having log2(FC) ≥ 2. The number of 
genes up-regulated in more than one contrast is as follows: 386 genes were found up-
regulated in two contrasts, 61 genes in three contrasts and 3 genes in four contrasts. There 
were no genes found log2(FC) ≥ 2 for all five contrasts and 3,472 genes were enriched in 
one contrast only. 
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Figure 4.11.2 Venn diagram showing overlaps between four 
differential gene expression contrasts (lung contrasts 
combined) 
 
 
 
Figure 4.11.2. This figure shows the overlapping up-regulated genes with log2(FC) ≥ 2 
from four tissue contrasts. In this figure, the two lung differential gene expression 
experiments were combined to give a single result (the more up-regulated of the two). 
Each coloured circle represents one differential gene expression contrast. Endothelial 
Specific Molecule 1 (ESM1) is the only gene found in all four tissue contrasts and is 
shown to be a pan-VT of all tissue types/organs used in this work. 23 genes were up-
regulated in three contrasts, 358 in two contrasts and 3,540 genes in a single contrast. 
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Figure 4.11.3 ESM1 pan vascular target up-regulated in tumour endothelium of lung, bladder, 
colon and tumour Huvec 
 
Figure 4.11.3; This shows a genomic overview of ESM1 and a histogram of reads mapping to the ESM1 exons. It is evident that this 
gene is highly expressed in tumour endothelium of lung, colon and bladder organs, as well as the tumour conditioned Huvec. 
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Figure 4.11.4 ESM1 pan vascular target very little expression in normal endothelium of lung and 
colon 
 
Figure 4.11.4; In contrast to tumour endothelium, ESM1 expression is almost absent from the normal colon and lung samples.
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Table 4.11.1 Pan-vascular targets; membrane domain containing 
genes that were found enriched in two or more RNA-seq 
contrasts 
No. of 
contrasts 
Gene Product Angio 
log2(FC) 
Endo 
log2(FC) 
Class 
2 MYCT1 myc target 1 4.97 8.47 M 
3 FJX1 four jointed box 1 (Drosophila) 2.04 -0.43 M 
3 TNFRSF10D tumor necrosis factor receptor superfamily, 
member 10d, decoy with truncated death 
domain 
3.17 -1.87 M 
2 GP1BB glycoprotein Ib (platelet), beta polypeptide 7.83  M 
2 GLCE glucuronic acid epimerase 0.61 6.73 M 
2 SELE selectin E 0.02 6.08 M 
2 DLL4 delta-like 4 (Drosophila) 0.39 3.7 M 
2 INSR insulin receptor -0.57 4.3 M 
2 DTNA dystrobrevin, alpha 0.88 2.72 M 
2 GPR143 G protein-coupled receptor 143 0.84 2.31 M 
2 VMP1 vacuole membrane protein 1 0 2.64 M 
2 TMEM41A transmembrane protein 41A 0.29 1.98 M 
2 FCGR2A Fc fragment of IgG, low affinity IIa, receptor 
(CD32) 
0.25 1.75 M 
2 CLDN3 claudin 3 1.3  M 
2 PAQR7 progestin and adipoQ receptor family 
member VII 
-0.01 1.23 M 
2 GPX8 glutathione peroxidase 8 (putative) -0.94 2.04 M 
2 FAM171A1 family with sequence similarity 171, member 
A1 
-0.7 1.75 M 
2 UPK1B uroplakin 1B -0.8 1.55 M 
2 ADAM12 ADAM metallopeptidase domain 12 1.82 -1.71 M 
2 MAL2 mal, T-cell differentiation protein 2 
(gene/pseudogene) 
1.49 -3.61 M 
2 GPRC5A G protein-coupled receptor, family C, group 
5, member A 
1.07 -3.88 M 
2 MS4A1 membrane-spanning 4-domains, subfamily A, 
member 1 
1.26 -6.1 M 
3 DARC Duffy blood group, chemokine receptor -0.03  M 
3 BIRC6 baculoviral IAP repeat containing 6 -0.18 -0.21 M 
3 S1PR3 sphingosine-1-phosphate receptor 3 0.76 -1.66 M 
3 BAMBI BMP and activin membrane-bound inhibitor 
homolog (Xenopus laevis) 
0.29 -1.68 M 
3 CD200 CD200 molecule 0.29 -2.64 M 
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3 ERRFI1 ERBB receptor feedback inhibitor 1 -1.47 -2.06 M 
3 GALNT14 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-
T14) 
-0.89 -3.04 M 
3 CLDN1 claudin 1 -0.78 -8.23 M 
3 TMEM27 transmembrane protein 27 -5.09 -7.59 M 
2 GRIN2D glutamate receptor, ionotropic, N-methyl D-
aspartate 2D 
0.02 0.82 M 
2 CXorf61 chromosome X open reading frame 61  0.82 M 
2 NOX5 NADPH oxidase, EF-hand calcium binding 
domain 5 
0.79  M 
2 PROM2 prominin 2 -0.22 0.82 M 
2 F2R coagulation factor II (thrombin) receptor -0.16 0.65 M 
2 SLC4A11 solute carrier family 4, sodium borate 
transporter, member 11 
-0.44 0.82 M 
2 CXCL9 chemokine (C-X-C motif) ligand 9 0.2  M 
2 PROCR protein C receptor, endothelial 0.4 -0.36 M 
2 GPR157 G protein-coupled receptor 157   M 
2 TMEM116 transmembrane protein 116 -0.99 0.82 M 
2 TSPAN6 tetraspanin 6 -0.49 0.21 M 
2 SLC16A1 solute carrier family 16, member 1 
(monocarboxylic acid transporter 1) 
-0.01 -0.55 M 
2 MPZL3 myelin protein zero-like 3 -0.7  M 
2 SLC39A4 solute carrier family 39 (zinc transporter), 
member 4 
-1.08  M 
2 FOLH1 folate hydrolase (prostate-specific 
membrane antigen) 1 
-1.18  M 
2 C20orf24 chromosome 20 open reading frame 24 0.35 -1.78 M 
2 CXCR7 chemokine (C-X-C motif) receptor 7 -0.04 -1.68 M 
2 CLDN10 claudin 10 -1.44 -0.42 M 
2 F2RL1 coagulation factor II (thrombin) receptor-like 
1 
-0.17 -1.8 M 
2 MUC20 mucin 20, cell surface associated 0.26 -2.24 M 
2 TPBG trophoblast glycoprotein -0.05 -2.42 M 
2 ADRA2B adrenergic, alpha-2B-, receptor -2.6  M 
2 SDC4 syndecan 4 -1.65 -0.96 M 
2 GDPD5 glycerophosphodiester phosphodiesterase 
domain containing 5 
-0.25 -2.64 M 
2 KCTD11 potassium channel tetramerisation domain 
containing 11 
-0.44 -2.64 M 
2 ABCG2 ATP-binding cassette, sub-family G (WHITE), 
member 2 
0.39 -3.61 M 
2 SLC6A8 solute carrier family 6 (neurotransmitter 
transporter, creatine), member 8 
0.26 -3.61 M 
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2 IER3 immediate early response 3 -0.19 -3.37 M 
2 DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 
4 
-1.31 -3.57 M 
2 RASL11B RAS-like, family 11, member B 0.61 -7.03 M 
2 CEACAM6 carcinoembryonic antigen-related cell 
adhesion molecule 6 (non-specific cross 
reacting antigen) 
0.97 -7.59 M 
2 ITGB6 integrin, beta 6 0.79 -7.59 M 
2 C3orf52 chromosome 3 open reading frame 52 -0.29 -7.03 M 
2 CLCA2 chloride channel accessory 2 -1.02 -7.03 M 
2 MUC1 mucin 1, cell surface associated 0.72 -9.56 M 
2 CLDN4 claudin 4 -0.92 -9.3 M 
2 TACSTD2 tumor-associated calcium signal transducer 2 -0.83 -9.67 M 
2 RNF128 ring finger protein 128 -0.36 -11.21 M 
Table 4.11.1; There were 69 genes predicted to have transmembrane domains that were  
enriched in tumour endothelium from two or more contrasts.  
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Table 4.11.2 Pan-vascular targets; secreted/extracellular genes 
that were found enriched in two or more RNA-seq contrasts 
No. of 
contrasts 
Gene Product Angio 
log2(FC) 
Endo 
log2(FC) 
Class 
3 MMP1 matrix metallopeptidase 1 (interstitial 
collagenase) 
1.38 12.12 E 
3 ANGPT2 angiopoietin 2 2.32 10.68 E 
3 MMP10 matrix metallopeptidase 10 (stromelysin 
2) 
1.14 7.45 E 
2 ADAMTS6 ADAM metallopeptidase with 
thrombospondin type 1 motif, 6 
6.22 5.01 E 
2 ADAMTS18 ADAM metallopeptidase with 
thrombospondin type 1 motif, 18 
6.22 4.5 E 
2 PTX3 pentraxin 3, long 6.33 1.98 E 
2 CCL20 chemokine (C-C motif) ligand 20 3.4 4.15 E 
2 COL15A1 collagen, type XV, alpha 1 1.2 4.15 E 
4 ESM1 endothelial cell-specific molecule 1 0.26 8.35 E 
3 COL10A1 collagen, type X, alpha 1 4.97  E 
3 SAA2-SAA4 SAA2-SAA4 readthrough 2.76  E 
3 COL11A1 collagen, type XI, alpha 1 1.48  E 
3 LOXL2 lysyl oxidase-like 2 2.15 -1.8 E 
3 PGF placental growth factor 3.08 -3.57 E 
3 MMP11 matrix metallopeptidase 11 (stromelysin 
3) 
2.66 -7.03 E 
2 MMRN1 multimerin 1 0.97 9.54 E 
2 APLN apelin 0.78 7.75 E 
2 CST1 cystatin SN 7.43  E 
2 CRLF1 cytokine receptor-like factor 1 6.87  E 
2 DKK2 dickkopf homolog 2 (Xenopus laevis) 4.97  E 
2 TNF tumor necrosis factor 3.69  E 
2 KLK12 kallikrein-related peptidase 12 3.69  E 
2 IL1B interleukin 1, beta 5.45 -2.64 E 
2 INS-IGF2 INS-IGF2 readthrough 2.76  E 
2 S100A8 S100 calcium binding protein A8 -0.26 2.84 E 
2 EREG epiregulin -1.23 3.29 E 
2 FAM3B family with sequence similarity 3, 
member B 
1.94  E 
2 S100A11 S100 calcium binding protein A11 0.41 1.47 E 
2 SERPINE1 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), 
member 1 
-1.05 2.83 E 
2 LYPD6B LY6/PLAUR domain containing 6B 1.77  E 
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2 ULBP2 UL16 binding protein 2 1.51 0.05 E 
2 C2CD4A C2 calcium-dependent domain containing 
4A 
1.41 -0.17 E 
2 SFRP2 secreted frizzled-related protein 2 1.14  E 
2 CRTAC1 cartilage acidic protein 1 1.12  E 
2 MMP2 matrix metallopeptidase 2 (gelatinase A, 
72kDa gelatinase, 72kDa type IV 
collagenase) 
1.41 -1.02 E 
2 F2RL2 coagulation factor II (thrombin) receptor-
like 2 
-2.45 1.75 E 
2 IGF2 insulin-like growth factor 2 (somatomedin 
A) 
2.86 -3.92 E 
2 PLXDC1 plexin domain containing 1 1.79 -3.2 E 
2 PRG2 proteoglycan 2, bone marrow (natural 
killer cell activator, eosinophil granule 
major basic protein) 
4.65 -7.59 E 
2 EGFL6 EGF-like-domain, multiple 6 2.98 -7.03 E 
2 INHBB inhibin, beta B 1.7 -6.1 E 
2 NOV nephroblastoma overexpressed gene 1.44 -8.31 E 
2 COL1A1 collagen, type I, alpha 1 1.71 -9.18 E 
2 MMP12 matrix metallopeptidase 12 (macrophage 
elastase) 
2.63 -11.05 E 
4 IL8 interleukin 8 -0.23 -1.71 E 
3 HSPH1 heat shock 105kDa/110kDa protein 1 -0.36 0.23 E 
3 SERPINE2 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), 
member 2 
0.53 -2.03 E 
3 BPIFA1 BPI fold containing family A, member 1 -1.53  E 
3 C9orf47 chromosome 9 open reading frame 47 -2.26 -6.1 E 
3 GDF15 growth differentiation factor 15 0.38 -9.3 E 
3 SPP1 secreted phosphoprotein 1 -1.19 -9.16 E 
2 DEFB1 defensin, beta 1 0.81 0.82 E 
2 CEACAM5 carcinoembryonic antigen-related cell 
adhesion molecule 5 
0.45 0.82 E 
2 IGFBP7 insulin-like growth factor binding protein 
7 
0.64 0.17 E 
2 NMB neuromedin B 0.61  E 
2 EFNA1 ephrin-A1 0.27 0.26 E 
2 SFRP4 secreted frizzled-related protein 4 0.15  E 
2 PRSS22 protease, serine, 22 0.13  E 
2 INS insulin   E 
2 MAGEA9B melanoma antigen family A, 9B   E 
2 TGIF2-
C20ORF24 
TGIF2-C20orf24 readthrough   E 
2 CILP2 cartilage intermediate layer protein 2   E 
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2 HTRA3 HtrA serine peptidase 3 -0.06  E 
2 AGT angiotensinogen (serpin peptidase 
inhibitor, clade A, member 8) 
-0.11  E 
2 BOLA1 bolA homolog 1 (E. coli) -0.13  E 
2 HTRA1 HtrA serine peptidase 1 0.27 -0.51 E 
2 ANGPTL4 angiopoietin-like 4 0.38 -0.74 E 
2 IL23A interleukin 23, alpha subunit p19 -0.44  E 
2 CXCL17 chemokine (C-X-C motif) ligand 17 -0.7  E 
2 PPIA peptidylprolyl isomerase A (cyclophilin A) 0.12 -0.92 E 
2 INHBA inhibin, beta A 0.29 -1.23 E 
2 HSPD1 heat shock 60kDa protein 1 (chaperonin) 0.84 -1.9 E 
2 HSPG2 heparan sulfate proteoglycan 2 0.15 -1.28 E 
2 IL11 interleukin 11 -0.13 -1.36 E 
2 ADM adrenomedullin -0.37 -1.3 E 
2 BAIAP3 BAI1-associated protein 3 -1.69  E 
2 STC1 stanniocalcin 1 -1.82 -0.08 E 
2 PDGFD platelet derived growth factor D -0.23 -2.24 E 
2 C1orf63 chromosome 1 open reading frame 63 0.03 -2.64 E 
2 IL1RN interleukin 1 receptor antagonist -0.06 -2.64 E 
2 S100A9 S100 calcium binding protein A9 0.8 -6.1 E 
2 IGFBP3 insulin-like growth factor binding protein 
3 
0.31 -6.13 E 
2 ACP6 acid phosphatase 6, lysophosphatidic -0.17 -6.1 E 
2 EPOR erythropoietin receptor 0.68 -7.03 E 
2 VWA1 von Willebrand factor A domain 
containing 1 
0.65 -7.03 E 
2 SAA2 serum amyloid A2 -0.62 -6.1 E 
2 EGFLAM EGF-like, fibronectin type III and laminin G 
domains 
-0.63 -6.1 E 
2 ANXA8 annexin A8 -1.26 -6.1 E 
2 SPESP1 sperm equatorial segment protein 1 0.42 -8 E 
2 S100A2 S100 calcium binding protein A2 -0.91 -7.03 E 
2 CXCL3 chemokine (C-X-C motif) ligand 3 -1.85 -6.1 E 
2 RNF215 ring finger protein 215 -2.24 -6.1 E 
2 GDF3 growth differentiation factor 3 -5.66 -3.04 E 
2 SFN stratifin 0.67 -9.56 E 
2 LTF lactotransferrin -0.37 -8.57 E 
2 SAA1 serum amyloid A1 -3 -6.1 E 
2 SAA4 serum amyloid A4, constitutive -2.36 -7.03 E 
2 AZGP1 alpha-2-glycoprotein 1, zinc-binding -1.58 -8.79 E 
2 SPOCK3 sparc/osteonectin, cwcv and kazal-like 
domains proteoglycan (testican) 3 
-4.38 -7.59 E 
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Table 4.11.2; 99 extracellular/secreted protein genes were significantly enriched in two 
or more contrasts, which included ESM1 that was enriched in all four organ tumours 
tested. It also included genes that had been previously reported as tumour angiogenesis 
markers: ANGPT2, IGFBP7, IL8, PLXDC1, EREG, MMP1 and MMP2.  
 
4.12 pan-Vascular Targets Biological Process functional 
enrichment 
To investigate any functional representational groups within the 450 genes that were 
found enriched in tumour endothelium in two or more contrasts, the Database for 
Annotation, Visualization and Integrated Discovery (DAVID, [129]) was used, selecting 
Gene Ontology, Biological Process. This identified biological processes such as blood 
vessel/vascular development, angiogenesis, response to wounding, regulation of cellular  
proliferation, ectoderm/epidermis development and regulation of cytokine production. 
Table 4.12.1 has the full list of the 26 enriched functional categories, with an FDR ≤ 2%.
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Table 4.12.1 Functional enrichment of 450 genes, tumour endothelial enriched for two or more 
contrasts 
GO Biological Process Term Genes Count % P-Value Benjamini FDR 
response to wounding DARC, ELF3, S100A8, S100A9, ADM, ANXA8, 
CCL20, CXCL3, CXCL9, F2R, F2RL1, F2RL2, 
CCNB1, CYP1A1, EREG, GP1BB, IGF2, INS-IGF2, 
ITGB6, IL1RN, IL1B, IL11, , IL8, MAP1B, MMRN1, 
PTX3, PROCR, SPP1, SELE, SERPINE1, SAA1, 
SAA2, SAA4, SPRR3, S1PR3, TNF 
36 8.4 1.40E-08 3.10E-05 
ectoderm development ELF3, SOX9, COL1A1, EVPL, EREG, FOXQ1, IRF6, 
KRT13, KRT14, KRT15, KRT16, KRT17, KRT5, 
KRT6A, LEF1, OVOL1, PTGS2, SPRR1A, SPRR3, 
SFN 
20 4.7 1.40E-07 1.50E-04 
epidermis development ELF3, SOX9, COL1A1, EVPL, EREG, FOXQ1, IRF6, 
KRT13, KRT14, KRT15, KRT16, KRT17, KRT5, 
LEF1, OVOL1, PTGS2, SPRR1A, SPRR3, SFN 
19 4.4 2.10E-07 1.50E-04 
regulation of cell proliferation BNIPL, CEBPA, KLF5, NKX3-1, S100A11, 
SERTAD1, SOX9, ADM, AZGP1, AGT, BIRC6, F2R, 
CDKN2D, CDKN3, DHRS2, DLX5, EREG, GAS8, 
HES1, HHEX, INSR, IGFBP3, IGFBP7, IRF6, IL1B, 
IL11, IL8, KRT5, KRT6A, MCTS1, MMP12, PNP, 
PPARG, PGF, KCTD11, PTGS2, SCIN, SERPINE1, 
S1PR3, SFN, TNF, MYCN 
43 10 2.10E-07 1.20E-04 
response to vitamin CDKN2D, CYP1A1, CYP24A1, INSR, IGFBP7, IL1B, 
MEST, MAP1B, MUC1, PPARG, PTGS2, SPP1 
12 2.8 2.50E-07 1.10E-04 
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response to nutrient UGT1A9, UGT1A10, UGT1A4, UGT1A6, UGT1A8, 
UGT1A7, UGT1A3, UGT1A1, UGT1A5, COL1A1, 
CDKN2D, CYP1A1, CYP24A1, INSR, IGFBP7, IL1B, 
MEST, MAP1B, MUC1, PPARG, PTGS2, SPP1, 
STC1 
15 3.5 3.70E-06 1.30E-03 
negative regulation of cell proliferation BNIPL, CEBPA, NKX3-1, S100A11, ADM, AZGP1, 
AGT, F2R, CDKN2D, CDKN3, DHRS2, EREG, 
GAS8, IGFBP3, IGFBP7, IRF6, IL1B, IL8, KRT5, 
PPARG, PTGS2, SCIN, SFN, TNF 
24 5.6 8.80E-06 2.70E-03 
inflammatory response DARC, ELF3, S100A8, S100A9, CCL20, CXCL3, 
CXCL9, F2R, ITGB6, IL1RN, IL1B, IL23A, IL8, 
PTX3, SPP1, SELE, SAA1, SAA2, SAA4, S1PR3, 
TNF 
22 5.1 1.80E-05 4.80E-03 
response to vitamin D CDKN2D, CYP24A1, INSR, IL1B, PTGS2, SPP1 6 1.4 2.10E-05 5.10E-03 
defense response DARC, ELF3, S100A8, S100A9, CCL20, CXCL3, 
CXCL9, F2R, CCNL2, DEFB1, HIST1H2BG, 
HIST2H2BE, INHBA, INHBB, ITGB6, IL1RN, IL1B, 
IL23A, IL8, LTF, BPIFA1, PTX3, PPARG, PRG2, 
SPP1, SELE, SAA1, SAA2, SAA4, S1PR3, TNF 
32 7.5 2.90E-05 6.20E-03 
wound healing ANXA8, F2R, F2RL1, F2RL2, CCNB1, EREG, 
GP1BB, IGF2, IL1B, IL11, MMRN1, PROCR, 
SERPINE1, SAA1, SAA2, SPRR3 
16 3.7 3.20E-05 6.20E-03 
regulation of growth BNIPL, HTRA1, HTRA3, SERTAD1, TSPYL2, AGT, 
CDKN2D, ESM1, FOXS1, GDF3, INHBA, INSR, 
IGF2, IGFBP3, IGFBP7, MCTS1, MAP1B, NOV, 
PPARG, KCTD11, SPP1, SFN 
22 5.1 3.60E-05 6.50E-03 
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regulation of cell growth HTRA1, HTRA3, SERTAD1, TSPYL2, AGT, 
CDKN2D, ESM1, INHBA, IGF2, IGFBP3, IGFBP7, 
MAP1B, NOV, PPARG, SPP1, SFN 
16 3.7 3.80E-05 6.30E-03 
response to extracellular stimulus UGT1A9, ADM, COL1A1, CDKN2D, CYP1A1, 
CYP24A1, INSR, IGFBP7, IL1B, MEST, MAP1B, 
MUC1, PPARG, PTGS2, SFRP2, SPP1, STC1 
17 4 4.40E-05 6.90E-03 
response to nutrient levels UGT1A9, ADM, COL1A1, CDKN2D, CYP1A1, 
CYP24A1, INSR, IGFBP7, IL1B, MEST, MAP1B, 
MUC1, PPARG, PTGS2, SPP1, STC1 
16 3.7 4.50E-05 6.50E-03 
blood vessel development KLF5, LMO2, ADRA2B, ANGPT2, ANGPTL4, AGT, 
ANXA2P3, CXCL17, COL1A1, COL15A1, DLL4, 
EREG, IL1B, IL8, JMJD6, MMP2, PGF, PLXDC1 
18 4.2 4.70E-05 6.30E-03 
vasculature development KLF5, LMO2, ADRA2B, ANGPT2, ANGPTL4, AGT, 
ANXA2P3, CXCL17, COL1A1, COL15A1, DLL4, 
EREG, IL1B, IL8, JMJD6, MMP2, PGF, PLXDC1 
18 4.2 6.30E-05 8.00E-03 
regulation of cytokine production AGT, F2R, EREG, HSPD1, INHBA, INHBB, IGF2, 
IGF2BP3, IL1B, PPARG, RNF128, SAA1, SAA2, 
S1PR3, TNF 
15 3.5 6.90E-05 8.30E-03 
epithelial cell differentiation ELF3, AGT, DLX5, EVPL, EREG, IRF6, KRT14, 
KRT5, PPARG, SPRR1A, SPRR3, SFN, UPK1B 
13 3 6.90E-05 7.80E-03 
regulation of response to external stimulus AGT, ANXA2P3, F2R, F2RL1, GPX2, IGF2, IL8, 
PPARG, PTGS2, SPP1, SELE, SERPINE1, SAA1, 
SAA2 
14 3.3 7.00E-05 7.60E-03 
blood coagulation ANXA8, F2R, F2RL1, F2RL2, GP1BB, IL11, 
MMRN1, PROCR, SERPINE1, SAA1, SAA2 
11 2.6 1.10E-04 1.10E-02 
Coagulation ANXA8, F2R, F2RL1, F2RL2, GP1BB, IL11, 
MMRN1, PROCR, SERPINE1, SAA1, SAA2 
11 2.6 1.10E-04 1.10E-02 
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bone development SOX9, COL1A1, CYP24A1, FHL2, HSPG2, IGF2, 
IGFBP3, JUND, MMP2, PTGS2, SPP1, STC1 
12 2.8 1.10E-04 1.10E-02 
Angiogenesis KLF5, ADRA2B, ANGPT2, ANGPTL4, ANXA2P3, 
CXCL17, COL15A1, DLL4, EREG, IL1B, IL8, PGF, 
PLXDC1 
13 3 1.40E-04 1.40E-02 
Hemostasis ANXA8, F2R, F2RL1, F2RL2, GP1BB, IL11, 
MMRN1, PROCR, SERPINE1, SAA1, SAA2 
11 2.6 1.70E-04 1.60E-02 
regulation of cell cycle CKS2, H2AFX, SERTAD1, TSPYL2, ANLN, CDK1, 
CCNB1, CDKN2D, CDKN3, CYP1A1, EREG, 
INHBA, INSR, IGF2, IL1B, PIM3, PTGS2, SFN, 
TNF, UBE2C 
20 4.7 2.10E-04 1.80E-02 
Table 4.12.1; This table lists the top 26 GO Biological Processes, functional enrichment categories found to be enriched in the 450 
genes found up-regulated in tumour endothelium with greater or equal to two contrasts. Functional enrichment was seen for processes 
relating to tumour/tissue growth and tumour angiogenesis. 
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4.13 Genes with published links to tumour angiogenesis 
To test for known involvement in tumour and/or angiogenesis, an AngioScore term was 
derived by keyword matching in abstract searches of the 3,922 genes found (the same as 
performed in the cDNA library chapter). The full list of results can be found in appendix 
table A.4.13.1 and the top 39 genes with the highest AngioScore of ≥ 60 are shown in 
table 4.13.1. 
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Table 4.13.1 39 RNA-seq contrast genes with the highest 
AngioScore 
Gene Number of 
contrasts 
Product Class Angio 
Score 
DLEU2L 1 deleted in lymphocytic leukemia 2-like intracellular 100 
LOC613037 1 nuclear pore complex interacting protein 
pseudogene 
intracellular 100 
CHEK2P2 1 checkpoint kinase 2 pseudogene 2 intracellular 100 
VEGFA 1 vascular endothelial growth factor A extracellular 95 
VEGFC 1 vascular endothelial growth factor C extracellular 93 
HIF1A 1 hypoxia inducible factor 1, alpha subunit 
(basic helix-loop-helix transcription factor) 
intracellular 90 
EDN1 1 endothelin 1 extracellular 87 
PROCR 2 protein C receptor, endothelial membrane 80 
HIC1 2 hypermethylated in cancer 1 intracellular 79 
VEGFB 1 vascular endothelial growth factor B extracellular 76 
IRAK1BP1 1 interleukin-1 receptor-associated kinase 1 
binding protein 1 
intracellular 75 
NOS3 1 nitric oxide synthase 3 (endothelial cell) intracellular 74 
CA9 1 carbonic anhydrase IX intracellular 74 
VASH1 1 vasohibin 1 extracellular 73 
COL18A1 1 collagen, type XVIII, alpha 1 extracellular 70 
VCAM1 1 vascular cell adhesion molecule 1 membrane 70 
CD248 1 CD248 molecule, endosialin membrane 70 
PTTG1 1 pituitary tumor-transforming 1 intracellular 69 
PGF 3 placental growth factor extracellular 68 
ESM1 4 endothelial cell-specific molecule 1 extracellular 68 
ANGPT2 3 angiopoietin 2 extracellular 66 
PDPN 1 podoplanin membrane 66 
MCAM 1 melanoma cell adhesion molecule membrane 65 
LIPG 1 lipase, endothelial extracellular 65 
TNFRSF12A 1 tumor necrosis factor receptor 
superfamily, member 12A 
membrane 65 
MIR210 1 microRNA 210 intracellular 65 
PTK6 1 PTK6 protein tyrosine kinase 6 intracellular 64 
NUAK1 1 NUAK family, SNF1-like kinase, 1 intracellular 64 
IGFBP7 2 insulin-like growth factor binding protein 7 extracellular 63 
TRAF5 1 TNF receptor-associated factor 5 intracellular 63 
MAGEA4 1 melanoma antigen family A, 4 extracellular 63 
MIR126 1 microRNA 126 intracellular 63 
MEN1 1 multiple endocrine neoplasia I intracellular 62 
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TNF 2 tumor necrosis factor extracellular 60 
EGFL7 1 EGF-like-domain, multiple 7 extracellular 60 
MAGEA2 1 melanoma antigen family A, 2 extracellular 60 
CCDC34 1 coiled-coil domain containing 34 intracellular 60 
MIR650 1 microRNA 650 intracellular 60 
DLL4 2 delta-like 4 (Drosophila) membrane 60 
Table 4.13.1; This table ranks RNA-seq enriched genes based on the AngioScore. 39 
genes were found to have an AngioScore ≥ 60.  
 
4.14 RNA-seq, ranking by a cDNA endothelial screen 
RNA-seq tumour endothelial enriched genes were cross checked with endothelial screen 
results from the cDNA library analyses. The aim of this was to best target the genes that 
are most likely expressed by endothelial cells. The results can be seen in table 4.14.1, 
which shows 35 RNA-seq endothelial enriched genes based on cDNA library analyses 
results of log2(FC) ≥ 6 enriched in endothelial cells. Notably, 9 of these genes were also 
found in more than one RNA-seq contrast. 
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Table 4.14.1 Ranking RNA-seq genes with a cDNA endothelial 
cell expression evidence 
Gene Number of 
contrasts 
Product Endothelial 
log2(FC) 
MMP1 3 matrix metallopeptidase 1 (interstitial collagenase) 12.12 
ANGPT2 3 angiopoietin 2 10.68 
CLDN11 1 claudin 11 10.65 
FLJ41200 1 hypothetical LOC401492 9.89 
MMRN1 2 multimerin 1 9.54 
HHIP 1 hedgehog interacting protein 9.22 
LINC00152 1 long intergenic non-protein coding RNA 152 9.21 
MYCT1 2 myc target 1 8.47 
ESM1 4 endothelial cell-specific molecule 1 8.35 
ATP5H 1 ATP synthase, H+ transporting, mitochondrial Fo 
complex, subunit d 
8.31 
ELTD1 1 EGF, latrophilin and seven transmembrane domain 
containing 1 
7.99 
APLN 2 Apelin 7.75 
RHOJ 1 ras homolog gene family, member J 7.74 
PLK1S1 1 polo-like kinase 1 substrate 1 7.65 
B3GALTL 1 beta 1,3-galactosyltransferase-like 7.57 
MMP10 3 matrix metallopeptidase 10 (stromelysin 2) 7.45 
NUDT19 1 nudix (nucleoside diphosphate linked moiety X)-type 
motif 19 
7.4 
GIPC2 1 GIPC PDZ domain containing family, member 2 7.19 
C3orf58 1 chromosome 3 open reading frame 58 7.13 
LPAR6 1 lysophosphatidic acid receptor 6 7.04 
BMX 1 BMX non-receptor tyrosine kinase 7.02 
GALNTL2 1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2 
7.01 
LRRC70 1 leucine rich repeat containing 70 6.93 
CRIM1 1 cysteine rich transmembrane BMP regulator 1 (chordin-
like) 
6.87 
GLCE 2 glucuronic acid epimerase 6.73 
MMRN2 1 multimerin 2 6.71 
ZNF521 1 zinc finger protein 521 6.61 
LAMP3 1 lysosomal-associated membrane protein 3 6.57 
TMEM59L 1 transmembrane protein 59-like 6.52 
CLEC14A 1 C-type lectin domain family 14, member A 6.18 
SELE 2 selectin E 6.08 
MIER1 1 mesoderm induction early response 1 homolog 6.08 
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(Xenopus laevis) 
TM6SF1 1 transmembrane 6 superfamily member 1 6.08 
LOC10050
7254 
1 hypothetical LOC100507254 6.04 
TNFSF4 1 tumor necrosis factor (ligand) superfamily, member 4 6.01 
Table 4.14.1; 35 endothelial enriched genes based on cDNA library analyses results of 
log2(FC) ≥ 6 enriched in endothelial cells. 9 of these genes were also found in more than 
one RNA-seq contrast. 
 
4.15 RNA-seq, ranking by a cDNA angiogenic screen 
RNA-seq tumour endothelial enriched genes were cross checked with 
foetal/tumour/angiogenic screen results from the cDNA library analyses. This screen 
aimed to dissect out any contaminating normal tissue expressed gene passengers found in 
the RNA-seq results. The results of this can be seen in table 4.15.1, which shows 45 
foetal/tumour/angiogenic enriched genes based on cDNA library analyses results of 
log2(FC) >= 5 enriched in foetal/tumour/angiogenic bulk tissues versus normal bulk 
tissues. 8 of these genes were also found in more than one RNA-seq contrast. 
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Table 4.15.1 Ranking RNA-seq genes with a cDNA 
angiogenic/tumour expression evidence 
Gene No. of 
RNA-seq 
contrasts 
Product Angio 
log2(FC) 
HBG1 1 hemoglobin, gamma A 8.21 
GP1BB 2 glycoprotein Ib (platelet), beta polypeptide 7.83 
TUBB2B 1 tubulin, beta 2B 7.58 
MMP9 1 matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) 
7.48 
CST1 2 cystatin SN 7.43 
SLC35D3 1 solute carrier family 35, member D3 7.21 
ETV4 1 ets variant 4 7.15 
FCGR1A 1 Fc fragment of IgG, high affinity Ia, receptor (CD64) 7.09 
SEMA5B 1 sema domain, seven thrombospondin repeats (type 1 
and type 1-like), transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 5B 
7.09 
TROAP 1 trophinin associated protein (tastin) 6.87 
CRLF1 2 cytokine receptor-like factor 1 6.87 
AURKB 1 aurora kinase B 6.72 
ZCCHC18 1 zinc finger, CCHC domain containing 18 6.54 
FAM83D 2 family with sequence similarity 83, member D 6.44 
LDLRAD3 1 low density lipoprotein receptor class A domain 
containing 3 
6.44 
PTX3 2 pentraxin 3, long 6.33 
ADAMTS6 2 ADAM metallopeptidase with thrombospondin type 1 
motif, 6 
6.22 
ADAMTS18 2 ADAM metallopeptidase with thrombospondin type 1 
motif, 18 
6.22 
KIF20A 1 kinesin family member 20A 6.22 
IVL 1 Involucrin 6.22 
HOXB2 1 homeobox B2 5.96 
FABP6 1 fatty acid binding protein 6, ileal 5.96 
ZNF134 1 zinc finger protein 134 5.81 
DLGAP5 1 discs, large (Drosophila) homolog-associated protein 5 5.81 
CECR2 1 cat eye syndrome chromosome region, candidate 2 5.81 
PCDHB4 1 protocadherin beta 4 5.81 
DLX2 1 distal-less homeobox 2 5.81 
LHX6 1 LIM homeobox 6 5.64 
GPR84 1 G protein-coupled receptor 84 5.64 
PCDHB10 1 protocadherin beta 10 5.64 
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ZMYND19 1 zinc finger, MYND-type containing 19 5.64 
MIR612 1 microRNA 612 5.64 
MARCH4 1 membrane-associated ring finger (C3HC4) 4 5.45 
IL1B 2 interleukin 1, beta 5.45 
BMP8B 1 bone morphogenetic protein 8b 5.45 
NCKAP5L 1 NCK-associated protein 5-like 5.45 
NHLH2 1 nescient helix loop helix 2 5.45 
S100A7 1 S100 calcium binding protein A7 5.45 
POU5F1B 1 POU class 5 homeobox 1B 5.45 
AKIRIN2-AS1 1 AKIRIN2 antisense RNA 1 (non-protein coding) 5.45 
DAPL1 1 death associated protein-like 1 5.45 
EPHX4 1 epoxide hydrolase 4 5.45 
CDC25A 1 cell division cycle 25 homolog A (S. pombe) 5.23 
TLX1 1 T-cell leukemia homeobox 1 5.23 
PI3 1 peptidase inhibitor 3, skin-derived 5.12 
Table 4.15.1; Ranking RNA-seq 2nd generation sequence data using angiogenic/tumour 
cDNA screen. 45 genes with an angiogenic screen results of log2(FC) ≥ 5 enriched in 
foetal/angiogenic/tumour bulk tissues versus normal bulk tissues were found. 8 of these 
genes were also found in more than one RNA-seq contrast. 
4.16 RNA-seq, ranking by combined endothelial and angiogenic 
cDNA library screens 
In the previous two analyses, the cDNA library screens of endothelial cells versus normal 
non-endothelial cells and the foetal/tumour/angiogenic bulk tissues versus normal bulk 
tissues were independently scrutinised to produce rankings of the RNA-seq contrast 
results. In this third approach, both cDNA libraries screens were combined to produce a 
tumour endothelial confirmed approach. So not only are genes putatively enriched in 
freshly isolated tumour endothelium, they are also up-regulated in both endothelial cells 
and foetal/tumour/angiogenic tissues from the cDNA library analyses. The results of this 
third incorporation of cDNA libraries can be seen in table 4.16.1 (in both endothelial and 
foetal cDNA screens, only a minimum log2(FC) ≥ 1 was considered). 126 genes were 
found using this criterion. 15 of these genes were found to be tumour enriched in more 
than on RNA-seq contrast. 20 genes are membrane, 16 extracellular and the remaining 90 
are intracellular. 
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Table 4.16.1 Ranking RNA-seq enriched genes with 
tumour/angiogenesis and endothelial cDNA expression evidence 
No. of 
RNA-seq 
contrasts 
Gene Product Angio 
log2(FC) 
Endo 
log2(FC) 
Class 
3 MMP1 matrix metallopeptidase 1 
(interstitial collagenase) 
1.38 12.12 E 
3 ANGPT2 angiopoietin 2 2.32 10.68 E 
3 MMP10 matrix metallopeptidase 10 
(stromelysin 2) 
1.14 7.45 E 
2 MYCT1 myc target 1 4.97 8.47 M 
2 ADAMTS6 ADAM metallopeptidase with 
thrombospondin type 1 motif, 6 
6.22 5.01 E 
2 ADAMTS18 ADAM metallopeptidase with 
thrombospondin type 1 motif, 18 
6.22 4.5 E 
2 PTX3 pentraxin 3, long 6.33 1.98 E 
2 CCL20 chemokine (C-C motif) ligand 20 3.4 4.15 E 
2 DIAPH3 diaphanous homolog 3 (Drosophila) 1 5.89 I 
2 HIST1H4C histone cluster 1, H4c 1.99 3.77 I 
2 COL15A1 collagen, type XV, alpha 1 1.2 4.15 E 
2 SNORA52 small nucleolar RNA, H/ACA box 52 2.76 1.75 I 
2 MYCN v-myc myelocytomatosis viral 
related oncogene, neuroblastoma 
derived (avian) 
1.86 2.31 I 
2 FAM43A family with sequence similarity 43, 
member A 
1.14 2.56 I 
2 C4orf46 chromosome 4 open reading frame 
46 
1.48 1.62 I 
1 FLJ41200 hypothetical LOC401492 1.2 9.89 I 
1 LY96 lymphocyte antigen 96 4.25 5.73 E 
1 MOV10L1 Mov10l1, Moloney leukemia virus 
10-like 1, homolog (mouse) 
4.25 4.6 I 
1 ZNF600 zinc finger protein 600 4.97 3.87 I 
1 LOC100507254 hypothetical LOC100507254 2.76 6.04 I 
1 C2orf27A chromosome 2 open reading frame 
27A 
4.65 3.7 I 
1 GALNTL2 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 
2 
1.32 7.01 I 
1 ZNF134 zinc finger protein 134 5.81 2.31 I 
1 TNFSF4 tumor necrosis factor (ligand) 
superfamily, member 4 
1.77 6.01 E 
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1 TMEM59L transmembrane protein 59-like 1.22 6.52 M 
1 CENPW centromere protein W 2.18 5.49 I 
1 SOX4 SRY (sex determining region Y)-box 4 1.37 5.98 I 
1 MARCH4 membrane-associated ring finger 
(C3HC4) 4 
5.45 1.75 I 
1 ZNF630 zinc finger protein 630 3.69 3.51 I 
1 LHX6 LIM homeobox 6 5.64 1.4 I 
1 CENPI centromere protein I 4.25 2.72 I 
1 ZNF267 zinc finger protein 267 2.35 4.5 I 
1 ZNF304 zinc finger protein 304 2.76 4.02 I 
1 TTC13 tetratricopeptide repeat domain 13 3.87 2.72 M 
1 PLA2G10 phospholipase A2, group X 4.65 1.75 E 
1 MYCL1 v-myc myelocytomatosis viral 
oncogene homolog 1, lung 
carcinoma derived (avian) 
4.65 1.75 I 
1 CCDC23 coiled-coil domain containing 23 1.36 5.01 I 
1 INTS7 integrator complex subunit 7 1.56 4.78 I 
1 HRH1 histamine receptor H1 1.05 5.21 M 
1 DAPK1 death-associated protein kinase 1 1.91 4.28 I 
1 PLXNA4 plexin A4 2.02 4.15 M 
1 LOC283143 hypothetical LOC283143 2.18 3.87 I 
1 CCNE1 cyclin E1 3.32 2.72 I 
1 ZNF610 zinc finger protein 610 1.99 4.02 I 
1 CSF2RA colony stimulating factor 2 receptor, 
alpha, low-affinity (granulocyte-
macrophage) 
1.82 4.15 E 
1 THAP2 THAP domain containing, apoptosis 
associated protein 2 
1.7 4.15 I 
1 RPSAP9 ribosomal protein SA pseudogene 9 1.56 4.28 I 
1 ZNRD1 zinc ribbon domain containing 1 1.86 3.87 I 
1 C2CD4B C2 calcium-dependent domain 
containing 4B 
3.98 1.75 I 
1 CYP21A1P cytochrome P450, family 21, 
subfamily A, polypeptide 1 
pseudogene 
4.65 1.04 I 
1 FRAT2 frequently rearranged in advanced T-
cell lymphomas 2 
2.4 3.29 I 
1 WDR89 WD repeat domain 89 1.08 4.6 I 
1 NANP N-acetylneuraminic acid 
phosphatase 
1.24 4.39 I 
1 MGST2 microsomal glutathione S-
transferase 2 
1.86 3.76 I 
1 FAM26E family with sequence similarity 26, 
member E 
1.56 3.87 M 
1 HEY1 hairy/enhancer-of-split related with 1.86 3.51 I 
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YRPW motif 1 
1 IPO11 importin 11 2.04 3.19 I 
1 TNFRSF25 tumor necrosis factor receptor 
superfamily, member 25 
1.91 3.29 M 
1 AKR7A2P1 aldo-keto reductase family 7, 
member A2 pseudogene 1 
2.76 2.31 I 
1 SACS spastic ataxia of Charlevoix-
Saguenay (sacsin) 
2.48 2.51 I 
1 TMEM119 transmembrane protein 119 1.36 3.51 M 
1 ZNF23 zinc finger protein 23 (KOX 16) 1 3.87 I 
1 SLC44A5 solute carrier family 44, member 5 1.77 3.03 M 
1 PDGFB platelet-derived growth factor beta 
polypeptide 
2.31 2.44 E 
1 STAC SH3 and cysteine rich domain 1.05 3.7 I 
1 ENG Endoglin 1.11 3.63 M 
1 SLC36A4 solute carrier family 36 
(proton/amino acid symporter), 
member 4 
1.67 3.03 M 
1 LOC654342 lymphocyte-specific protein 1 
pseudogene 
2.87 1.81 I 
1 TAF3 TAF3 RNA polymerase II, TATA box 
binding protein (TBP)-associated 
factor, 140kDa 
2.87 1.75 I 
1 KANSL2 KAT8 regulatory NSL complex 
subunit 2 
2.69 1.93 I 
1 MED11 mediator complex subunit 11 1.33 3.29 I 
1 PDCL3 phosducin-like 3 1 3.6 I 
1 LOC100128822 hypothetical LOC100128822 1.82 2.72 I 
1 GOLGA6L5 golgin A6 family-like 5 (pseudogene) 1 3.51 I 
1 TIPRL TIP41, TOR signaling pathway 
regulator-like (S. cerevisiae) 
2.4 2.1 I 
1 CEP128 centrosomal protein 128kDa 2.18 2.31 I 
1 ADNP2 ADNP homeobox 2 1.84 2.58 I 
1 NSUN6 NOP2/Sun domain family, member 6 1.38 3.03 I 
1 SLC36A1 solute carrier family 36 
(proton/amino acid symporter), 
member 1 
1.02 3.29 I 
1 C2orf68 chromosome 2 open reading frame 
68 
1 3.31 I 
1 CA13 carbonic anhydrase XIII 1.56 2.72 I 
1 GLT25D1 glycosyltransferase 25 domain 
containing 1 
2.12 2.15 I 
1 PLK4 polo-like kinase 4 2.5 1.75 I 
1 MT1A metallothionein 1A 1.51 2.72 I 
1 PLXNB3 plexin B3 1.91 2.31 M 
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1 IGFLR1 IGF-like family receptor 1 1.84 2.31 M 
1 ADAP2 ArfGAP with dual PH domains 2 1.82 2.31 I 
1 LOC283663 hypothetical LOC283663 1.7 2.31 I 
1 RANBP1 RAN binding protein 1 1.4 2.47 I 
1 GPATCH1 G patch domain containing 1 1.14 2.72 I 
1 ZNF420 zinc finger protein 420 1.51 2.31 I 
1 TXNDC5 thioredoxin domain containing 5 
(endoplasmic reticulum) 
1.29 2.53 I 
1 MTCP1NB mature T-cell proliferation 1 
neighbor 
2.06 1.75 I 
1 SLC44A3 solute carrier family 44, member 3 1.08 2.72 M 
1 SPRY1 sprouty homolog 1, antagonist of 
FGF signaling (Drosophila) 
1.46 2.31 I 
1 SULF2 sulfatase 2 1.76 2 E 
1 PDPN Podoplanin 1.86 1.75 M 
1 KLHL4 kelch-like 4 (Drosophila) 1.2 2.4 I 
1 SULT1E1 sulfotransferase family 1E, estrogen-
preferring, member 1 
1.84 1.75 I 
1 COL4A1 collagen, type IV, alpha 1 1.47 2.09 E 
1 SMOX spermine oxidase 1.77 1.75 I 
1 NDUFB2 NADH dehydrogenase (ubiquinone) 
1 beta subcomplex, 2, 8kDa 
1.01 2.51 I 
1 FUK Fucokinase 1.2 2.31 I 
1 LOC388152 hypothetical LOC388152 1.67 1.75 I 
1 CDKAL1 CDK5 regulatory subunit associated 
protein 1-like 1 
1.08 2.31 M 
1 MRPS24 mitochondrial ribosomal protein S24 1.27 2.09 I 
1 NCOA2 nuclear receptor coactivator 2 1.56 1.75 I 
1 RPL26L1 ribosomal protein L26-like 1 1.54 1.75 I 
1 TMEM241 transmembrane protein 241 1.94 1.32 M 
1 PCDHA9 protocadherin alpha 9 1.51 1.75 M 
1 OLFML1 olfactomedin-like 1 1.48 1.75 E 
1 AAED1 AhpC/TSA antioxidant enzyme 
domain containing 1 
1.48 1.75 I 
1 DIAPH2 diaphanous homolog 2 (Drosophila) 1.41 1.81 I 
1 GALNT10 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 
(GalNAc-T10) 
1.66 1.43 I 
1 JAG2 jagged 2 1.33 1.75 M 
1 TOMM6 translocase of outer mitochondrial 
membrane 6 homolog (yeast) 
1.64 1.4 I 
1 FANCI Fanconi anemia, complementation 
group I 
1.7 1.29 I 
1 ZNF618 zinc finger protein 618 1.29 1.62 I 
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1 URGCP-MRPS24 URGCP-MRPS24 readthrough 1.44 1.46 I 
1 CSTB cystatin B (stefin B) 1.59 1.26 I 
1 ATP5L2 ATP synthase, H+ transporting, 
mitochondrial Fo complex, subunit 
G2 
1.05 1.75 M 
1 ZNF83 zinc finger protein 83 1.07 1.72 I 
1 HIF1A hypoxia inducible factor 1, alpha 
subunit (basic helix-loop-helix 
transcription factor) 
1.12 1.49 I 
1 ADAT2 adenosine deaminase, tRNA-specific 
2 
1.29 1.25 I 
1 C17orf69 chromosome 17 open reading frame 
69 
1.28 1.04 I 
1 CKS1B CDC28 protein kinase regulatory 
subunit 1B 
1.08 1.02 I 
Table 4.16.1; 126 genes were found to have, for both an endothelial and angiogenic 
results, a  log2(fold change) ≥ 1. 15 of these genes were found to be tumour enriched in 
more than on RNA-seq contrast. 20 genes are membrane, 16 extracellular and the 
remaining 90 are intracellular for cellular component. The key to the final column 
(Class): M = membrane, E = extracellular and I = intracellular. 
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4.17 Endothelial transcriptome, tumour and normal 
Transcriptome assemblies were built using Cufflinks 1.3.0 program on each of the 9 
different RNA-seq samples used in this work. The resulting multiple Cufflink 
transcriptomes were merged together into a single assembly with the Cuffmerge program 
[104], where each transcript was partitioned into one of several classes. The different 
classes and the number of different transcripts in each class can be gleaned from table 
4.17.1. One novel intergenic transcript had 51 exons (accession number 
TCONS_00079877) and in total there were 21,351 potential novel, new genome 
transcripts found. For known genes, 20,948 potential new isoforms were predicted. For 
the whole set of novel and new isoform transcriptome FASTA sequences, please see 
http://sara.molbiol.ox.ac.uk/userweb/jherbert/. 
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Table 4.17.1 Endothelial transcriptome, a table showing 
differently classed transcripts produced with Cufflinks  
Priority Code Description Count 
1 = Transcript matches the intron chain and exons agree with a 
known gene 
38,554 
2 c Transcript is contained within a transcript of a known gene 0 
3 j This is potentially a novel isoform of a known gene as, at 
least, one splice junction is shared with a reference transcript 
20,948 
4 e A single exon transcript that overlaps both an exon and a 
reference intron. This suggest a possible pre-mRNA.  
0 
5 i An intronic transcript  20 
6 o Transcript overlaps an exon of a reference transcript 584 
7 p A PCR run-on, possibly connecting two genes 1 
8 r Transcript overlaps with lower-case bases in genome and is 
classed as a repeat. 
0 
9 u Novel intergenic transcript 21,351 
9.5 U Long novel intergenic transcript with ≥ 10 exons  
(presence of multiple splice sites) 
19 
10 x Transcript that overlaps an exon but on the opposite strand 1,707 
11 s Mapping errors where an intron of a transcript maps over a 
reference intron but on the opposite strand.  
34 
12 . Multiple classifications of the above but is deciphered in the 
tracking file.  
0 
Table 4.17.1; Different classes of transcript and counts; the above table is based on the 
that of Cufflinks web-page manual, with the addition of frequency of differently classed 
transcripts and a new class, a capital U, standing for novel intergenic transcripts that have 
10 or more exons (see Cufflinks manual [130]).  
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4.18 Differentially expressed novel transcripts 
The output of the Cuffmerge program was a Gene Transfer Format (GTF) file that was 
subsequently used in differential gene expression experiments using Cuffdiff that 
included novel transcripts from the 7 merged  transcriptome assemblies. Precedence was 
given to multiple exon novel transcripts with a log2(FC) ≥ 1 enrichment in tumours, as 
well as choosing transcripts that had the largest average expression (transcripts expressed 
at a low level were ignored). This filtering was performed manually and candidates were 
further investigated using BLAST (similarity and homology searches), BLAT with the 
University of California Santa Cruz  (UCSC) Genome browser for exon architecture, and 
functional domain prediction using InterProScan [131]. One such promising novel 
transcript candidate was transcript TCONS_00068524, which had a log2(FC) ≥ 2 in both 
bladder tumour endothelial cells and tumour conditioned HUVEC (see figure 4.18.1). An 
enrichment was also seen in tumour colon and tumour lung endothelium (Illumina) but 
not in the SOLiD4 tumour lung. This transcript had an average expression FPKM of 157.  
 
The nucleotide and 3rd frame translation sequences of TCONS_00068524 are given 
below.  
>TCONS_00068524 mRNA sequence chr6:144521416-144522188;  
TAGCACCGCTCAGGCTGCACTGCGCTTGCTGCAAGCTTCAGGCTCCTGCTAAG
CTAGTGCTGCATCGTCTCCCTTCAGCCGCCATCATGATTATCTACCGCGACCT
CATCAGCCACGATGAGATGTTTTCCGACATCTACAAGATCTGGGAGATCATG
GACGGGCTGTACCTGGAGGTGGAGGGGAAGATGGTCAAAAGCACAGTAATC
ACTGGTGTTGATATTTTCTTTAATTGTGAAAACATGAATCCAGATGGCATGGT
TGCTCTATTGGACTACCGTGAAGATGGTGTGACCCCATATATGATTTTCTTTA
AGGATGATTTAGAAATGGAAAAATGTTAACAAATTTGGCAATTACTTTGATC
TATCACCTGTCATTGTAACTGGCTTCTGCTTGTCATCCACACAACACCAGGAC
TTAAGACAAATTGGGGCTGATGTCATCTTGAGCTCTTCATTTATTTTGACCGT
GATTTATTTGGAGTGGAGGCATTGTTTTTAAGAAAAAC 
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>TCONS_00068524 (Third frame translation of the novel transcript. The longest open 
reading frame is in green to the first stop codon, which is the frame that matches a Refseq 
protein sequence) 
XXXXXXLAPLRLHCACCKLQAPAKLVLHRLPSAAIMIIYRDLISHDEMFSDIYKI
WEIMDGLYLEVEGKMVKSTVITGVDIFFNCENMNPDGMVALLDYREDGVTPYM
IFFKDDLEMEKC*QIWQLL*SITCHCNWLLLVIHTTPGLKTNWG*CHLELFIYFDR
DLFGVEALFLRK 
 
A BLAST search of the 6 frame translation of this sequence to the Refseq database of 
proteins found similarities to a tumour induced protein in an Orangutan species 
(Sumatran orangutan, Pongo abelii), accession number XP_002831390. A three exon 
sequence architecture was derived by aligning the nucleotide sequence to the human 
genome (HG19) using BLAT at the UCSC genome browser. The results of this can be 
seen in figure 4.18.2 in the top panel. The bottom panel shows the results of the 
functional domain scan as performed using InterProScan.  
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Figure 4.18.1 Differentially expressed novel transcript 
TCONS_00068524 
 
Figure 4.18.1; A differentially expressed novel transcript, TCONS_00068524, was 
identified up-regulated in tumour conditioned HUVEC and tumour bladder endothelial 
cells; enrichment of expression was also seen in tumour endothelial cells of lung and 
colon (but slight down regulation in tumour lung, SOLiD4). Log2-fold change of tumour 
versus normal endothelium expression is reported.  
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Figure 4.18.2 TCONS_00068524 genome and domain 
architecture  
 
 
Figure 4.18.2; Top panel; UCSC genome browser genomic architecture overview of the 
3 exon differentially expressed novel transcript. Bottom panel; functional domain 
prediction of the translation of the novel transcript, TCONS_00068524. The results from 
InterProScan at the EBI database show conserved functional domains of mammalian 
translational controlled tumour protein (TCTP) in the novel transcript 
TCONS_00068524.  
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4.19 Isoform switching; does this occur in tumour endothelium? 
The extracellular matrix around tumours contains specific forms of Fibronectin 1(FN1) 
and Tenascin C (TNC), which are structurally different to those expressed under normal 
physiological conditions due to differential splicing events [132]. These differential 
isoforms can affect the behaviour of tumour cells, with the TNC isoform having a pro-
migratory and proliferative effect on tumour cells at sites of breast cancer [133]. FN1 
expresses an extra-domain B (EDB) that is found enriched on tumour vasculature but also 
in the lymph nodes of lymphoma patients; an EDB specific antibody has been used as a 
targeted cancer therapy for lymphoma disease [134].  
 
In this work it was interesting to validate isoforms using Cufflinks where two protein 
sequences from the same gene appeared tumour and normal enriched respectively. 
Isoform switching genes were chosen where the longer protein isoform was up-regulated 
in tumour endothelium and the shorter protein enriched in normal endothelium. Both the 
Refseq and Ensembl transcriptomes were used in conjunction with Cufflinks [104] to 
identify possible candidates. Table 4.19.1 lists the 9 isoform switch candidates, which 
includes the FPKM expression level and the length of each protein isoform. Figure 4.19.1 
shows the functional/structural domain architecture of the long and short forms of 
Cadherin 5, type 2 (vascular endothelium, CDH5), (Ensembl based). The expression 
results suggest a longer form of CDH5 is enriched in tumour Huvec and a shorter protein, 
only containing the cytoplasm Cadherin domain, is normal lung enriched.  
149 
 
Table 4.19.1 Cufflinks isoform switch candidate genes 
Gene Tumour Up 
protein 
Prot
ein 
lengt
h 
Tumour 
Up RPKM 
Normal up 
protein 
Protei
n 
lengt
h 
Normal 
Up RPKM 
Tissue 
contrasts the 
differences 
were found 
CDH5 ENSP00000
437691 
525 120_9 ENSP00000
461880  
223 0_16 Tumour Huvec 
PKM2 ENSP00000
334983 
531 219_45 ENSP00000
413887 
458 2_293 Lung (Illumina) 
SPARC
L1 
ENSP00000
414856 
664 240_6 ENSP00000
438188  
127 0_21 Lung (SOLiD4) 
PPP1R
15A 
ENSP00000
200453 
674 415_32 ENSP00000
443279 
632 0_86 Lung (Illumina) 
VCAM
1 
NP_001069 739 28_5 NP_001186
763 
677 0_8 Lung (Illumina) 
CD99 NP_002405 185 25_0 NP_001116
370 
169 0_38 Lung (SOLiD4) 
CTLA4 NP_005205 223 5_0 NP_001032
720 
174 0_8 Bladder 
PMEP
A1 
NP_064567 287 26_3 NP_954638 252 1_12 Lung (Illumina) 
C2orf7
4 
NP_001137
431 
194 9_0 NP_001137
432 
115 0_19 Lung (SOLiD4) 
Tumour Huvec 
FN1 NP_997647 2477  NP_997643 2330  EDB domain 
Control 
Table 4.19.1; This table lists the genes with Cufflinks evidence of isoform switching. 
The expression levels of each isoform are given with two FPKM values separated by an 
underscore character ("_"); an example is 100_2, which means in tumour endothelium, 
this isoform had an expression level of 100 FPKM and in normal, 2 FPKM. The 
expression in tumour endothelium is the first number in both "Tumour Up FPKM" and 
"Normal Up FPKM" headed columns in the table. In total, 9 potential isoform switching 
genes were identified, with Fibronectin 1 also listed as a control. 
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Figure 4.19.1 CDH5 domain overview, long and short isoforms 
 
 
Figure 4.19.1; The functional and structural domain architecture of the long and short 
isoforms of CDH5 predicted to be differentially expressed in tumour Huvec versus 
normal bulk lung. The longer isoform (bottom panel) contains both the Cadherin repeats 
that are extracellular and in the cytoplasm; this isoform was up-regulated in tumour 
Huvec. The shorter protein, up-regulated in normal lung, only contains the cytoplasm 
Cadherin domain (top panel).  
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4.20 Results of isoform switching 
For all isoforms in table 4.19.1, primers were designed that span intron boundaries that 
are specific to each isoform, with a generic reverse primer suitable for both isoforms. 
Lung tumour and normal endothelial cDNA isolates were used as input to SYBR green 
qPCR. With the exception of VE-cadherin (CDH5), CTLA4 and the positive control, 
FN1, no significant isoform switching or differential expression was evidenced. This is a 
surprising result, as, for example, according to Cufflinks the results for gene PPP1R15A 
has considerable FPKM expression differences between isoforms. Cufflinks uses a 
statistical model to assign expression measures to different isoforms of genes, based on 
read to genome alignments from tophat [103, 104]. It is possible that this model is not 
always accurate in assigning quantitative measures to different isoforms.  
 
On a more positive note, there was a clear difference in expression between the long and 
short forms of CDH5 according to the qPCR results. It is not isoform switching but the 
small version appears to be 16 fold up-regulated in normal versus tumour, whereas the 
long form is 4 fold up-regulated in normal. It is possible that the short form of CDH5 is 
switched off in tumour endothelial cells because of the high cycle threshold number for 
this gene. The longer isoform is present in tumour and normal but is down regulated in 
tumour endothelium. One interesting note is that CDH5 is on a region of chromosome 16 
which suffers loss of heterozygosity in some cancers [135]. However, as endothelial cells 
are apparently genetically stable, this an unlikely cause of down-regulated expression in 
tumour endothelium. Another possibility is the fact that Cadherins are involved in cell to 
cell adhesion, which is destabilised during invasion and metastasis of tumour cells. A 
hallmark of endothelial cells around tumours is that vessels are crooked and fragile, 
which gives a feasible reason as to why both isoforms of CDH5 are down-regulated in 
angiogenic primed tumour endothelium versus normal, manifested by weaker cell to cell 
junctions. 
 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) shows evidence of isoform switching. The 
larger protein is 3 fold up-regulated in tumour endothelium versus normal endothelium, 
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whilst the shorter protein shows modest up-regulation in normal endothelium. Searching 
literature does not find evidence of CTLA4 expressed in endothelium. A search of the 
Unigene cluster for this gene also shows no evidence of vascular expression and analyses 
using Cancer Genome Anatomy Project SAGE libraries also failed to produce any 
endothelial gene expression evidence. This gene has been reported to be a T-cell receptor, 
on the surface of T-helper immune system cells. When activated by a ligand, it initiates 
an inhibitory signal to the T-cell, which ultimately leads to repression of the immune 
response [136]. This has a possible connection to tumour growth, as suppression of the 
immune system against cancer cells and surrounding tissues will aid growth and 
metastasis. It is possible some T-cells were co-isolated with the tumour endothelium.  
 
4.21 Endothelial organ specific expression 
Although not directly related to vascular targeting, it is of scientific interest to look at 
endothelial expression in specific organs or tissue compartments. This was carried out 
using an RPKM analyses (see above) for lung, bladder, colon, liver and tumour 
conditioned HUVEC. For each compartment, gene expression RPKM values were 
compared to the average of all other endothelial cell types using a log2 fold change ratio. 
A cut-off of 4 fold change was applied. A further Venn overlap analyses was employed to 
identify any genes had high ratios in two or more tissues (there were 102 genes like this, 
Figure 4.21.1). From the combined RPKM and Venn analyses, the breakdown of 
compartment enriched genes was;  
 Lung enriched = 1,168 genes 
 Liver enriched = 2,190 genes 
 Colon enriched = 1,527 genes 
 Bladder enriched = 2,438 genes 
 Tumour conditioned HUVEC = 1,956 genes 
The full list of 9,279 genes for each compartment, together with AngioScore, Endothelial 
cDNA library analyses and Angiogenic cDNA library screen, can be found in a download 
Excel file at the following link, selecting the download file called "Endothelial 
compartment/organ enriched genes (RPKM)";  
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http://sara.molbiol.ox.ac.uk/userweb/jherbert/tissue_diffex/appendix_files.html 
A full transcriptome RPKM sheet is also in this file so that a user can look up a gene of 
interest to see its endothelial expression profile across different organs. 
Figure 4.21.1 Overlap of compartment enriched endothelial 
expression  
 
Figure 4.21.1; Combining log ratios of compartments versus all others with a Venn 
analyses finds 9,279 compartment enriched genes.    
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4.22 Summary  
For the first time, short read RNA-seq data of bead-isolated tumour endothelium from 
multiple organs has been used to identify pan-VT targets with deep sequencing 
technology. To aid selection of best VT's, several different rank orders of genes were 
generated based on cDNA library and published data. A new endothelial transcriptome 
has been constructed, which identifies differentially expressed novel transcripts. From 
results here, there was no compelling evidence for the existence of isoform switching at 
the expressed transcript level within tumour endothelium. However, CDH5 and FN1 
showed differential regulation between tumour and normal endothelium. In summary, a 
valuable list of vascular targets has been produced, which can be taken by others for 
validation. A proportion of the candidates genes are currently undergoing experimental 
validation and it is hoped a manuscript will be ready for the end of the year.  
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CHAPTER 5; IDENTIFYING VASCULAR TARGETS 
IN LUNG CANCER USING MICROARRAY DATA 
FROM MULTIPLE PATIENT TUMOUR 
ENDOTHELIUM 
5.1 Introduction 
In previous chapters, vascular targets were sought with sequencing technologies where 
the cost prohibited analyses of multiple biological replicates. In this chapter, biological 
replicates and patient variability were accounted for in an analysis of 4 patient samples of 
non-small cell lung cancer (NSCLC). Tumour and adjacent normal lung endothelial cells 
were isolated from fresh bulk tissues and these were then hybridised on to the latest 
Agilent gene expression array chips to identify differentially expressed genes. Standard 
bioinformatics tools were then used to decipher which genes would be the most 
targetable via the blood supply. Please note, appendix tables are given in a separate 
volume, also downloadable from 
http://sara.molbiol.ox.ac.uk/userweb/jherbert/tissue_diffex/appendix_files.html. 
5.2 Sample collection, preparation and bioinformatics analyses 
Lung tumour and distant normal tissues were obtained immediately after surgery with 
patient consent. Tissues were weighed, minced and then digested for 1.5 hours with 
Dulbecco’s modified Eagle’s medium containing the enzyme Collagenase. The digested 
supernatant was filtered through a 70 micron filter and Ulex europaeus lectin coated 
beads, which bind L-fucose sugar molecules that were then used to positively select out 
endothelial cells [74]. Total RNA was extracted using the RNA-easy minikit of Qiagen 
and cRNA was generated and subject to amplification and labelling. The amplified cRNA 
was hybridized onto Agilent whole human gene expression microarrays. The 
Bioconductor packages preprocessCore [137] and Limma were used to background 
subtract and Quantile normalize probe signal intensities, prior to differential gene 
expression analyses using Linear Models for Microarrays (Limma) [108]. 1- Correlation 
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distances, 2d-clustering and principle component analyses were performed in 
R/Bioconductor [138].   
5.3 Patient and sample variability  
Gene expression heterogeneity between samples was expected as they were collected and 
processed from different patients and on different days. Several global measures of gene 
expression (microarrays in this case) collect an extreme higher number of variables 
compared to the number of samples being assayed. Because of this high dimensionality 
of microarray gene expression data, visualization of global gene expression differences 
between different samples and how they are related to each other is difficult. One way 
this is made possible is by using a principle component analysis that minimizes the 
dimensions of the data whilst keeping a maximal amount of the variation contained 
within the data [139, 140]. It identifies straight line directions that have the maximal 
amount of variation and these are called the principle components. Samples are able to be 
separated along the principle components using a low numbers of variables that make it 
possible to group/visualise similarities and differences between the different samples and 
sample groups. In these circumstances, the variability between samples and sample 
groups can be seen as an advantage as genes significantly up-regulated will be so in spite 
of sample differences. Therefore, any gene that is consistently up-regulated in tumour 
endothelium versus normal will be a general marker of NSCLC but other genes that are 
up-regulated in a subset of tumours or grades are sample specific and will not be 
identified. Figures 5.3.1 and 5.3.2 show principle component analyses on global gene 
expression and on the most significantly differentially expressed genes respectively. This 
provides evidence that there exists some general tumour endothelial markers of NSCLC. 
A Dendrogram of 1 - correlation co-efficient of global gene expression data shows that 
tumour sample 1 (T1) is clearly different to other tumour and all normal samples (Figure 
5.3.3). Further evidence of clear gene expression differences is exemplified when 
performing Hierarchical clustering on the most statistically significantly differentially 
expressed genes. This results in clear distinctions between sample groups and gene 
expression levels (Figure 5.3.4).  
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Figure 5.3.1 Principle Component Analyses of global gene 
expression data 
 
 
 
Figure 5.3.1; A principle component analysis (PCA) plot of samples using all of the gene 
expression data (normalized probe intensities and replicate probes averaged). As with the 
correlation distance analyses (see figure 5.3.3), it is clear tumour sample 1 (T1) is very 
different from all other samples. Along the first principle component, it is evident that 
normal samples N1 and N4 are different from normal samples N2 and N3 at a global 
level of gene expression. The variability shown by the different samples will lead to 
identification of genes that are consistently regulated despite the heterogeneity in 
samples. Tumour samples T1 to T4 are coloured in red and blue labels N1 to N4 are the 
normal samples. 
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Figure 5.3.2 Principle Component Analyses of the most 
differentially expressed genes 
 
 
 
Figure 5.3.2; A principle component analysis (PCA) plot of samples using only the most 
significantly differentially expressed genes. The first principle component (PC1) shows 
the largest variation of data in one dimension and there is a clear distinction between the 
tumour and normal sample groups; despite sample heterogeneity as shown when using 
the complete gene expression set of data, this plot provides evidence of significantly 
differentially expressed genes regardless of sample heterogeneity. Tumour samples T1 to 
T4 are coloured in red and in green are the N1 toN4 labelled normal samples.   
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Figure 5.3.3 Distance calculated as 1- correlation of global gene 
expression as a dendrogram of samples 
 
 
Figure 5.3.3; Distances between different samples can be calculated with various 
methods, for example Euclidean distance. Here a 1 minus Pearson Correlation Co-
efficient was used to generate a Dendrogram. It is clearly visible that tumour sample 1 
(T1) is very different to the other tumour samples and all normal samples.   
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Figure 5.3.4 Hierarchical clustering  of the top 70 differentially expressed genes  
 
Figure 5.3.4; The top 70 most significantly differentially expressed genes were subject to 2 dimensional clustering using 1 - 
correlation as a distance measure and the Ward method of hierarchical clustering. There is a clear distinction between sample groups 
and differentially expressed genes. 
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5.4 The most consistent and significantly differentially 
expressed genes 
Differentially expressed genes were analysed using the Linear Models for Microarray 
Bioconductor package [108, 138]. This produced a table of results that included the 
following for each probe/gene: a moderated T-statistic (where the standard errors were 
worked out and moderated using all genes) and a B statistic. The B statistics is the 
logarithm of odds that a gene is differentially expressed. The exponential function in 
Excel returns e (which is a constant number based on the rate of growth that all 
constantly growing processes posses [141]), to the power of a provided number (in this 
case the B statistic). The B statistic of the most significantly differentially expressed gene 
was 8.44 (MMP11). The odds of this gene being differentially expressed is; the e constant 
to the power of 8.44 is 4,629, and the probability that MMP11 is differentially expressed 
in this data set is 4,629/(1+4,629) is 0.99; or a 99% chance that MMP11 was 
differentially expressed between tumour and normal samples (up-regulated in this case). 
When a B statistic of zero is found, there is a 50% chance the gene is differentially 
expressed [142]; genes determined as statistically significantly differentially expressed 
were those with a positive B value and a multiple correction (Benjamini and Hochberg 
[143]) adjusted p-value ≤ 0.04.  The total number of genes found at this significance level 
was 747. The number of genes from this that were up-regulated in tumour endothelium 
versus normal endothelium = 343 and these are listed in table 5.4.1 (284 of these are 
known genes), along with cDNA library results, AngioScore and cellular component. In 
terms of the best candidates to validate experimentally based on access via blood supply, 
the breakdown of the cellular component is as follows: 36 genes were found to be 
extracellular, 45 membrane and the remaining 262 intracellular.  
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Table 5.4.1 Significantly differentially expressed genes 
Systematic Name Gene Log2 
FC 
adj. 
P.Val 
Endo 
Log2(FC) 
Angio 
Log2(FC) 
Angio 
Score 
Cell 
comp. 
NM_004887 CXCL14 6.7 0.04 -2.64 -0.59 31 E 
NM_000088 COL1A1 5.1 0.04 -9.18 1.71 6 E 
NM_006274 CCL19 4.0 0.04  1.26 18 E 
NM_000090 COL3A1 3.8 0.04 -12.44 2.12 14 E 
NM_005940 MMP11 3.6 0.00 -7.03 2.66 36 E 
NM_015886 PI15 3.5 0.03  0.23 33 E 
NM_003013 SFRP2 3.4 0.04  1.14 26 E 
NM_020127 TUFT1 3.3 0.03 -2.47 -0.55 0 E 
NM_006072 CCL26 3.3 0.03  1.99 20 E 
NM_002426 MMP12 3.1 0.02 -11.05 2.63 19 E 
NM_006274 CCL19 3.0 0.03  1.26 18 E 
NM_006419 CXCL13 2.8 0.02  1.41 17 E 
NM_015973 GAL 2.8 0.01 -6.1 -0.7 11 E 
NM_024746 HHIPL2 2.7 0.02 -6.1 3.69 0 E 
NM_000493 COL10A1 2.6 0.04  4.97 6 E 
NM_001145031 PLAU 2.5 0.03 -3.4 0.33 38 E 
NM_002658 PLAU 2.5 0.04 -3.4 0.33 38 E 
NM_016584 IL23A 2.3 0.01  -0.44 12 E 
NM_201442 C1S 2.3 0.03 -6.6 0.17 4 E 
NM_003811 TNFSF9 2.2 0.01 -6.1 0.23 49 E 
NM_001734 C1S 2.1 0.03 -6.6 0.17 4 E 
ENST00000390282 2.0 0.03    E 
NM_153221 CILP2 1.9 0.03   19 E 
NM_002674 PMCH 1.8 0.04 4.02 -1.26 3 E 
NM_000435 NOTCH3 1.8 0.04 -8 0.35 40 E 
NM_152890 COL24A1 1.8 0.04  3.69 17 E 
NM_001733 C1R 1.7 0.04 -5.04 -0.32 5 E 
NM_002415 MIF 1.5 0.01 -2.75 1.57 27 E 
NM_144651 PXDNL 1.3 0.03  5.23 11 E 
NM_000034 ALDOA 1.2 0.01 -4.46 -0.17 4 E 
NM_005101 ISG15 1.2 0.04 -3.22 0.46 13 E 
ENST00000402102 THNSL2 1.2 0.03 -7.59 -0.78 13 E 
NM_144772 APOA1BP 1.1 0.03 -3.84 0.75 17 E 
NM_144772 APOA1BP 1.0 0.03 -3.84 0.75 17 E 
NM_000918 P4HB 0.9 0.03 -3.2 0.99 9 E 
NM_021130 PPIA 0.7 0.04 -0.92 0.12 9 E 
NM_012449 STEAP1 3.9 0.01 4.02 -2.67 43 M 
NM_001216 CA9 3.4 0.01  2.04 74 M 
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NM_173076 ABCA12 3.3 0.04  -6.38 0 M 
NM_012449 STEAP1 2.9 0.01 4.02 -2.67 43 M 
NM_003039 SLC2A5 2.5 0.01 -7.59 -0.21 16 M 
NM_024893 SYNDIG1 2.5 0.04  0.48 0 M 
NM_173843 IL1RN 2.5 0.03 -2.64 -0.06 12 M 
NM_144717 IL20RB 2.4 0.04 7.6 0.94 13 M 
NM_024628 SLC12A8 2.3 0.03 -1.85 -0.7 0 M 
NM_012484 HMMR 2.3 0.01 4.86 1.59 36 M 
NM_152999 STEAP2 2.2 0.03 2.87 -1.53 20 M 
NM_002402 MEST 2.2 0.03 -9.56 1.14 18 M 
NM_172229 KREMEN2 2.2 0.03 0.82 -0.7 0 M 
NM_004476 FOLH1 2.1 0.03  -1.18 31 M 
NM_001042422 SLC16A3 2.0 0.03 -4.18 0.85 9 M 
NM_013314 BLNK 2.0 0.04 -8 0.73 2 M 
NM_178865 SERINC2 1.9 0.03 -8.57 -0.39 14 M 
NM_018423 STYK1 1.9 0.04 -0.52 -2.26 6 M 
NM_003360 UGT8 1.9 0.03 1.75 -3.1 0 M 
NM_001033113 ENTPD8 1.9 0.04  0.79 0 M 
NM_002589 PCDH7 1.9 0.03 1.75 -0.05 8 M 
NM_001466 FZD2 1.8 0.01 -1.68 2.76 5 M 
NM_004603 STX1A 1.7 0.03 -1.68 2.51 1 M 
NM_017514 PLXNA3 1.7 0.02 -8.31 1.25 21 M 
NM_012140 SLC25A10 1.7 0.04 -8 -0.82 0 M 
NM_182690 EFNA4 1.7 0.01 -3.57 -0.85 18 M 
NM_014353 RAB26 1.7 0.03  2.44 17 M 
NM_033544 RCCD1 1.6 0.03 -5.11 1.85 0 M 
NM_004442 EPHB2 1.5 0.01 0.69 1.76 39 M 
NM_001193472 FOLH1 1.4 0.04  -1.18 31 M 
NM_017821 RHBDL2 1.4 0.03 5.01 0.86 8 M 
NM_012378 OR8B8 1.3 0.03   0 M 
NM_017767 SLC39A4 1.3 0.02  -1.08 7 M 
NM_001077263 TMPRSS13 1.3 0.03 -2.64 1.26 13 M 
NM_003885 CDK5R1 1.2 0.02  2.08 8 M 
NM_024298 MBOAT7 1.2 0.03 -1.33 -0.32 8 M 
NM_173517 VKORC1L1 1.2 0.04  -0.7 0 M 
NM_178148 SLC35B2 1.1 0.02 -0.35 0.85 7 M 
NM_030650 KIAA1715 1.0 0.02 -0.34 -0.13 0 M 
NM_001146082 MBOAT7 1.0 0.02 -1.33 -0.32 8 M 
NM_004720 LPAR2 0.9 0.03  0.16 29 M 
NM_032871 RELT 0.8 0.04 -3.92 1.41 30 M 
NM_014184 CNIH4 0.8 0.04 3.95 1.43 0 M 
NM_031905 ARMC10 0.8 0.03 -0.66 0.11 7 M 
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NM_031905 ARMC10 0.7 0.03 -0.66 0.11 7 M 
NM_002653 PITX1 5.2 0.02 -1.85 -0.64 13 I 
XM_001718065  4.3 0.02    I 
NM_014736 KIAA0101 3.9 0.01 -3.89 0.99 25 I 
NM_004701 CCNB2 3.9 0.01 -0.43 2.12 10 I 
NM_014791 MELK 3.9 0.02 0.03 0.58 12 I 
NM_016343 CENPF 3.8 0.02 0 3.69 15 I 
NM_031942 CDCA7 3.8 0.02 2.31 3.09 15 I 
NM_018136 ASPM 3.7 0.03 5.39 2.24 11 I 
NM_181803 UBE2C 3.7 0.02 -1.2 3.62 28 I 
NM_005515 MNX1 3.6 0.01  1.77 12 I 
NM_018492 PBK 3.5 0.02 0.94 0.94 28 I 
lincRNA:chr7:7928975-7996750_R 3.4 0.01    I 
NM_001012271 BIRC5 3.4 0.01 0.09 2.24 39 I 
NM_018410 HJURP 3.3 0.02 -0.88 1.09 0 I 
NM_001067 TOP2A 3.3 0.03 0.3 3.78 24 I 
NM_003283 TNNT1 3.3 0.03  -0.13 2 I 
NM_013282 UHRF1 3.2 0.02 0.05 2.76 16 I 
NM_001005464 HIST2H3A 3.2 0.02   2 I 
ENST00000397186 LOC645249 3.2 0.02  5.23 0 I 
NM_006907 PYCR1 3.0 0.03 -4.86 1.42 13 I 
NM_014176 UBE2T 3.0 0.01 -1.29 1.12 20 I 
NM_001827 CKS2 3.0 0.03 2.52 0.85 35 I 
NM_004219 PTTG1 3.0 0.01 3.21 0.67 69 I 
NM_014750 DLGAP5 3.0 0.01 0.98 5.81 25 I 
NM_018131 CEP55 3.0 0.01 0.47 2.14 23 I 
NM_021067 GINS1 2.9 0.04 -0.96 2.14 14 I 
NM_012310 KIF4A 2.9 0.04 -0.26 -1.02 11 I 
NM_018685 ANLN 2.9 0.01 0.53 -0.7 12 I 
NM_003579 RAD54L 2.9 0.01 -3.57 2.18 14 I 
NM_006902 PRRX1 2.9 0.04 -7.59 -0.12 14 I 
NM_020675 SPC25 2.9 0.03 -1.66 0.06 0 I 
NM_182507 KRT80 2.8 0.04 -8.57 0.09 0 I 
NM_006845 KIF2C 2.8 0.01 -1.65 1.65 12 I 
NM_003509 HIST1H2AI 2.8 0.01 -6.1  20 I 
ENST00000377836 HES2 2.8 0.03 -0.24 -1.08 25 I 
NM_005346 HSPA1B 2.8 0.04 -1.28 1.72 13 I 
lincRNA:chr2:216585154-
216585719_F 
2.8 0.01    I 
NM_016359 NUSAP1 2.8 0.01 1.78 3.14 8 I 
NM_021127 PMAIP1 2.8 0.03 -1.66 -0.7 35 I 
NM_004336 BUB1 2.7 0.02 -0.88 1.41 24 I 
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NM_003514 HIST1H2AM 2.7 0.03  2.76 8 I 
NM_012112 TPX2 2.7 0.03 -0.86 2.31 19 I 
NM_006101 NDC80 2.7 0.03 1.06 -0.53 13 I 
NM_032117 MND1 2.7 0.03 -3.62 4.65 0 I 
NM_023940 RASL11B 2.7 0.02 -7.03 0.61 17 I 
A_33_P3223860  2.7 0.03    I 
NM_005651 TDO2 2.6 0.03 -7.03 -2.36 8 I 
NM_020436 SALL4 2.6 0.01  2.76 20 I 
NM_178229 IQGAP3 2.6 0.01 3.03 2.87 0 I 
NM_006461 SPAG5 2.6 0.02 -0.12 1.41 13 I 
NM_005192 CDKN3 2.6 0.03 0.49 3.49 28 I 
NM_032899 FAM83A 2.6 0.02 -1.85 0.51 33 I 
NM_152562 CDCA2 2.6 0.01 0.54 1.24 0 I 
NM_020242 KIF15 2.6 0.03 0.24 2.63 11 I 
NM_080668 CDCA5 2.6 0.02 -9.56 1.79 5 I 
NM_003537 HIST1H3B 2.5 0.03   2 I 
NM_006607 PTTG2 2.5 0.01   50 I 
NM_003504 CDC45 2.5 0.03 -3.2 2.76 5 I 
NM_001114173 CTSC 2.5 0.02 -0.75 0 2 I 
NM_024629 MLF1IP 2.5 0.03 -0.88 1.14 4 I 
NM_002875 RAD51 2.5 0.03 -2.16 1.26 20 I 
NM_032997 ZWINT 2.5 0.03 -0.96 0.44 10 I 
NM_005480 TROAP 2.5 0.03 -2.86 6.87 0 I 
NM_182687 PKMYT1 2.5 0.03 -4.19 -0.29 8 I 
NM_198433 AURKA 2.5 0.01 -0.2 3.08 40 I 
NM_005729 PPIF 2.5 0.03 -4.52 0.38 0 I 
NM_004523 KIF11 2.4 0.03 2.13 -0.32 11 I 
NM_016095 GINS2 2.4 0.02 -0.18 2.06 12 I 
NM_207006 FAM83A 2.4 0.02 -1.85 0.51 33 I 
NM_004260 RECQL4 2.4 0.03 -7.03 6.22 15 I 
NM_001211 BUB1B 2.4 0.01 -2.08 6.33 22 I 
NM_030928 CDT1 2.4 0.03 -9.3 7.02 5 I 
ENST00000293743 SPC24 2.4 0.02  2.76 0 I 
NM_001002876 CENPM 2.4 0.02 -8.57 1.14 14 I 
NM_007280 OIP5 2.4 0.04 1.75 4.25 20 I 
NM_138555 KIF23 2.3 0.03 2.87 0.13 5 I 
NM_001071 TYMS 2.3 0.03 0.22 -0.08 23 I 
NM_003686 EXO1 2.3 0.03 3.87 6.33 6 I 
NM_001024599 HIST2H2BF 2.3 0.03 0.82 -1.11 0 I 
A_24_P177553  2.3 0.03    I 
NR_024377 FER1L4 2.3 0.03 3.03 -0.23 0 I 
NM_018101 CDCA8 2.3 0.01 -0.42 1.52 8 I 
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NM_025108 C16orf59 2.3 0.03 -6.1 0.79 0 I 
NM_002263 KIFC1 2.3 0.04 -7.03 6.22 6 I 
NM_016426 GTSE1 2.2 0.01 -2.64 2.58 7 I 
NM_001002033 HN1 2.2 0.03 -1.24 1.6 14 I 
NM_005192 CDKN3 2.2 0.03 0.49 3.49 28 I 
NM_001238 CCNE1 2.2 0.03 2.72 3.32 36 I 
NM_002358 MAD2L1 2.2 0.03 -2.44 -1.16 26 I 
NM_001002032 HN1 2.2 0.03 -1.24 1.6 14 I 
NM_001114121 CHEK1 2.2 0.02 -0.98 -0.08 26 I 
NM_003511 HIST1H2AL 2.1 0.02   7 I 
NM_031966 CCNB1 2.1 0.01 0.33 1.45 23 I 
NM_014501 UBE2S 2.1 0.04 -5.1 1.32 14 I 
NM_145697 NUF2 2.1 0.04 -1.65 1.2 15 I 
NM_138555 KIF23 2.1 0.03 2.87 0.13 5 I 
NM_032997 ZWINT 2.1 0.03 -0.96 0.44 10 I 
NM_153696 FOLH1B 2.1 0.03   29 I 
ENST00000369159 2.1 0.02    I 
NM_001136137 RPL28 2.1 0.02 -3.93 0.48 0 I 
NM_002497 NEK2 2.0 0.02 -1.17 0.25 11 I 
NM_170589 CASC5 2.0 0.02 -1.36 0.79 23 I 
NM_004936 CDKN2B 2.0 0.02 -4.18 -0.29 25 I 
NM_202002 FOXM1 2.0 0.03 0.19 1.6 53 I 
NM_004237 TRIP13 2.0 0.03 -1.44 1.02 5 I 
NM_001024599 HIST2H2BF 2.0 0.02 0.82 -1.11 0 I 
NM_002417 MKI67 2.0 0.03 -0.08 3.31 40 I 
NM_031299 CDCA3 1.9 0.03 -4.14 4.21 0 I 
NM_003541 HIST1H4K 1.9 0.04   8 I 
NM_001237 CCNA2 1.9 0.03 -0.76 7.21 26 I 
NM_018131 CEP55 1.9 0.01 0.47 2.14 23 I 
NM_016343 CENPF 1.9 0.04 0 3.69 15 I 
lincRNA:chr6:86381806-
86396056_R 
1.9 0.03    I 
NM_005225 E2F1 1.9 0.02 -4.54 1.82 39 I 
lincRNA:chr1:173831852-
173837202_F 
1.9 0.02    I 
NM_005914 MCM4 1.8 0.03 -1.1 1.08 9 I 
NM_002417 MKI67 1.8 0.03 -0.08 3.31 40 I 
NM_002863 PYGL 1.8 0.02 -0.23 0.08 0 I 
ENST00000425412 1.8 0.03    I 
NM_138432 SDSL 1.8 0.04 -4.54 0.07 0 I 
NM_020726 NLN 1.8 0.03 -0.14 0.82 6 I 
NM_021065 HIST1H2AD 1.8 0.01   0 I 
NM_024745 SHCBP1 1.8 0.02 0.61 -0.42 0 I 
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NM_002573 PAFAH1B3 1.7 0.02 -2.23 2.38 6 I 
NM_005052 RAC3 1.7 0.03 -8.98 2.63 21 I 
NM_018012 KIF26B 1.7 0.01  0.6 0 I 
lincRNA:chr4:15657202-
15695627_R 
1.7 0.01    I 
A_33_P3417305  1.7 0.03    I 
lincRNA:chr4:53579544-
53580304_F 
1.7 0.04    I 
NM_001813 CENPE 1.7 0.03 6.27 2.48 6 I 
NM_018645 HES6 1.7 0.02 -8.57 2.57 20 I 
NM_001826 CKS1B 1.7 0.03 1.02 1.08 18 I 
NM_005733 KIF20A 1.7 0.02 -0.08 6.22 9 I 
lincRNA:chr6:86381806-
86396056_R 
1.7 0.03    I 
NM_002357 MXD1 1.7 0.03 4.78 -0.43 20 I 
NM_006455 LEPREL4 1.7 0.04 -1.3 0.54 17 I 
NM_001012985 C1orf31 1.7 0.04 1.9 0.87 8 I 
NR_003098 SNHG1 1.7 0.03 -4 0.69 0 I 
NM_002357 MXD1 1.7 0.03 4.78 -0.43 20 I 
NM_004083 DDIT3 1.7 0.04 -1.19 -0.89 24 I 
XR_037614  1.6 0.01    I 
NM_002105 H2AFX 1.6 0.03 -4.56 1.54 19 I 
NM_198949 NUDT1 1.6 0.04 -8 1.84 11 I 
lincRNA:chr20:32861439-
32866564_R 
1.6 0.03    I 
NR_002734 PTTG3P 1.6 0.03   25 I 
NM_005461 MAFB 1.6 0.01 1.75 0.49 13 I 
lincRNA:chr9:37876125-
37881925_F 
1.6 0.04    I 
NM_002497 NEK2 1.6 0.03 -1.17 0.25 11 I 
NM_003655 CBX4 1.5 0.02 -1.68 0.16 9 I 
NM_001079675 ETV4 1.5 0.03 -5.98 7.15 52 I 
BC036909 LOC284889 1.5 0.02 0.82 1.28 33 I 
NM_003513 HIST1H2AB 1.5 0.03   0 I 
NM_003536 HIST1H3H 1.5 0.03 -2.64  9 I 
NM_182470 PKM2 1.5 0.01 -3.83 1.62 33 I 
NM_001040874 HIST2H2AA4 1.5 0.03   0 I 
A_33_P3321923  1.5 0.01    I 
NM_021018 HIST1H3F 1.5 0.03   13 I 
NM_153824 PYCR1 1.5 0.02 -4.86 1.42 13 I 
A_33_P3368636  1.5 0.01    I 
NM_001039841 ARHGAP11B 1.5 0.01  1.2 0 I 
NM_001195228 FAM64A 1.5 0.03 -0.88 6.44 0 I 
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NM_017779 DEPDC1 1.5 0.03 -0.82 2.18 0 I 
NM_005310 GRB7 1.5 0.03 -6.1 0.66 37 I 
NM_003536 HIST1H3H 1.5 0.03 -2.64  9 I 
NM_020183 ARNTL2 1.5 0.04 4.7 0.39 19 I 
NM_002627 PFKP 1.5 0.02 -1.7 0.9 9 I 
NM_001009936 PHF19 1.4 0.03 -0.43 2.96 29 I 
NM_002627 PFKP 1.4 0.03 -1.7 0.9 9 I 
NM_148170 CTSC 1.4 0.02 -0.75 0 2 I 
NM_203463 CERS6 1.4 0.03 -1.66 0.45 21 I 
NM_002046 GAPDH 1.4 0.01 -2.44 1.38 13 I 
NM_013312 HOOK2 1.4 0.04 -7.03 -0.33 0 I 
NM_198175 NME1 1.4 0.03 -0.25 0.82 47 I 
lincRNA:chr21:30566954-
30600954_F 
1.4 0.01    I 
NM_138433 KLHDC7B 1.4 0.04  -6.06 0 I 
NM_024680 E2F8 1.4 0.04  1.51 15 I 
A_33_P3239184  1.3 0.03    I 
NM_032246 MEX3B 1.3 0.03 0.82 1.56 0 I 
NM_001039140 C20orf27 1.3 0.03 -8.57 0.76 7 I 
NM_005208 CRYBA1 1.3 0.03   0 I 
NM_005461 MAFB 1.3 0.03 1.75 0.49 13 I 
lincRNA:chr4:15669186-
15683175_R 
1.3 0.03    I 
NM_152463 EME1 1.3 0.04 -0.74 0.23 4 I 
NM_024656 GLT25D1 1.3 0.02 2.15 2.12 13 I 
NM_001039140 C20orf27 1.3 0.02 -8.57 0.76 7 I 
NM_016545 IER5 1.3 0.03 -0.52 1.09 0 I 
NM_003528 HIST2H2BE 1.3 0.03 -8 0.82 6 I 
NM_001136136 RPL28 1.3 0.03 -3.93 0.48 0 I 
NM_003107 SOX4 1.3 0.01 5.98 1.37 29 I 
lincRNA:chr4:15669186-
15683175_R 
1.3 0.02    I 
NM_018455 CENPN 1.3 0.03 0.75 0.03 0 I 
NM_139160 DEPDC7 1.3 0.04 -7.03 -1.47 33 I 
NM_003524 HIST1H2BH 1.2 0.04   0 I 
NM_003521 HIST1H2BM 1.2 0.03   5 I 
NM_001043229 METTL12 1.2 0.03 3.03 -0.14 0 I 
NM_032340 C6orf125 1.2 0.03   0 I 
NR_002187 TPI1P2 1.2 0.03 1.75 3.69 0 I 
NM_004095 EIF4EBP1 1.2 0.03 -3.21 1.12 21 I 
NM_007215 POLG2 1.2 0.01 4.5 0.1 10 I 
NM_003527 HIST1H2BO 1.2 0.03   0 I 
NM_003525 HIST1H2BI 1.2 0.03   9 I 
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NM_003530 HIST1H3D 1.2 0.03 -2.64 -2.92 8 I 
A_33_P3241043  1.2 0.01    I 
NM_006554 MTX2 1.2 0.02 -0.46 -1 0 I 
NM_003512 HIST1H2AC 1.1 0.02 -4.54 -1.12 0 I 
ENST00000454548 LOC340340 1.1 0.03   0 I 
NM_000365 TPI1 1.1 0.03 0.05 -0.12 4 I 
NM_178014 TUBB 1.1 0.03 -2.21 2.25 6 I 
NM_021058 HIST1H2BJ 1.1 0.03   6 I 
NM_004049 BCL2A1 1.1 0.03 -7.03 -0.7 25 I 
XR_017567 LOC647086 1.1 0.03  3.69 0 I 
NM_001255 CDC20 1.1 0.03 -3.63 1.64 12 I 
NM_001040716 PC 1.1 0.03 -6.1 -1.05 0 I 
NM_002512 NME2 1.1 0.01 -0.42 -0.26 43 I 
NM_002949 MRPL12 1.1 0.03 -9.15 1.08 6 I 
NM_003519 HIST1H2BL 1.1 0.03   4 I 
A_24_P647682  1.1 0.03    I 
NM_175856 CHSY3 1.1 0.03  0.23 0 I 
NM_016535 ZNF581 1.1 0.04 -1.92 -0.7 0 I 
NM_001003714 ATP5J2 1.1 0.03 2.14 0.69 7 I 
NM_019116 UBFD1 1.1 0.03 0.19 -0.1 0 I 
A_33_P3265205  1.1 0.03    I 
NM_001039613 IAH1 1.1 0.02 -1.07 0.08 0 I 
NM_080596 HIST1H2AH 1.1 0.03   5 I 
NM_000291 PGK1 1.1 0.02 -0.69 0.01 10 I 
NM_004037 AMPD2 1.0 0.03 -4.91 -0.54 0 I 
lincRNA:chr2:217380530-
217421230_F 
1.0 0.02    I 
NM_001069 TUBB2A 1.0 0.03 -3.48 3.41 3 I 
NM_004911 PDIA4 1.0 0.03 -0.72 0.5 6 I 
XR_109904  1.0 0.04    I 
NM_199285 PRR19 1.0 0.03 -7.03 1.05 0 I 
NM_003526 HIST1H2BC 1.0 0.03 1.75 -0.7 13 I 
NM_021062 HIST1H2BB 1.0 0.04   0 I 
NM_004889 ATP5J2 1.0 0.03 2.14 0.69 7 I 
NM_001790 CDC25C 1.0 0.04 -0.88 3.49 14 I 
NM_175065 HIST2H2AB 1.0 0.03   4 I 
NM_003510 HIST1H2AK 1.0 0.02   5 I 
NM_012321 LSM4 1.0 0.04 -3.89 1.44 0 I 
NR_023920 WT1-AS 1.0 0.04  0.26 50 I 
NM_002949 MRPL12 1.0 0.04 -9.15 1.08 6 I 
NM_016071 MRPS33 1.0 0.03 1.03 0.33 0 I 
NM_080593 HIST1H2BK 1.0 0.03 -7.59 0.16 6 I 
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NR_026878 MGC12982 1.0 0.04 -7.59 2.4 0 I 
NM_003821 RIPK2 1.0 0.03 -1.06 0.61 15 I 
ENST00000435388 LOC1006527
64 
1.0 0.03 0.82 2.18 0 I 
NM_021063 HIST1H2BD 1.0 0.03  -1.46 4 I 
ENST00000362079 COX3 0.9 0.03   0 I 
lincRNA:chr2:2165
82765-
216584147_F 
XLOC_00185
1 
0.9 0.03   0 I 
NM_007208 MRPL3 0.9 0.03 -0.99 0.53 0 I 
NM_006527 SLBP 0.9 0.03 -0.21 2.08 3 I 
NM_001014812 FAM96A 0.9 0.03 -1.65 -0.21 0 I 
NM_001039182 BOLA2B 0.9 0.03 -2.96 -0.25 0 I 
NM_016587 CBX3 0.8 0.03 -1.36 0.16 6 I 
NM_001001436 C16orf87 0.8 0.03 -2.24 -0.62 0 I 
NM_001039182 BOLA2B 0.8 0.04 -2.96 -0.25 0 I 
NM_003514 HIST1H2AM 0.8 0.03  2.76 8 I 
NM_153702 ELMOD2 0.8 0.04 -1.09 0.51 0 I 
NM_013299 SAC3D1 0.8 0.04 0.82 0.18 0 I 
NM_033118 MYLK2 0.7 0.03   6 I 
lincRNA:chrX:100696094-
100725244_R 
0.7 0.04    I 
NM_001008388 CISD2 0.7 0.04 -1.43 -0.3 0 I 
NM_005984 SLC25A1 0.7 0.04 -9.97 0.1 0 I 
Table 5.4.1; This table lists the 343 significantly up-regulated genes. The last column has 
the cellular component based on a combination of gene ontology cellular component, 
signal sequence and transmembrane domain predictions. The key of classifications is; E = 
an extracellular gene, M = a membrane bound gene and I = an intracellular gene. 36 
genes were found to be extracellular, 45 membrane and the remaining 262 intracellular.   
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5.5 Combining RNA-seq and microarray data for candidate TEMs 
In alternative screening, potential tumour endothelial markers were generated by 
combining lung array genes with the multi organ RNA-seq contrasts from chapter 4. This 
time statistical significance was ignored and lung microarray genes chosen with a 
log2(FC) ≥ 1 enrichment in tumour endothelium. This identified further candidate genes, 
which are listed in appendix table A.5.5.1. A total of 790 genes were found in this screen, 
11 with three RNA-seq contrasts and 146 with two RNA-seq contrasts.  
5.6 Summary 
In this analysis, genes were identified that were statistically significantly over expressed 
in tumour endothelial cells from NSCLC samples. It attempted to account for tumour and 
sample variability to identify the most likely pan-lung tumour vascular targets. The lung 
screen was also combined with the multi-contrast RNA-seq data from chapter 4 as an 
extra source of possible vascular targets. Genes found were compared with the other data 
sets and are discussed in more detail in chapter 6.  
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CHAPTER 6; DISCUSION; COMBINING DATA 
SETS TO FIND CANDIDATE VASCULAR TARGETS  
6.1 Introduction 
In order to gain a better understanding of the tumour endothelial transcriptome and find 
vascular targets, 5 analyses of different data sources were carried out in chapters 2, 3, 4 
and 5. Vascular targets were sought using a variety genomic gene expression measure 
techniques, including proteomic, first generation sequenced cDNA libraries, 2nd 
generation sequenced RNA-seq libraries and microarray. In each of those chapters, the 
resulting gene lists were not investigated but are investigated here, first separately for the 
proteomic and RNA-seq data, and then all analyses combined with a comparison to those 
vascular targets and angiogenesis genes that have already been published. The aim of this 
chapter is to discuss a selection of genes with published data and to identify some that are 
possibly worth further experimental validation or possible targeting. Ultimately, it will be 
stated that this work serves as a starting point for laboratories looking to find novel 
tumour endothelial or just vascular genes by providing an array of possible candidates 
from a variety of data sets.  
6.2 In-vivo biotinylation novelty 
In this work in-vivo biotinylation and perfusion was combined with mass spectrometry 
and bioinformatic analyses to deduce the extra cellular matrix and vascular proteome 
from the chicken embryo. For an embryonic organism, this is the first time it has been 
performed, which facilitates a description of the ECM and vasculature proteome. To add 
more gene signature models to the results, this approach was also applied to U87 glioma 
cells implanted onto a CAM and to granulation tissue as a result of wounds inflicted on 
the CAM. Although many studies have previously taken place to investigate gene 
signatures of different chicken systems using proteomics, like studies of the chicken 
cardiovascular system [144] or analyses of chicken cerebro-spinal fluid [145], these 
studies did not use the high-resolution proteomic procedures or in-vivo capture of blood 
vessel system proteins or the comprehensive bioinformatics used here.  
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6.3 High quality proteomic data 
High quality proteomic data was attained from the in-vivo biotinylation perfusion and 
proteomic mass-spectrometry analyses, which is evidenced by the high minimum 
correlation coefficient scores derived for all biological replicates (0.84). From the full 
proteomic data, all the proteins were searched against the Refseq human proteome to 
decipher the most likely ortholog of the chicken protein. 1,157 total non-redundant 
orthologs were assigned for all proteins and 51% of them were extracellular or membrane 
genes, which is in line with the Rybak et al. in-vivo biotinylation study [53].  
 
Although the results show a significant number of intracellular proteins, possibly derived 
through tissue injury caused by reactive biotin or from cell apoptosis due to experimental 
procedures, these proteins were characteristic of derived tissues; for example, in the 
tumour sample there were glycolytic enzymes. PKM2 (pyruvate kinase muscle isozyme) 
is a glycolytic enzyme that is found to be expressed in cells that are dependent on a high 
metabolic rate. It has been shown that PKM2 contributes to the Warbug effect in tumour 
cells, evidenced by the swapping of PKM2 for PKM1 causing loss of the Warburg effect 
in cancer cells [146]. The Warburg effect in cancer details the different way cancer cells 
derive their energy. They derive energy through a high metabolic rate of glycolysis in the 
cytosol, mediated by enzymes like PKM2, which produces stockpiles of lactic acid due to 
extra fermentation. In contrast, normal cells have a low metabolic rate and perform 
glycolysis reactions and subsequent oxidation of pyruvate in the mitochondria [147]. 
6.4 Functional enrichment consistent with embryonic 
development 
A functional enrichment analysis revealed biological processes and molecular pathways 
consistent with the biology of a developing embryo. It is evident that all tissues from the 
embryo are enriched for extracellular matrix and cellular adhesion biological processes. 
Wound healing, blood vessel development and response to wounding are categories also 
consistent with the granulation tissue and with a developing embryonic system. Focal 
adhesion pathways were switched on in these samples, suggesting the occurrences of 
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cellular construction and cytoskeleton building. The functional enrichment analysis was 
consistent with the biological systems being analysed.  
6.5 Differentially expressed genes found between tumour and 
wound 
Malignant tumours have been known to develop at sites of chronic injury and the 
environment of an injury can catalyse malignant disease [148]. In fact, it was once 
proposed that tumours are actually wounds that never heal because of the almost identical 
characteristics between the tumour stroma development and wound granulation tissue 
formation [149]. Tumours and wounds are known to have many molecular signature 
similarities and it has been shown that inflammation is a key step in both processes, as is 
angiogenesis. For instance, there was a study that found 77% of genes were concordant 
between renal regenerating cells (similar to the wound healing model) and renal cell 
carcinoma (a mimic of the tumour model). The other 23% of genes changed in the 
opposite directions [150]. In this study we performed CAM models of wound and 
tumours, and, thus, it was possible to elucidate the gene expression differences between 
these two models. The analyses revealed 16 genes enriched in the tumour model and 18 
genes enriched in the wound. For a subset of these genes, an investigation of published 
literature was taken to assess their relevance to either model. It will attempt to address the 
question; Are these molecular differences characteristic of the differences between 
tumours and wounds?  
6.6 Tumour enriched NAMPT; evidence for tumour and 
angiogenesis involvement  
NAMPT is the HUGO gene symbol of the enzyme Nicotinamide 
phosphoribosyltransferase. This enzyme is critically important in the biosynthesis of 
nicotinamide-adenine-dinucleotide (NAD). This enzyme catalyzes 5-phosphoribosyl-
pyrophosphate and nicotinamide condensation to produce the new 2 products of 
nicotinamide mononucleotide and inorganic pyrophosphate. This enzyme is rate limiting 
for the NAD synthesis salvage pathway. NAMPT was the most tumour/CAM enriched 
gene (64 fold up-regulated) versus the wound/CAM samples. In the literature, NAMPT 
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has previously been shown to be up-regulated ≥ 6 fold in colon cancer at both mRNA and 
protein levels [151, 152]. In addition, it has also been shown to be up-regulated in glioma 
and has been proposed as a serum prognostic marker of glioblastoma [153]. Additional 
evidence is that NAMPT could also have a role in angiogenesis. A Korean group has 
published several papers relating to the adipokine Visfatin (which is another name for 
NAMPT but this isoform is proposed to be extracellular) and its involvement in 
angiogenesis. An example is Kim et al. who showed in 2007 that NAMPT promotes 
angiogenesis and is a potent activator of in-vivo neovascularization of the chick 
chorioallantoic membrane [154]. There is now evidence that Notch1-dependent 
production of FGF2 is induced in NAMPT-primed endothelial angiogenesis and several 
groups have shown NAMPT/Visfatin can influence angiogenesis [154-158]. Lastly, 
NAMPT has been shown to induce proliferation and tube formation in Human Umbilical 
Vein Endothelial Cells (HUVECs) in a dose moderating manner [159]. Additionally a 
compound, FK866, has been reported to inhibit NAMPT and starve tumour cells that rely 
on NAD metabolism for energy. This is a potential therapy for cancer [159]. Combining 
the multiple publication sources of evidence for NAMPT induced angiogenesis and over-
expression in the U87/CAM tumour model, gives compelling evidence that NAMPT is a 
marker of glioma and angiogenesis in the CAM tumour model.  
6.7 S100P was found to be a tumour enriched gene 
S100 calcium binding protein P (S100P) was 4 fold higher in its expression in 
glioblastoma versus granulation tissue. The P in S100P stands for placenta as this protein 
was first found in the placenta but it has also been found to be expressed in the 
fibroblasts, in the cell line 3T3, where it was shown to activate the inflammatory pathway 
of NFκB [160]. It has subsequently been found to be expressed in several tissues, 
including expression in different brain tumours [161]. There is other compelling evidence 
that this gene is involved in several cancers and cell proliferation. According to the Atlas 
of Genetics and Cytogenetics in Oncology and Haematology [162], the entry for S100P 
gene has many articles demonstrating S100P over expression in cancer cells and it is 
reported to be linked to the progression of a number of cancer types that include, breast, 
lung prostate, colon and pancreatic cancers [163-167]. From these studies, a relationship 
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between over expression of S100P and different tumour like phenotypes was noticed. 
These included elevated survival, resistance to treatment and incidence of metastasis. The 
Koltzscher group noted that an intracellular form of S100P could increase metastasis, cell 
growth and survival upon binding to and activating the gene EZR (Ezrin) [168]. EZR 
itself is implicated in cancer cells by affecting cell surface structure adhesions, cellular 
migration and cell order. An extracellular form of S100P has been shown to bind the 
receptor of advanced glycation end products (RAGE) [169], which can also effect cancer. 
S100P is also a target of glucocorticoid signalling in tumour cells [170]. In summary, 
there is a significant amount of published evidence linking S100P over expression to 
cancer and it appears that this is the first time the over expression of S100P has been 
reported in a CAM model of glioblastoma. 
6.8 OAS3 tumour and angiogenesis gene? 
In a study where epithelial cells were stimulated with Amyloid-B protein to mimic the 
effects of Age-related macular degeneration (AMD), which includes inflammation and 
pathological angiogenesis [171], the gene 2'-5'-oligoadenylate synthetase 3 (OAS3) was 
found to be 4 fold up-regulated on stimulation. β-amyloid peptide has also been used in 
an Alzheimer's model, where it was shown to induce angiogenesis several days after 
introduction [172]. This gene has also been shown to be highly expressed during early 
glioma tumour development prior to a fully vascularised tumour, prior to the angiogenic 
switch [173]. Another study showed up-regulation of OAS3 after multiple doses of 
radiation in glioma and breast cancer cells [174]. β-amyloid induced angiogenesis shows 
OAS3 over expression, which could be a link to over expression in the tumour cam 
model. However, angiogenesis is also a characteristic of wound healing, so it is not clear 
why OAS3 would be over expressed in glioma compared to the wound. It should be 
noted that OAS3 was shown to be up-regulated on day 2 in vascularisation of the tumour 
CAM model [174].  
6.9 TNFAIP6 tumour endothelial gene  
This gene is involved in angiogenesis/inflammation and has already been found to be up-
regulated in a CAM tumour model using HIF1A primed Small Cell Lung Carcinoma 
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cells [175]. There is also a patent for this gene as a tumour endothelial marker of Ovarian 
cancer, where they are targeting the gene with an inhibitory compound [176]. TNFAIP6 
has recently been shown to play a regulatory role in FGF2 mediated angiogenesis by up-
regulating angiogenesis through its mopping up binding to PTX3; since this reduces the 
availability of PTX3 to bind to FGF2, which inhibits angiogenesis [175]. As TNFAIP6 
can induce angiogenesis, then it is feasible this gene has a role in neovascularisation of 
gliomas in the CAM, which is exemplified by the fact that it has also been reported as a 
tumour endothelial marker [177, 178], albeit in ovarian cancer. 
6.10 CD276, found over-expressed in the wound 
CD276 was previously identified as a tumour endothelial marker in mouse using SAGE 
library analyses from endothelial cells that were isolated from tumour tissues using 
antibody coupled magnetic beads [71]. In humans, the CD276 protein has been identified 
to be expressed by trophoblasts in the placenta, to act as a decoy for maternal leukocytes, 
which ultimately assists in preventing foetal immune attack from the mothers immune 
system [179]. A recent publication shows that the endothelium of tumours have an 
elevated expression of CD276 and that cancer cells themselves also express this 
molecule. Its expression in cancer is associated with a lower survival rate [180]. Taking 
this evidence together, it makes some sense that this molecule could help a tumour 
deactivate the immune system (causing a more potent tumour) as it does in the placenta 
to keep a mother's immune system from attacking the foetus. However, with these results 
showing the over expression of CD276 in the wound versus the tumour, this suggests it is 
helping prevent the immune system from causing excessive scaring or attacking other 
molecules that are only expressed in developing tissues, such as in wound healing.   
6.11 CALCRL was found to be a wound enriched gene 
Calcitonin receptor-like protein (CALCRL) was found to be 64 fold up-regulated in 
wound model versus the tumour model. This gene is part of the Adrenomedullin receptor 
complex that is involved in vasodilation. This gene has also been shown to be up-
regulated in hypoxia, which in conjunction with Adrenomedullin, can enhance 
endothelial cell survival and migration [181]. Another publication shows that CALCRL 
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has an effect of increasing vessel permeability and can facilitate the migration of white 
blood cells [182], which gives a feasible role for CALCRL in wound healing as white 
blood cells are delivered to a wound to substantiate an immune response and stimulate 
macrophages to perform phagocytosis of necrotic tissue. 
6.12 H1F0 was found to be a wound enriched gene 
Retinoic acid (Vitamin A) is an absolute prerequisite for normal wound healing 
(epithelialisation, immune system function and production of proteoglycans) [183-185]. 
The mouse H1 histone family, member 0 (H1F0) is up-regulated in mouse in response to 
retinoic acid [186]. Therefore, there is a possible link between the up-regulation of H1F0 
in wound granulation tissue versus the tumour sample.  
6.13 EPB41 was found to be a wound enriched gene 
EPB41 has been shown to have a pivotal role in wound healing in mice. It was 
demonstrated that EPB41 knockout mice show a phenotype of wound healing impairment 
[187]. In the same study, it was also shown that keratinocytes with silenced EPB41 
exhibited reduced adhesion, cell spreading, migration and motility. In addition, a gene 
called DLG1, has been reported to promote wound healing and it is proposed that the 
transglutiminase EPB41 binds to DLG1 [188].  
6.14 Recent literature on discovering VT genes   
To discuss vascular targets in the proteomic and other data sets, first a list of publications 
relating to the identification of endothelial, tumour endothelial, angiogenic and vascular 
target genes was collected. Although it is not possible to investigate all related previous 
publications, a selection was chosen that spanned the last 12 years of research into 
identifying endothelial genes and vascular targets, which, if totalled, is 883 non-
redundant genes. Some genes are classed as both endothelial and tumour endothelial 
genes, depending on research type (tumour endothelial = 244, endothelial = 815). This 
includes 2 reviews that evaluate the field and the history, thus providing good overviews 
of what the state of play is today. The publications of previous vascular, endothelial and 
tumour endothelial enriched genes are listed in table 6.14.1. 
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Table 6.14.1 Publications on vasculature and tumour vasculature gene discoveries 
Publication Title Year TEMs Endothelial or 
general 
angiogenesis 
Total 
Stan, R. V., L. Ghitescu, et al. (1999). "Isolation, cloning, and localization of rat PV-1, a novel endothelial 
caveolar protein." J Cell Biol 145(6): 1189-1198. 
1999 0 1 1 
St Croix, B., C. Rago, et al. (2000). "Genes expressed in human tumor endothelium." Science 289(5482): 
1197-1202. 
2000 25 25 50 
Huminiecki, L. and R. Bicknell (2000). "In silico cloning of novel endothelial-specific genes." Genome Res 
10(11): 1796-1806. 
2000 2 35 37 
Ho, M., E. Yang, et al. (2003). "Identification of endothelial cell genes by combined database mining and 
microarray analysis." Physiol Genomics 13(3): 249-262. 
2003 0 64 64 
Chi, J. T., H. Y. Chang, et al. (2003). "Endothelial cell diversity revealed by global expression profiling." 
Proc Natl Acad Sci U S A 100(19): 10623-10628. 
2003 0 45 45 
Madden, S. L., B. P. Cook, et al. (2004). "Vascular gene expression in nonneoplastic and malignant 
brain." Am J Pathol 165(2): 601-608. 
2004 5 16 21 
Rybak, J. N., A. Ettorre, et al. (2005). "In vivo protein biotinylation for identification of organ-specific 
antigens accessible from the vasculature." Nat Methods 2(4): 291-298. 
2005 9 0 9 
Oh, P., Y. Li, et al. (2004). "Subtractive proteomic mapping of the endothelial surface in lung and solid 
tumours for tissue-specific therapy." Nature 429(6992): 629-635 
2004 2 0 2 
Neri, D. and R. Bicknell (2005). "Tumour vascular targeting." Nat Rev Cancer 5(6): 436-446. 2005 41 0 41 
van Beijnum, J. R., R. P. Dings, et al. (2006). "Gene expression of tumor angiogenesis dissected: specific 
targeting of colon cancer angiogenic vasculature." Blood 108(7): 2339-2348. 
2006 17 48 65 
Seaman, S., J. Stevens, et al. (2007). "Genes that distinguish physiological and pathological 
angiogenesis." Cancer Cell 11(6): 539-554. 
2007 13 51 64 
Herbert, J. M., D. Stekel, et al. (2008). "A novel method of differential gene expression analysis using 
multiple cDNA libraries applied to the identification of tumour endothelial genes." BMC Genomics 9: 
153. 
2008 9 457 466 
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Bhati, R., C. Patterson, et al. (2008). "Molecular characterization of human breast tumor vascular cells." 
Am J Pathol 172(5): 1381-1390. 
2008 13 15 28 
Wallgard, E., E. Larsson, et al. (2008). "Identification of a core set of 58 gene transcripts with broad and 
specific expression in the microvasculature." Arterioscler Thromb Vasc Biol 28(8): 1469-1476. 
2008 0 58 58 
Pasqualini, R., B. J. Moeller, et al. (2010). "Leveraging molecular heterogeneity of the vascular 
endothelium for targeted drug delivery and imaging." Semin Thromb Hemost 36(3): 343-351. 
2010 15 0 15 
Sasaroli, D., P. A. Gimotty, et al. (2011). "Novel surface targets and serum biomarkers from the ovarian 
cancer vasculature." Cancer Biol Ther 12(3): 169-180.  
Buckanovich, R. J. and an earlier paper by the same group; D. Sasaroli, et al. (2007). "Tumor vascular 
proteins as biomarkers in ovarian cancer." J Clin Oncol 25(7): 852-861. 
2011 93 0 93 
Table 6.14.1; This tables lists a selection of publications that span the last 12 years of research involved in identifying tumour 
endothelial and vascular endothelial genes using an assortment of methods. There are over 800 genes in this list when sorted non-
redundantly. They serve as a guide to validation of the putative targets found in this work. It should be noted that endothelial genes, 
though not necessarily tumour endothelial, will be used as evidence for expression in endothelial cells. Some studies were performed 
in mice (E.g. Seaman et al. and Wallgard et al.); nevertheless, this table used human orthologs for those mouse genes if they exist. 
Note, Sasaroli et al. and Buckanovich et al. are a merged data set as their works are from the same group and have the same purpose.   
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6.15 A sweet shop of vascular genes 
The proteomic analyses from chapter 2 was preferentially to acquire membrane and 
extracellular proteins from a developing chicken embryo. Since angiogenesis is a process 
pivotal to both embryonic development and tumour growth, a comparison to angiogenic 
and endothelial library screens was performed to rank human orthologs as potential 
vascular targets. 205 genes were enriched in endothelium alone and 136 genes had a 
positive fold change in both endothelial and angiogenic screens. Several genes among 
these are ANGPT2, ANGPTL2, ANXA5, COL15A1, EPHB1, EPHB2, IGFBP7, 
IL31RA, JAM3, DKK3, MMP15, PLXNA2, PLXNA4, PTX3, SULT1E1, SPARC, 
PXDN, COL4A1, NID1 and VIM. These are very encouraging results since some are 
already published as tumour endothelial markers or vascular targets. For instance the 
genes COL4A1, SPARC, VIM and IGFBP7 were reported by van Beijnum et al. as 
tumour angiogenesis genes [68]. And the genes PXDN, PLXNA2, NID1 and DKK3 were 
reported as endothelial markers of brain or colon tumours [69, 73]. Therefore, in this list 
there could be other potential tumour endothelial genes.  
 
Another notable fact is that 204 genes in the proteomic data have previously been 
published as endothelial or tumour endothelial genes, some of them without the cDNA 
library confirmation. This includes some established markers of endothelium: PECAM1, 
KDR, VWF, MCAM, CDH5, CD93, TIE1, THBS1, TEK, NRP1, LYVE1, PROCR and 
LAMA4. Similarly, there are also other published tumour endothelial markers. These 
include: COL4A2, THY1, MMP2, TEM5, TEM8, COL1A1, INSR and TNC [68, 69, 73, 
77, 132, 177, 178]. In summary, there are a multitude of endothelial and tumour 
endothelial genes here that provide clear proof that this chicken embryonic model system 
is a great source of vascular targets, either in conjunction with other data sets, like cDNA 
libraries, or alone. Looking down the list of genes, ones without publications from table 
6.14.1, another gene is quickly found. Plexin D1 (PLXND1) is a membrane gene that, 
when looked up, has also been identified as a marker of tumour endothelium and, in 
addition, has been used to mark tumour endothelium when targeted with antibodies for 
imaging [189]. This one data source is a great resource of vascular genes and it would be 
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very interesting to analyse data from more samples of CAM implanted tumour cells from 
different tumour types.  
6.16 Deep sequencing for the first time on fresh tumour 
endothelium 
One massive challenge in tumour endothelial biology is to acquire a pure population of 
endothelial cells. Endothelial cells are embedded amongst an ensemble of different cell 
types. Antibody coupled bead isolation has been performed with different positive and 
negative selection markers. St. Croix used MCAM as a positive selection marker 
following negative selection of non-endothelial cell types with anti EPCAM, CD45, 
CD64 and CD14 [69]. van Beijnum et al. used anti-PECAM1 and anti-CD34 to isolate 
endothelium and Madden et al. anti-MCAM and Ulex europaeus agglutinin 1 (UEA-1) 
[68, 73]. Bhati et al. used micro-dissection on breast samples to isolate endothelial cells 
[77]. In this work UEA-1 alone was used as a positive magnetic bead selection marker for 
fresh endothelial cell isolates from bladder, colon and lung tumour and normal tissues 
prior to deep sequencing (chapter 4). Human hepatic sinusoidal endothelial cells (HSEC) 
were immunomagnetic selected for using anti-PECAM1, which was used in the RPKM 
analyses (liver endothelial cells, 24hrs at 1% oxygen).  
 
New technologies, like Illumina Hiseq sequencers, give this experiment the opportunity 
to discover new genes or alternative isoforms not yet available in public databases. 
Although the human genome is sequenced, it is not known whether all gene transcripts 
have been found. Annotation relies on gene prediction programs and the presence of 
cDNA sequences in databases like dbEST. Both microarrays and traditional 
transcriptomic techniques such as cDNA and SAGE libraries are limited. Microarrays are 
limited by the fact that you have to have knowledge of the sequence before it can appear 
on the chip and traditional transcriptomics by the problems of cost of sequencing and 
generation time. Now these limitations have been removed by the advent of new 
technologies such as Illumina or 454 that can generate millions of bases for several 
thousand pounds, in a short time frame [190]. In this project, we have utilised new 
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technologies, Roche 454, Illumina and SOLiD4 to decipher new vascular targets and 
construct an endothelial transcriptome.  
 
RNA-seq and/or deep sequencing has already been used in many studies, including 
transcriptomes of novel species and various cell types. However, not many have been 
reported sequencing endothelial cells [191-193]. Here, deep sequencing has been 
performed for the first time on fresh isolated endothelium from bladder, colon and lung 
tumours, as well as on tumour conditioned HUVEC as a pure population of endothelial 
cells. These analyses provide genes that could be pan vascular targets across multiple 
organ tumours.  
6.17 pan-VT genes, markers of multiple tumour endothelium 
types 
The data in chapter 4 was presented in a series of 6 views, ranking genes with 2 or more 
contrast results with other sources of evidence. Here, some of the candidate genes from 
the different ranks will be investigated and discussed in terms of how likely the gene is 
related to angiogenesis and endothelial biology.  
 
When looking at genes that were found in more than a single contrast, GPR143 is an 
interesting result. This gene is associated with being expressed in the eye and has a role 
in nystagmus and ocular albinism, which is surprising as this gene was found in 2 
contrasts of bladder and colon tumour endothelium. It was also found expressed in 
endothelial cells but at a low level from the cDNA library results. There is a tenuous link 
between GPR143 and angiogenesis. The L-3,4-dihydroxyphenylalanine (L-Dopa) factor 
is able to induce angiogenesis. In the rat model of Parkinson disease, a disease that is 
characterised by an increase in number of endothelial cells around neurons [194], L-Dopa 
was found to induce endothelial cell proliferation and angiogenesis [195]. The tenuous 
link comes from the fact that L-Dopa has also been shown to be a ligand for the GPR143 
receptor [196]. However, the aforementioned angiogenic effect in the rat model, was 
caused by L-Dopa binding to dopamine receptor D1 rather than GPR143.  
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Four jointed box 1 (Drosophila) (FJX1) was also found in multiple contrasts (lung and 
bladder tumour endothelium) and this gene has been reported to be a tumour endothelial 
marker of Ovarian cancer [177]. It has also been established that this gene is targeted 
downstream in the notch signalling pathway [197]. This makes some logical sense as 
delta-like 4 (Drosophila) (DLL4) was also found enriched in bladder and lung in this 
analysis, providing supporting evidence for Notch signalling during tumour endothelium 
activation. The Dll4 and Notch signalling pathway is important in sprouting angiogenesis 
as it tightly co-ordinates endothelial tip and stalk cell differentiation [198]. 
 
Sphingosine-1-phosphate receptor 3 (S1PR3) or EDG3 is a receptor that is activated 
through the lipid ligand molecule Sphingosine 1-phosphate (S1P), which itself is an 
initiator of angiogenesis. S1P stimulates EDG3 and activates endothelial cells into a 
proliferative and migratory state [199, 200]. In the RNA-seq data sets, this gene was 
found enriched in tumour endothelium from two organs (lung and colon).  
 
Dystrobrevin, alpha (DTNA) was found to be up-regulated in both lung and bladder 
tumour endothelium. Research shows that A-catulin (CTNNAL1) is important in vascular 
remodelling in the vascular system and that DTNA has a role in transporting A-catulin to 
signalosomes, which enhances GPCR signalling of the α(1D)-Adrenergic receptors. 
α(1D)-Adrenergic receptor itself is reported to induce angiogenesis following binding of 
the phenylephrine ligand in low oxygen conditions [201]. In addition, A-catulin itself has 
been implicated to have a role in wound healing [202]. The combination of these genes 
and the published research provides a clue as to how DTNA could be involved in tumour 
angiogenesis.   
 
Gaorav et al. showed that the multi-contrast genes: MMP1 (tumour HUVEC, lung and 
colon), MMP2 (tumour HUVEC and lung) and EREG (lung and colon) are mediators of 
tumour angiogenesis [203]. There is strong evidence that endothelial cells are expressing 
both MMP1 and MMP2 but this is not so for EREG as there are no ESTs in the EREG 
Unigene cluster from a vascular tissue source.  
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6.18 Endothelial Specific Molecule 1; pan vascular target of 
multiple tumours from deep sequencing 
Endothelial Specific Molecule 1 (ESM1) was one of the best performing markers of 
tumour endothelium in this work. It has been published in 5 of the publications used as 
benchmarks in this chapter (table 6.14.1) and was found to be enriched in all 3 human 
tumour organ types as well as the tumour conditioned HUVEC sample, plus the RPKM 
and cDNA analyses. From these results, ESM1 appears to be a pan vascular target and it 
also has a high AngioScore of 68%. There is extensive literature linking ESM1 to 
angiogenesis and different cancers, so the result in this work is not a surprise but serves 
as a positive control that the analyses have found relevant genes [204-213].  
6.19 BAMBI; possible pan vascular target of multiple tumours 
from deep sequencing 
BMP and activin membrane-bound inhibitor homolog (BAMBI) was found in lung and 
bladder tumour endothelium, which makes it a possible pan-vascular target. BAMBI has 
been shown to interact with Frizzled5 (Wnt receptor), in conjunction with LRP6 (co-
receptor) and DVL2, which culminates in the signalling and translocation of beta-catenin 
to the nucleus. The beta-catenin/Wnt pathway enhances cell proliferation and is important 
for embryonic growth and tumour progression. BAMBI has already been shown to inhibit 
the TGF-B signalling pathway by acting as a decoy pseudo-receptor but it has also been 
identified as a target for beta-catenin in liver and colon tumour cells [214]. BAMBI has 
an endothelial cell specific gene expression profile [215] and in BAMBI knockout mice, 
there is not an obvious phenotype, except that the endothelial cells of the kidney and 
heart are prominent and swollen. In response to TGFB, inflating the expression of 
BAMBI, reduced capillary growth and migration, whereas the opposite was seen if 
BAMBI was knocked down. BAMBI knockdown caused an increase of free TGFB, 
which stimulated phosphorylation of the genes SMA1/5 and ERK1/2 [215].   
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6.20 Combining multiple analyses 
There have been several studies that have identified organ specific tumour endothelial 
markers. For instance, van Beijnum et al. and St. Croix et al. both found markers of colon 
cancer [68, 69], Bhati et al. markers of breast cancer [77] and Sasaroli et al. markers of 
ovarian cancer [178]. In this work, deep sequencing of multiple organ fresh isolated 
endothelium was performed for the first time and the results were combined with that of 
multiple experiments: proteomic, tumour conditioned HUVEC, public cDNA libraries 
and microarray data. There were 5 different data sets and analyses in the earlier chapters 
that aimed to find tumour endothelial genes. A short letter code, bold type face in the list, 
will be used to refer to each of the different analyses and the key to these is given below, 
along with the number of genes found.  
 
 in-vivo biotinylation data (chapter 2) = full embryonic data = PROT = 1,157 
genes 
 cDNA library (chapter 3) endothelial and angiogenic screens (Extracellular and 
Membrane) = cDNA = 698 genes 
 RPKM analyses (chapter 4) of tumour conditioned HUVEC + low oxygen liver 
endothelial cells versus combined normal tissues = RPKM = 753 genes 
 RNA-seq multi-contrast (chapter 4) of fresh tumour endothelial cells versus 
normal endothelial cells = NGS = 3,922 genes 
 Microarray of 4 biological replicates (chapter 5) of fresh lung tumour 
endothelium vs. normal lung endothelium data = LUNG = 284 genes 
 
For all analyses, the combined non-redundant list = 5,892 genes. An AngioScore analyses 
of all genes produces 162 genes that have a score ≥ 50. The number of genes that are 
predicted to be membrane or containing a transmembrane domain is 1,240, those 
predicted to be extracellular is 706 and the remaining 3,946 are intracellular. A table with 
all genes combined with the number of publications, identity of analyses, AngioScores 
and product information can be found in appendix table 6.20.1. Figure 6.20.1 shows the 
overlap counts between the different analyses. Not a single gene was found in all five 
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analyses, with the following found in multiple analyses: 7 genes found in four analyses, 
101 genes found in three analyses and 699 genes found in two analyses. The remaining 
5,085 genes were found in a single data set. One possible criterion for selecting genes 
could be to only consider those genes found in more than one analysis, which would give 
a total 807 genes. 
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 Figure 6.20.1 Overlap between the different data sets 
 
 
 
 
Figure 6.20.1; This figure shows overlaps between the five different data set analyses 
carried out in this work. In total there were 5,892 genes found to be enriched in tumour 
endothelial cells from all five analyses combined. Not a single gene was found in all five 
analyses, with the following found in multiple analyses: 7 genes found in four analyses, 
101 genes found in three analyses and 699 genes found in two analyses. The remaining 
5,085 genes were found in a single data set.  The labels and corresponding data sets' and 
chapters are: chick = Proteomic data from chapter 2, cDNA = cDNA library results from 
chapter 3, RPKM = chapter 4, the RPKM analyses of endothelial cells versus bulk 
normal tissue results, RNAseq = the multi organ tumour endothelial results from chapter 
4 (RNA-seq) and LungArray = the lung array results from chapter 5.  
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6.21 Combined data finds published tumour endothelial genes 
When comparing all the genes found in this work, from all analyses, with published 
genes from table 6.14.1, 104 genes have been reported to be endothelial or tumour 
endothelial in 2 or more publications. Similarly, the total number of genes reported as 
endothelial or tumour endothelial in any number of publications is 495. The different data 
sets can be broken down into a percentage of total genes published from each data set: 
PROT = 18%, NGS = 7%, LUNG = 7%, RPKM = 18% and cDNA = 13%. A rough 
measure of efficiancy would suggest that the proteomics and RPKM analyses performed 
best for finding known target genes in this work. About 6 thousand genes were found in 
this work and this represents ~24% of the transcriptome (based on transcriptome 
estimates [216]). Although endothelial cells have been reported to be very 
transcriptionally rich [217], it is likely that some genes found in these data sets will be 
passengers, either expressed due to other cell contaminants or expressed due to individual 
differences. False positives are an important consideration as choosing the wrong genes 
can lead to unnecessary experimental work.  
 
In contrast, it is surprising that 388 genes published to be endothelial and/or tumour 
endothelial were not found here. Serum deprivation response (SDPR), RAS interacting 
protein 1 (RASIP1) and RhoGEF and PH domain containing 5 (FGD5) were found in 
multiple publications [62, 63, 218, 219] but were not found in this study. This is possibly  
due to the focus on tumour endothelial gene discovery in this work, rather than the 
emphasis on endothelial gene discovery in these publications. 
 
A list of the 7 genes that were found in 4 different analyses is as follows: angiopoietin 2 
(ANGPT2), peptidylprolyl isomerase A (PPIA), Pentraxin-related protein 3, (PTX3), 
EGF containing fibulin-like extracellular matrix protein 1 (EFEMP1), endoglin (ENG), 
Ephrin type-B receptor 2 (EPHB2) and triosephosphate isomerase 1 (TPI1). Four of these 
genes have publications (from table 6.14.1) relating to endothelial cell expression 
(ANGPT2, EFEMP1,  ENG and PPIA). Although there were no reports from the 
benchmark publications for TPI1, it has been reported as a marker of renal cell carcinoma 
and also to be up-regulated in response to sokotrasterol sulfate (an apparent angiogenesis 
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promoting steroid) [220, 221]. EPHB2 is reported to regulate angiogenesis and be 
sensitive to both VEGF and hypoxia. It is up-regulated at sites of neovascularisation 
[222-224]. 
 
Pentraxin-related protein 3 (PTX3) is an ECM gene found enriched in 4 different 
analyses. This is a somewhat surprising result as this gene is reported to sequester 
fibroblast growth factor 2 (FGF2) by interacting with and inhibiting the molecule; FGF2 
is a potent pro-angiogenic growth factor. However, it is also reported that the effects of 
PTX3 can be quenched in the presence of another gene, Tumor necrosis factor-inducible 
gene 6 (TSG-6), which binds to PTX3 in the same position as FGF2. Leali et al. propose 
this competitive binding between FGF2-PTX3 and TSG-6-PTX3 offers a fine control 
mechanism for FGF2 mediated angiogenesis [225]. Tumour angiogenesis is a hallmark of 
tumour growth, and with PTX3 been over expressed in 4 analyses, it is possible that 
TSG-6 is also over expressed. However, TSG-6 was only found in the embryonic 
proteome data. It is possible that tumour angiogenesis is not using specifically the FGF2 
angiogenic pathway or it could be that the body is attempting to quell the tumour 
pathological angiogenesis by elevating the expression of PTX3 over TSG-6 to 
commandeer active FGF2. Alternatively, it could be that FGF2 mediated angiogenesis is 
utilized more in the chicken embryo, hence the dual presence of PTX3 and TSG-6. 
Alternatively, PTX3 could share similar promoter machinery with FGF2 and therefore be 
always co-expressed with FGF2. It should be noted that TSG-6 was up-regulated in the 
tumour versus wound as reported in an earlier chapter.  
 
ANGPT2 is a late stage angiogenesis gene, which has been shown to orchestrate 
angiogenesis using the integrin and TEK signalling pathways and is involved in vessel 
maturation. ANGPT2 acts in an autocrine way (produced mainly by ECs) to destabilize 
vessels. Depending on cell type, it is able to activate or inhibit the TEK receptor [226] 
and its purpose is to act as an Angiopoietin 1 factor and TEK receptor negative regulator, 
which ends up controlling the level of response endothelial cells have to cytokines [227].  
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Matrix metalloprotease-1 (MMP1) was identified as a general angiogenesis gene by van 
Beijnum et al. using subtractive hybridisation and microarray analyses [68] and was later 
found to be highly expressed in endothelial cells [62]. It has been shown that stimulation 
of G protein coupled receptor protease activated receptor 1 (PAR1) by MMP1 promotes 
angiogenesis and metastasis in mouse models of ovarian cancer, whereby it compels 
cancer cells to release pro-angiogenic molecules such as Interleukin 8. This in turn leads 
to increased endothelial cell proliferation and sprouting. This form of angiogenesis is 
resistant to Avastin treatment and has been proposed as an alternative pathway target for 
treating ovarian cancer [228]. In total, 14 MMP genes were found in this work, 7 of 
which have been reported in the literature as being markers of angiogenesis (MMP2, 
MMP1, MMP11, MMP9, MMP3, MMP14, MMP10 [62, 68, 77] 
6.22 Lysyl oxidase-like 2; vascular target candidate 
807 genes were found in more than one experiment from all data sets combined. Of these, 
166 are published as endothelial or TEM genes. For instance the lysyl oxidase-like 2 
(LOXL2) gene is not published as a TEM but is found in 3 deep sequencing contrasts as 
well as from the PROT and RPKM analyses (3 different analyses). This family of 
secreted genes are usually involved in the cross-linking of the extracellular matrix. 
Although there are published links to cancer [229-232], with an AngioScore of 6 there is 
little current evidence of LOXL2 as a tumour endothelial marker but it is encouraging 
that it is found to be involved in sprouting angiogenesis; Bignon et al. performed a 
proteomics analyses on the ECM of endothelial cells grown in hypoxia (angiogenic state) 
[233] and report that LOXL2 is expressed in neovessels and amasses in the ECM. They 
also state that Morpholino knockdown of the LOXL2 ortholog in zebrafish leads to a loss 
of intersegmental vessels during development, and, that it is a pivotal enzyme in the 
assembly of ECM. They conclude that LOXL2 regulates angiogenesis in conjunction 
with collagen IV during ECM construction. This one publication provides encouraging 
evidence of LOXL2 being a tumour endothelial marker required for tumour vessel 
development, and coupled with the multi-contrast deep sequencing and RPKM/PROT 
results, gives compelling evidence for LOXL2 to be a vascular target.  
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6.23 Fibronectin leucine rich transmembrane protein 2; vascular 
target candidate 
Fibronectin leucine rich transmembrane protein 2 (FLRT2) was found in 3 analyses; it 
was up-regulated in the tumour conditioned HUVEC, the cDNA library analyses and in 
the chicken embryo. Haines et al. reported that this family of genes regulate FGF2 
signalling by interacting with Fibroblast growth factor receptor 1 (FGFR1) [234]. 
Magnuson et al. used Embryoid body and teratomas model systems to show that FGFR1 
has an inhibitory effect on endothelial cells, where inhibition of FGFR1 led to increased 
vascularisation [235]. FGFR1 deficient teratomas (originating from stem cells without 
FGFR1) also showed an increased rate of vessel growth and a distinct morphology. 
Magnuson et al. then used antibody targeting to show that the cytokines interleukin-4 and 
pleiotrophin have a negative and positive angiogenic effect on FGFR1 respectively and 
proposed this was the system that controls FGFR1 angiogenesis. FLRT2 and other family 
members have been shown to interact with FGFR1 and it has been proposed that the 
FLRT genes regulate FGF2 signalling through FGFR1 [234]. It is possible this gene plays 
a role in embryonic development as it was found in the chicken embryo but not found in 
any fresh tumour endothelial cell isolates. Nevertheless, this gene could be worth 
validating.  
6.24 Angiopoietin-like 4; vascular target candidate? 
Although differences have been noted between cultured endothelial cells versus fresh 
isolates [68, 69], for this gene we have both tumour HUVEC and bladder tumour 
endothelium, plus the chicken embryo and RPKM analyses. Angiopoietin-like 4 
(ANGPTL4) appears to be an excellent candidate based on its expression profile here and 
most notably because it has been shown to be orchestrated by hypoxia inducible factor 1 
(HIF1A),  which is a gene that induces VEGF secretion and drives angiogenesis under 
low oxygen conditions [236]. This is a bit surprising though as this gene has also been 
classed as an adipokine, being expressed in liver and fatty tissues, and so not restricted to 
tumour endothelium. It is possible that this is related to the dual domain protein structure 
of ANGPTL4, which has an N-terminal coiled-coil domain and a C-terminal fibrinogen 
like domain. It has been shown that the domains can be cleaved and released to apply 
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distinct biological effects. In a recent review, spanning 10 years of ANGPTL4 research, 
this gene has been found to have a variety of functions involved in wound healing, 
metastasis, angiogenesis, energy homoeostasis and redox regulation [237]. One concern 
in this work is that ANGPTL4 has little public EST evidence of endothelial cell 
expression and, if it is controlled by HIF1A, it is likely be expressed in tumour or 
perivascular cells rather than endothelium. 
6.25 MCT1 another positive control target found 
Monocarboxylate transporter 1 (MCT1 or SLC16A1) was found in the tumour 
conditioned HUVEC, lung and the PROT data sets. Recent research has shown that 
lactate saturation in normoxic endothelial cells causes the up-regulation of HIF-1alpha, 
which in turn leads to an increase in KDR and bFGF expression in the endothelial cells. 
The lactate transporter gene, MCT1, was then knocked down in endothelial cells and this 
inhibited lactate intake into endothelial cells. This ultimately abolished lactate induced 
Hif1-alpha tumor angiogenesis and has now been proposed as a new anti-angiogenic 
therapy [237].  
6.26 What was new in this work? 
 A new in-vivo biotinylation procedure used in an embryonic system for the first 
time, coupled with high-resolution proteomics and bioinformatics analyses to 
provide a list of vascular target genes. 
 2nd generation sequencing (Roche 454) was combined with public cDNA 
libraries to find vascular targets.  
 RPKM analyses of an in-vitro tumour conditioned endothelial cells and hypoxia 
liver endothelium versus normal bulk adult human tissues was performed to 
produce a third list of targets.  
 Deep sequencing RNA-seq data of freshly isolated tumour endothelium from 
multiple organs was provided for the first time to illuminate the tumour 
endothelial transcriptome and reveal pan-vascular-targets. 
 Finally, 4 biological replicate tumour lung and normal lung endothelium were 
used in a microarray analyses to find perpetual lung tumour endothelial markers. 
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 5,892 vascular target candidates were identified, with 1,240 membrane and 706 
extracellular genes. 
6.27 Summary and outlook 
Solid tumours remain one of the most deadly and most common diseases in man in the 
world today and there is an urgent need for new treatments. The classical treatments are 
limited by off-target delivery of therapeutics to a tumour and by the fact that the hypoxic 
environment of tumour cells can lead to resistance, through hyper-mutation. Surgical 
removal remains uncomfortable and there is a risk of relapse. Therefore, there are 
multiple reasons for finding more vascular targets: 1) the inefficiency of conventional 
treatments and 2) the expense of current anti-angiogenics, as emphasised in the 
introduction. There are many therapeutics currently being researched and some of them 
are approved by the FDA but ultimately, there is not one treatment that fits all tumour 
types. It is hoped that using multiple gene expression sources from a variety of model 
systems will lead to the identity of new molecules that can be used for vascular targeting 
of multiple tumours. 
 
Bioinformatics is only as good as the biological data it is given. Judging by the number of 
endothelial and tumour endothelial genes found in the data that are already published, the 
data is of high quality. All data sets analysed found published vascular related genes to 
some degree. Ultimately, using the latest deep sequencing technologies on fresh tumour 
endothelial cells, leads to novel gene expression signatures and this is a source of new 
vascular targets. Likewise, the customised in-vivo biotinylation embryo technique of the 
Bikfalvi group combined with high-resolution mass-spectrometry has also supplied 
another high quality data set that contains many classic endothelial and tumour 
endothelial genes. The ultimate take home message is that researchers or companies from 
anywhere should take some markers and validate them, which will hopefully result in 
patient benefits in the future.  
195 
 
6.28 Serving the scientific community 
The full list of 5,892 genes, together with annotation, will be available online as a 
downloading Excel file (if the thesis is published). The endothelial transcriptome 
assembled from multi deep sequencing experiments will also be available as a FASTA 
text file. Please note, there is an accompanying Appendix volume containing all 
appendix tables (also downloaded at the following link; 
 http://sara.molbiol.ox.ac.uk/userweb/jherbert/tissue_diffex/appendix_files.html).  
 
Some of this work was from "A new procedure for determining the genetic basis of a 
physiological process in a non-model species, illustrated by cold induced angiogenesis in 
the carp." [107]. The methods of AngioScore and endothelial cell expression signatures 
have been used by other researchers to identify genes most likely involved in 
angiogenesis and/or endothelial expressed from their data sets. The Pubmed identification 
numbers of these are listed: PMID: 20840761 [238], PMID: 19924294 [239], PMID: 
21706054 [240], PMID: 20080097 [241] and PMID: 22103505 [242]. 
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CHAPTER 7; METHODS 
7.1 Principle component analyses of proteomic data 
Protein abundance index values were imported as a table, using the read.delim function 
into R. The data was then logged to base 2 and then quantile normalized in R using the 
preprocessCore module [137] from Bioconductor [243]. The code for running a PCA in R 
was;  
 # import data matrix (either full data or most differentially expressed genes) 
pca=prcomp(t(Data_matrix_normalized_data), scale=T) 
mycolors <- c("red", "blue") 
plot(main="Tumour and normal lung", pca$x, type="n");  
text(pca$x, rownames(pca$x), col=mycolors[c(rep(1,4), rep(2,4))]) 
Images were copied into Microsoft PowerPoint to produce thicker borders and some 
colour customisations of symbols.  
7.2 Correlation coefficient analyses 
Correlation coefficient values were calculated using the cor function from R, with the 
default setting of Pearson coefficients. The returned coefficient values were copied into 
Microsoft Excel and a heatmap was generated. 
7.3 Human ortholog analyses of chicken proteins 
Protein sequences were downloaded from Uniprot [244] using the chicken accession 
numbers supplied from the proteomics group. The downloaded proteins were then 
BLAST [112] searched against the database of human proteins using a Refseq database 
of human proteins. If a best hit was significant, at a minimum of 1e-9, then that human 
protein was assigned the human ortholog of the chicken protein. The BLAST command 
line was run with the -m = 8 option and tabulated results were imported into Microsoft 
Excel for the making of tables.  
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7.4 Generating normal distributions of proteomic data and 
heatmaps 
Quantile and logged Protein Abundance Index value normal distributions were generated 
using the R function hist. Images of the distributions generated by hist were copied into 
Microsoft PowerPoint. To generate a heat maps of tissue specific genes, first a Microsoft 
Excel file was manipulated by hand to select genes required in the heat map, using gene 
symbol as the gene name. This was then imported into R using the read.delim function. 
The heatmap.2 function was used to generate the heat map images using this data, which 
were copied directly in to the thesis.   
7.5 Differential protein expression from the different samples 
Linear Models for Microarrays (Limma) [108] from Bioconductor was used to find 
differentially expressed genes. A moderated T-test was used and it required the data to be 
normally distributed. The data followed an approximate normal distribution and Limma 
analyses was carried out as follows: First the data was logged to the base 2 and then 
quantile normalized using the preprocessCore module [137] from Bioconductor [243]. A 
data matrix with those normalized values was run as a single colour differential gene 
expression analysis as previously described, both as an individual differential gene 
expression experiment as well as using the decideTests function [108, 245]. The volcano 
plot was made using the in-built Limma function, volcanoplot.  
7.6 Gene ontology analyses and literature searches 
The online DAVID resource was used to analyse gene lists for functional enrichment. 
This bioinformatic method clusters genes with alike functions, which were defined using 
gene ontology biological process and KEGG pathways [114].  
7.7 Identify human proteins from U87 model 
Human and chicken proteins were downloaded from the Uniprot database. Perl regular 
expressions were used to match mass-spectrum peptides from the U87 implanted sample 
against both human and chicken Uniprot proteins. If a peptide matched a human protein 
exactly and not a chicken protein, this was counted as a specific human peptide.  
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7.8 cDNA library analyses 
All methods were performed as published [62], with the exception of megablast instead 
of BLAST for the searches of EST to genes. A major part of the cDNA library analyses 
involved the collection and processing of data derived from the public domain. This 
required a relational database system that was made using MySQL. The database was 
pivotal to most analyses and the related programs can be downloaded from the article that 
was published during this work (please see the online additional files 30 to 36 from the 
manuscript [62]). The purpose of these programs was to manipulate the data and import 
data like genes and EST assignments into the database. Basic information about cDNA 
libraries was stored in the database, such as sources and accession numbers. Please see 
additional file 37 for a design of the database schema [62]. Genbank was searched and 
files were collected for relevant cDNA libraries [246]; these were imported into the 
database. mRNA sequences from the Refseq database project [247] were downloaded and 
related information imported into the database. 
 
This screen combined 1st and 2nd generation sequenced mRNA libraries from 
proprietary and public data. Firstly, endothelial cells isolated from liver using immuno-
magnetic beads were subject to Roche 454 titanium sequencing, which produced 
~800,000 sequences between 200 and 600bp in length. This library was added to the 
31,114 endothelial ESTs already collected from Genbank. This was the endothelial pool. 
A pool of non-endothelial libraries was collected from Genbank, those chosen by 
studying the CGAP library browser for non-endothelial cell characteristics. The total 
number of EST sequences for the non-endothelial was 136,336. ESTs from both pools 
were assigned to a gene symbol using megablast, searching each sequence against a 
Refseq of mRNA for human database. The best human gene hit from the mRNA database 
was assigned the hit. Each output was parsed with a Perl program in preparation for the 
differential gene expression experiments. Differential expression experiments were 
carried out online using the website that was created for this work (methods from [62] 
and site at [248]). The table of results returned from the website was manipulated in 
Microsoft Excel. The angiogenic screen was run in a similar manner.  
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7.9 Isolation of Human Umbilical Vein Endothelial Cells  
• Fresh umbilical cords  
• 70% Ethanol 
• PBS (Phosphate buffered saline) 
• HUVEC media with pen/strep and amphotericin B: Cells were grown in M199 
medium (Cancer Research UK Central Services, Clare Hall) supplemented 
with bovine brain extracts [35], 10 % foetal calf serum (FCS, PAA Cell 
Culture Company, Ontario, USA), 4 mM glutamine (Cancer Research UK 
Central Services, Clare Hall), 90 μg/ml of heparin (Sigma, Poole, UK) and 
optional antibiotics (Gentamicin/AmphotericinB, TCS Cell Works, 
Buckingham, UK). 
• Collagenase 1A (Sigma C2674-1g) 10x stock at 10 mg/ml in 1ml and filter 
sterilise if too turbid.  
• Biohazard yellow bucket 
• Metal dissecting tray (Fisher - DKB-350-030S) 
• paper towels 
• 20 ml syringes   
• 2 canulae attached to tubing 
• 2 plastic clamps (VWR - 229-0588) 
• cable ties  (RS components Ltd - 543-428) 
• mixing needles (Henley Medical Supplies  -  MN5) 
• scissors 
 
The reagents and materials above were prepared and the air flow cabinet sterilized. The 
cord was cut in a bag to leave the placenta. Cords were placed in a tray and 6 inches of 
cord was enough for a 1 x T25 flask of cells. The cords were cleaned on the outside by 
wiping with tissue and checked for damage. Clean ends were cut at right angles to the 
cord. An olive canula was inserted into one end of the cord and sealed with a cable tie. 
PBS was then injected into the cord to remove any possible clots. Flushing with PBS was 
continued until it was clear. The other end of the cord was now canulated the same as the 
other end. Clamps were then attached to each end but left open. Collagenase in M199 but 
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with no serum was syringed into the cord until the canula at the other end of the cord 
contained the liquid. The clamps were tightened and the cords placed in a tissue culture 
incubator for 15 to 20 minutes at 37
o
C. PBS was flushed through the cord and the 
contents collected into a 50 ml falcon tube. A further 20ml of air and then another10ml of 
PBS was flushed through. This step was repeated. During this procedure, the syringe was 
kept highest and the cord tilted lower, downwards towards the falcon tube. The cells in 
the falcon tube were centrifuged at 1200 rpm for 6 minutes. The supernatant was 
discarded and the cells re-suspended vigorously 20 times using a glass Pasteur. Cells 
were then plated onto a gelatine coated flask. Media was changed every two hours until 
80% confluent.  
7.10 creating tumour conditioned media at pH 6.8 
Custom made Dulbecco's Modified Eagle Medium (Cancer Research UK Central 
Services, Clare Hall). No Sodium Pyruvate, no glucose and no Sodium Bicarbonate. 10% 
foetal calf serum (FCS, PAA Cell Culture Company, Ontario, USA), 5mM glutamine 
(Cancer Research UK Central Services, Clare Hall) and VEGF at 5ng/ml (PEPROTECH, 
cat: 100-20) were added to the media. To gain a pH of 6.8 10mM PIPES (piperazine-
N,N′-bis(2-ethanesulfonic acid, cat no. 5625-37-6 Sigma) was added and the media 
adjusted using NaOH or HCL. 
7.11 Normoxic media at pH 7.4 
Dulbecco's Modified Eagle Medium (Cancer Research UK Central Services, Clare Hall) 
with 4.5g/L of glucose, Sodium Pyruvate, 10% fetal calf serum (FCS, PAA Cell Culture 
Company, Ontario, USA), 5mM glutamine (Cancer Research UK Central Services, Clare 
Hall) and no VEGF was made up. 10mM HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (cat no. 7365-45-9 Sigma) was added and the pH was 
adjusted to 7.4 using NaOH or HCL.  
 
10cm tissue culture plates of early passaged HUVECs containing both media were 
incubated for 24hours at 1% and 4% oxygen respectively. The pH was tested to check the 
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media pH did not change overnight. After this was confirmed, the passage 0 HUVECs 
were grown for 24 hours in the conditions stated above.  
7.12 Isolating RNA from the HUVEC and 2nd generation 
sequening 
The Qiagen RNEasy kit was used in accordance with the manufacturers’ instructions. 
Total RNA was sent to the Genepool sequencing service, Edinburgh, where 3 lanes of 
Illumina GII RNA-seq deep sequencing was performed. This was the tumour conditioned 
HUVEC sample.  
7.13 Quantitative PCR DLL4 and control gene FLOT2 
cDNA was amplified from 2 μg of RNA isolated from the HUVEC cells, using the High 
Capacity cDNA Archive Kit (Applied Biosystem, Foster City, USA). This was performed 
according to the manufacturers’ instructions. 
 
The Exiqon system (Vedbaek, Denmark) was employed for Quantitative PCR and 
performed on the Rotor-Gene RG-3000 (Corbett Research Limited, Sidney, Australia). 
Each reaction contained 10 ul of cDNA in a 25 μl final volume as follows: 12.5 μl qPCR 
Mastermix (Abgene, Epsom, UK), 1 μl of the forward and the reverse primer (10 μM), 
0.25 μl of an Exiqon probe and 0.25 μl of deionised sterile water. Samples were run with 
the following procedure: 95°C for 10 minutes, followed by 40 cylces at 95°C for 15 
seconds and 60°C for 45 seconds. Results of the QPCR were analysed with the Rotor-
Gene 6 software (Corbett Research Limited). 
 
QPCR primers and probes were defined at the online Roche design site.  
https://www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp 
Overview of the design of QPCR primers for DLL4 with transcript NM_019074: 
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Overview of the design of QPCR primers for FLOT2 with transcript NM_004475: 
 7.14 RNA-seq deep sequencing mapping reads 
The Reads Per Kilobase of exon model per Million reads mapped (RPKM) analyses was 
carried out as follows. First sequences of normal adult human tissues were downloaded 
from the Sequence Read Archive database for accession numbers: Lung = SRR014265, 
heart = SRR014263, liver = SRR014264, brain = SRR036966, cerebral cortex = 
SRR014262 and muscle = SRR014266. This was the normal tissue pool. Sequences from 
the Roche 454 liver endothelium (as used in the cDNA libraries analyses) was combined 
with the tumour conditioned HUVEC to be the endothelial pool. To determine fragment 
sizes of sequenced fragments, bowtie 0.12.7 [102] was run in paired end mode and parsed 
to establish fragment lengths and length standard deviations of the different samples. 
Following this, all reads were mapped to the human genome (version HG19) using 
Tophat version  1.3.1, using the standard commands detailed in the manual [103, 127].  
 
An example command is; 
tophat --library-type fr-unstranded -G RefseqHG19_gtf_gene -g 20 -o 
131modifOut -r 1 --mate-std-dev 80 -p 16 --closure-search --no-novel-indels --
butterfly-search --coverage-search --solexa1.3-quals hg19_genome 
lane_5_f,lane_6_f,lane_7_f lane_5_r,lane_6_r,lane_7_r 
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This command mapped the tumour HUVEC reads and the normal human adult tissues 
were run the same way. The program htseq-count [249] was then used to assign raw 
counts to genes in conjunction with a Refseq GTF file that was downloaded from UCSC 
genome browser (as guided in the manual [249]). Raw gene counts were copied to Excel. 
 
The normal adult human tissues were combined. For each individual sequencing library, 
a measure of RPKM was calculated which used the average transcript length for a gene. 
If a gene had 200 reads mapping to it, an average transcript length of 1Kb and a total of 2 
million reads were mapped, this would give an RPKM value of 100 RPKM. This was 
worked out for all genes in the transcriptome and for all samples separately. The 
endothelial pool (tumour HUVEC and liver endothelium) was averaged for RPKM and 
likewise, the normal human adult tissues were calculated separately and averaged. Log to 
base 2 fold changes were calculated between endothelium and normal tissues to derive 
the final results.  
 
Tophat mapping version 1.3.1 was also used to map the fresh isolated tumour and normal 
endothelial cell samples as detailed above. The output of Tophat is a BAM file, which is 
an indexed file used to store sequence read alignments. These BAM files for all samples 
were assembled into transcriptomes separately using Cufflinks (version 1.0.3 [104, 127, 
130]). The file RefseqHG19_gtf is a gene transfer format file that stores exon positions in 
the genome, which programs like Tophat and Cufflinks understand and use.  
A command line used was as follows;  
cufflinks -o ./tumour_lung_20m_saet -p 16 -g RefseqHG19_gtf gene  -M 
hg19_rRNA_mask.gtf  -b hg19.fa -u --library-type  fr-secondstrand  -N -L 
Colon_30mill_normal -q colon.bam  
The transcriptomes of all assemblies were merged together using Cuffmerge (part of the 
Cufflinks suite of tools) as shown in the published protocol [127]. The resulting merged 
transcriptome was used for the final transcriptome assembly in the results (this includes 
the novel transcripts and novel isoforms). The transcript sequences can be extracted using 
the "gffread" utility, which is part of the Cufflinks suite.  
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Finally, differential gene expression was carried using Cuffdiff on all the genome 
mapped files (BAM files). There were no biological replicates and the command that 
found differentially expressed genes was; 
cuffdiff -o All_results -M hg19_rRNA_mask.gtf -b hg19.fa -u -N -L 
tum_lung,norm_lung,tum_colon,norm_colon,tblad,thuvec, -p 16 tlung.bam 
nlung.bam tcolon.bam ncolon.bam tbladd.bam thuvec.bam > all_results 
 
The resulting Cuffdiff tab delimited "gene_exp.diff" output files were opened and 
manipulated in Microsoft Excel to produce the different tables of results.  
 
The isoform switching candidates were identified from Cuffdiff output file " 
cds_exp.diff". Gene symbols were sorted in Excel and genes for multiple different 
protein ids (multiple coding proteins), a search was performed to find proteins of 
different lengths that appeared reciprocally expressed between tumour and normal.   
7.15 Linear models for microarray analyses 
Microarray analyses was carried out using the Linear Models for Microarrays exactly as 
listed in the Matticks guide [245]. Tables of differentially expressed genes were exported 
in table format to be viewed and manipulated in Microsoft Excel.  
7.16 Principle component analyses of biological replicates 
Principle component analyses was carried out on the full data set and subsequently the 
most differentially expressed genes from Limma using code as earlier;  
 # import data matrix (either full data or most differentially expressed genes) 
pca=prcomp(t(Data_matrix_normalized_data), scale=T) 
mycolors <- c("red", "blue") 
plot(main="Tumour and normal lung", pca$x, type="n");  
text(pca$x, rownames(pca$x), col=mycolors[c(rep(1,4), rep(2,4))]) 
The PCA results were copied into the thesis directly from R.  
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7.18 AngioScore 
The programs to perform literature scanning were published during the time of this thesis  
(see Herbert et al. [107]). A list of gene symbols is provided to the program and a list of 
keywords relating to angiogenesis is searched against all abstracts assigned to that gene 
by the Entrez Gene database. This is done to generate an "AngioScore" for all 
differentially expressed genes. An "AngioScore" is calculated as the percentage of 
abstracts containing a given keyword divided by the total number of abstracts for that 
gene (only from publications that Entrez Gene at Genbank assign to a gene). A list of the 
keywords used is as follows "vascular", "tumour", "tumor", "angiogenic", "angiogenesis", 
"neovascularization", "neovascularisation", "vasculogenesis", "hypoxia", "endoth" and 
"VEGF". The total number of abstracts is returned, as well as the number of abstracts 
matching a keyword (abstract only counted once if multiple keywords present). In 
addition, the Pubmed ID numbers for the abstracts is also returned. The results of the 
literature scanning are imported into Microsoft Excel and an AngioScore percentage is 
calculated = number of abstracts containing a desired keyword divided by the total 
number of abstracts for that gene, multiplied by a hundred.  
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CHAPTER 8; PAPERS PUBLISHED 
8.1 First author publications 
3 first author publications were published during the time of this thesis and are listed 
below.  
8.2 cDNA library analyses from chapter 2 based on;  
Herbert JM, Stekel D, Sanderson S, Heath VL, Bicknell R. A novel method of 
differential gene expression analysis using multiple cDNA libraries applied to the 
identification of tumour endothelial genes. BMC Genomics. 2008 Apr 7;9:153. PubMed 
PMID: 18394197 
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8.3 The bioinformatics method of the AngioScore, ortholog 
searches and endothelial cell expression signatures are from 
this publication;  
Herbert JM, Buffa FM, Vorschmitt H, Egginton S, Bicknell R. A new procedure for 
determining the genetic basis of a physiological process in a non-model species, 
illustrated by cold induced angiogenesis in the carp. BMC Genomics. 2009 Oct 
23;10:490. PubMed PMID: 19852815 
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8.4 A book chapter was produced that describe methods to 
performing analyses with public or proprietary cDNA library data 
through a web browser and with the help of a text guide;  
Herbert JM, Stekel DJ, Mura M, Sychev M, Bicknell R. Bioinformatic methods for 
finding differentially expressed genes in cDNA libraries, applied to the identification of 
tumour vascular targets. Methods Mol Biol. 2011;729:99-119. PubMed PMID: 21365486 
 
 
 
8.5 co-author publications 
15 co-author publications are listed here, most of the methods applied in this work have 
assisted these other publications. 
 
1: Williams TD, Turan N, Diab AM, Wu H, Mackenzie C, Bartie KL, Hrydziuszko O, 
Lyons BP, Stentiford GD, Herbert JM, Abraham JK, Katsiadaki I, Leaver MJ, Taggart 
JB, George SG, Viant MR, Chipman KJ, Falciani F. Towards a system level 
understanding of non-model organisms sampled from the environment: a network 
biology approach. PLoS Comput Biol. 2011 Aug;7(8):e1002126. Epub 2011 Aug 25. 
PubMed PMID: 21901081; PubMed Central PMCID: PMC3161900. 
 
209 
 
2: Bailey RL, Herbert JM, Khan K, Heath VL, Bicknell R, Tomlinson MG. The emerging 
role of tetraspanin microdomains on endothelial cells. Biochem Soc Trans. 2011 
Dec;39(6):1667-73. Review. PubMed PMID: 22103505. 
 
3: Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, Durant S, Beesley JF, 
Herbert JM, Sheldon H, Andre M, Sanderson S, Glen K, Luu NT, McGettrick HM, 
Antczak P, Falciani F, Nash GB, Nagy ZS, Bicknell R. Identification and angiogenic role 
of the novel tumor endothelial marker CLEC14A. Oncogene. 2012 Jan 19;31(3):293-305. 
doi: 10.1038/onc.2011.233. Epub 2011 Jun 27. PubMed PMID: 21706054. 
 
4: Soulet F, Kilarski WW, Antczak P, Herbert J, Bicknell R, Falciani F, Bikfalvi A. Gene 
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